Pharmaudit Kenya.

"unlocking business potential"

About Us:

Pharmaudit Kenya is a healthcare management firm. It provides manual stocktaking, stock auditing and management consultancy services for pharmacies. It was created with the goal of creating a higher standard of stocktaking, stock auditing and pharmacy management in Kenya. For more information check out the other sections of this website. This news page is where you can find out what's happening in pharmacy. 

 

 


 



Job Vacancies- Pharmaceutical Technologists.

 

a busy medical Centre in Nairobi, is seeking to recruit Pharmaceutical Technologists:

Applicants for the job must have a diploma in Pharmacy, and have a valid annual practice licence.

 

Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on tohttp://www.pharmauditk.kbo.co.ke/news to send us your details.


Pharmacist-The Nairobi Hospital.

Job Details

The Nairobi Hospital, a leading health care institution in Eastern Africa has the following excellent career opportunities:

REF: HRD/PHR/09/12
Reporting to the Chief Pharmacist, the successful candidates will be responsible for the following amongst others:
• Checking prescriptions for accuracy and suitability to ensure safe, economical and rational use of drugs and pharmaceutical products.
• Clinical checks on all treatment sheets and prescriptions.
• Preparing and labelling extemporaneous preparations for both in and out patients.
• Participating in formulating and implementing Hospital policies on drug use and pharmacy standard operating procedures.
• Chemotherapy drug dispensing and reconstitution in accordance with the cytotoxic handling policy.
• Providing comprehensive and accurate drug information to patients and other users.
• Participating in continuous medical education lectures.
• Participating in drug stock takes.

Requirements

Qualifications, Skills and Experience:
• Bachelor’s degree in Pharmacy.
• Registration with the Pharmacy and Poisons Board.
• Possession of valid annual practicing license.
• One (1) year work experience.
• Good communication and interpersonal skills.

If your background, experience and competence match the above specifications, please send us your application quoting the reference. Include your current remuneration, testimonials and give full contact details of 3 referees to:
The Human Resources Manager 
The Nairobi Hospital
P.O. Box 30026
NAIROBI – 00100


To be received not later than Friday, 14th September 2012.

Only shortlisted candidates will be contacted.


Pharmaceutical Technologist-The Nairobi Hospital

Job Details

The Nairobi Hospital, a leading health care institution in Eastern Africa has the following excellent career opportunities:

REF: HRD/PTCH/09/12
Reporting to the Section Manager, the successful candidates will be responsible for the following amongst others:
• Processing prescriptions correctly and accurately for both in- and out – patients.
• Giving accurate drug information to patients, wards and other user departments.
• Assisting in preparation and labelling of extemporaneous preparations for in/outpatients.
• Participating in drug stocking in the pharmacies & drug stock taking.
• Checking the expiry dates of pharmacy drugs and ensuring compliance with the Short Expiry Drug Policy.
• Participating in the formulation and implementation of hospital policies on drug use and pharmacy standard operating procedures.
• Participating in the ward pharmacy service.
• Assisting in chemotherapy dispensing and reconstitution in strict accordance with the cytotoxic handling policy.

Requirements

Qualifications, Skills and Experience:
• Diploma in Pharmaceutical Technology.
• At least two (2) years experience after enrolment.
• Enrolment with the Pharmacy and Poisons Board
• Possession of valid annual practicing license.
• Good communication and interpersonal skills.


If your background, experience and competence match the above specifications, please send us your application quoting the reference. Include your current remuneration, testimonials and give full contact details of 3 referees to:
The Human Resources Manager
The Nairobi Hospital
P.O. Box 30026
NAIROBI – 00100
To be received not later than Friday, 14th September 2012.

Only shortlisted candidates will be contacted.


Pharmaceutical Technologist    

 

 

 

 

Employment Type:

Full-Time

 

 

Summary:

Please see our website www.alphamedicalafrica.com

Also we are in the process of expansion of the business that is the reason we are recruiting.

Description:

Job Description: 
The Marketing sales executive serves as the link between AMML and prospect clients like consultation doctors, hospitals, and community centers to sell different kinds of products and services offered by AMML. Ensure that you have a valid and unutilized license. The company can further discuss on the usage of your License and pay for the same.

Requirements:

Requirements: 
• Must be a diploma graduate of Pharmacy and hold relevant license from the Pharmacy & Poisons Board
• Must have at least 3 years and above experience in pharmaceuticals

Send your applications online.


Pharmaceutical Technologist    

Employment Type:

Full-Time

 

 

Summary:

Company Description: 

Esopharm is a start-up limited firm with interest in the pharmaceutical business. It seeks to provide affordable and quality drugs near to the people (of Kakamega county) coupled to great service and high standards of proffessionalism and ethics. We believe the health of our people comes first.We believe in availing to our doctors quality drugs,at affordable prices to their patients and strict adherance to the pharmaceutical business proffessional standards.

Description:

 

Requirements:

Requirements: 

  • Diploma in Pharmacy (need not to be registered by the PPB)
  • Computer Profiency a must
  • 1 year exprience in a chemist and/or hospital
  • Registration by the PPB a plus
  • Profiency in any of the western Kenya dialects a major plus
  • Lady candidates most prefered
  • Willing to work in an upcountry town

Closing Date:

06 October 2012

 

Contact Info:

Wycliffe
Esopharm


Pharmaceutical Technologist-Vacancy.

Medecins Sans Frontieres – Belgium is looking for a Pharmaceutical Technologist in Nairobi, Kibera Project, on a fixed term / extendable contract.

 

The selected candidate will report to the Project, Pharmacist and Medical Coordinator for daily and technical supervision respectively. 

 

He/she will be responsible for the good organisation and functioning of the medical store and clinics pharmacies in Kibera slum, in close collaboration with the Medical and Coordination teams, and in accordance with MSF standards.
 

Main tasks include, but not limited to:

  1. Order management
  2. Supply management
  3. Stock management
  4. Data management
  5. Technical support
  6. Providing tools, training and supervision

Requirements:

  • Experienced Pharmaceutical Technologist
  • Be registered with the Pharmacy and Poisons Board
  • Good organization skills
  • Coaching/Training skills, ability to analyse, propose and implement solutions.
  • Management and supervision
  • Able to create and sustain a positive team dynamic
  • Patience, flexibility and adaptation skills
  • Computer literate.

If you meet the above requirements, please send your CV, motivation letter, copy of certificates and any recommendation letters from previous employers to 

 

MSF-Belgium, 

ATTN Country Administrator, 

P.O. Box 38897 00623, 

Nairobi
 

or email to MSFOCB-Nairobi-Support-Admin@brussels.msf.org mentioning in the subject line: “Application: Pharmaceutical Technologist – Kibera Project”.
 

Application must be received on or before September 14, 2012. 

 

Interested candidates must avail themselves for interview shortly thereafter. 

 

Only shortlisted candidates will be contacted.
 

Starting Date: 1 October 2012.
 

MSF-B is an equal opportunity employer.

 


Pharmacists-vacancy  

A well established medical institution in Nairobi is urgently seeking to fill 2 pharmacist positions
Requirements
Over 3yrs experience in a busy Hospital Pharmacy is essential
Must have a degree in Pharmacy from recognised institution
Must be a registered member of Pharmacy and Poisons Board and have a current valid practicing licence.
Salary: Kshs.140,000
Deadline:

Applications: 
Please send an up to date CV, stating your current salary, accompanied by at least 3 referee telephone numbers/emailaddressesto:
application@summitrecruitment-kenya.com
Summit Recruitment & Training, Rhino House, Karen Road, Karen.  Only short listed candidates will be contacted. Please indicate in your email which position you are interested in.
PLEASE DO NOT APPLY IF YOU DO NOT MEET THE REQUIREMENTS OF THE JOB



Regulatory Affairs / Product Development Manager

Lords Healthcare Limited

Job Details

 

Job Profile

  • Preparation and submission of new product dossiers to Pharmacy & Poisons Board
  • Maintenance and updating of registration database for all company products
  • Annual retention of enlisted company products.
  • Application and renewal of annual licenses including Medical Representatives’ permits.
  • Application and follow up of imports and exports permits
  • Pharmacovigilance of company products and prompt reporting of all cases to PPB
  • Effective liaison with stakeholders e.g. Ministry of Health, NASCOP, KEMSA, Anti Counterfeit Agency.
  • Provide technical support to training department on product knowledge

Requirements

Qualification:

  • Bachelor of Pharmacy degree from a reputable institution
  • Must be registered with Pharmacy and Poisons Board, Kenya
  • In depth understanding of GMPs and GWPs.
  • Ability to mentor and impact basic training on pharmacology, product positioning and doctor selection
  • Good communication skills
  • Prior experience as a Regulatory Pharmacist is an added advantage

How to Apply:
 

1. Drop your application at our offices located at the Capitol Hill towers- Ground floor

 

Deadline for application 27th August 2012
 

NB: Only shortlisted candidates will be contacted
 

Website: www.lordshealthcare.com

ISO 9008:2001 certified



 Professional Service Representatives

Lords Healthcare Limited

Job Details


 

The Person
 

Do you have a passion and drive to succeed in pharmaceutical marketing?
 

Can you withstand pressure and deliver consistently?
 

Tired of the same old, being pushed around with no clear guidelines or training, no avenues for growth, walking with heavy bags full of promotional materials?
 

Tired of being followed around, assigned to drop samples or book appointments for your boss?
 

Is someone taking credit for your hard work?
 

Have you been trying to break into mainstream pharma-marketing without success?


Job Profile:

  • Day to day interactions with medical professionals to strategically position and improve on utilization of brands represented.
  • Critical thinker, strategic planner with ability to participate in formulation of marketing plans and execution.
  • Ability to handle sales targets and deliver consistently on time.
  • Definite growth curve. We only work with locals, NO EXPATRIATES, prove yourself and grow to the  next level.

DETERMINE HOW MUCH YOU WANT TO TAKE HOME PURELY BASED ON YOUR EFFICACY AND EFFICIENCY
 

Previous experience and database of clients previously handled will be an obvious advantage.
 

Requirements

Requirements

  • Minimum of first degree in pharmacy, nursing or Bachelor of Science in which pharmacology is a core taught unit
  • Minimum of one year experience in the industry with a proven track record
  • Must have a clean and valid driver’s license
  • Ability to be versatile and work in any region in Kenya

GRAB THIS CHANCE AND SEE IT PROPEL YOU IN YOUR CHOSEN CAREER PATH. SEE YOUR ODDS DRASTICALLY IMPROVE

How to Apply:
 

1. Drop your application at our offices located at the Capitol Hill towers- Ground floor
 

 

Deadline for application 27th August 2012
 

NB: Only shortlisted candidates will be contacted
 

Website: www.lordshealthcare.com

ISO 9008:2001 certified

 


Surgical and pharmaceutical medical representatives.

 

As the global leader in eye care, Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. 

 

This means that all Alcon associates strive to make significant contributions to preserve, restore and enhance vision.
 

Alcon is now expanding its operations in Nigeria and Kenya and have exciting career opportunities available to candidates who meet the criteria:
 

Surgical and pharmaceutical medical representatives.

 

Achievement of sales targets for the allocated territories and to contribute to the long term profitable growth of the business.

 

Criteria

  • Related tertiary qualification from a reputable institution.
  • Solid track record of successful medical sales experience gained in Africa markets (Medical Representative role only)
  • At least two years experience as a Service Engineer/Technician on medical devices (Field Service Engineer role only)
  • An understanding of the market dynamics
  • Excellent communication skills
  • Good organizational and planning skills
  • Display a sense of urgency; confident individual who is able to use initiative.
  • Computer literate

Interested candidates who meet the criteria listed above must please email their application together with an updated copy of their CV to: estelle.carstens@alconlabs.com.
 

Only shortlisted candidates will be contacted.


Job Vacancies for Pharmacists:

A rapidly growing Pharmacy Chain is in the process of recruiting for the following positions for Mombasa and Thika:

1.       Pharmacists : as Pharmacy Practice Managers : We encourage individuals that have the passion to provide quality professional services to their communities empowered with an opportunity of having the freedom of managing a pharmacy practice backed by a strong network to ensure personal success through best practices in business and service delivery.

2.       Pharmacists - full and part time. Registered to practice in Kenya with minimum 3 years experience.


Applicant candidates should:

  • Have strong leadership qualities and  be regarded as individuals of strong moral and ethical values
  • Goal and result oriented
  • Strong will to serve their communities and have an ethic of continuing education
  • Shall be empathetic, dedicated individuals that are well trained and conversant with the medical knowledge they need to serve the needs of customers within their communities.
  • Team player and thrives on engaging with customers, staff and professional colleagues
  • Desire to contribute to their Pharmacy Practice
  • Have an understanding and appreciation of the benefits of working within a network.

If you are a qualified and interested candidate, send your updated CV and a cover letter to pharmauditkenya@gmail.com by 17th August 2012. Kindly indicate the position applied for on the subject line.

Only short listed candidates will be contacted.



Job Vacancies for Pharmaceutical Technologists:

A rapidly growing Pharmacy Chain is in the process of recruiting for the following positions for Mombasa and Thika:

·         Pharmaceutical Technologist. Enrolled with a minimum of 5 years experience.

Applicant candidates should:

  • Have strong leadership qualities and  be regarded as individuals of strong moral and ethical values
  • Goal and result oriented
  • Strong will to serve their communities and have an ethic of continuing education
  • Shall be empathetic, dedicated individuals that are well trained and conversant with the medical knowledge they need to serve the needs of customers within their communities.
  • Team player and thrives on engaging with customers, staff and professional colleagues
  • Desire to contribute to their Pharmacy Practice
  • Have an understanding and appreciation of the benefits of working within a network.

If you are a qualified and interested candidate, send your updated CV and a cover letter to pharmauditkenya@gmail.com by 17th August 2012. Kindly indicate the position applied for on the subject line.

Only short listed candidates will be contacted.



Production supervisor.

A fast growing pharmaceutical manufacturing company dealing in the production of both Human and Veterinary products is currently looking for the most competent and suitable personnel to fill the vacant position of a production supervisor.

Requirements:

  1. Enrolled pharmaceutical technologist with PPB.
  2. At least 3 years’ experience in an active pharmaceutical manufacturing industry especially with knowledge in penicillin unit.
  3. Male candidates preferable.

 

If you are a qualified and interested candidate, send your updated CV and a cover letter to pharmauditkenya@gmail.com by 17th August 2012.

Only short listed candidates will be contacted.

 


Honey: A Sweet Alternative for Treating Cough in Children

Honey is more effective than a placebo in controlling nighttime cough in children with upper respiratory infections (URI), according to the results from a new randomized placebo-controlled, double-blind trial. The results were published online August 6 in Pediatrics.

The World Health Organization recommends honey as a nighttime treatment for coughing in young children with URIs. However, prior studies either tested only a single type of honey or were not blinded.

In the current study, children with URIs and nocturnal cough were given either 1 of 3 different honey products or a placebo 30 minutes before bedtime, based on a double-blind randomization plan. The primary outcome evaluated was a subjective change in cough frequency, based on parent surveys. Secondary outcomes measured included a change in cough severity, the effect of the cough on sleep for both the child and the parent, and the combined score on the pre- and postintervention surveys.

Herman Avner Cohen, MD, from the Pediatric Ambulatory Community Clinic, Petach Tikva, Israel, and colleagues compared symptom scores for each treatment group before and after the intervention and found that patients in all 3 honey groups demonstrated significant improvement compared with patients treated with placebo. There were no significant differences among the different types of honey.

"The results of this study demonstrate that each of the 3 types of honey (eucalyptus, citrus, and labiatae) was more effective than the placebo for the treatment of all of the outcomes related to nocturnal cough, child sleep, and parental sleep," the authors write.

The researchers enrolled 300 children with URIs, aged 1 to 5 years, who were seen at 1 of 6 general pediatric community clinics between January 2009 and December 2009. Patients were eligible if they had a nocturnal cough attributed to the URI. Children were excluded if they had symptoms of asthma, pneumonia, laryngotracheobronchitis, sinusitis, and/or allergic rhinitis. Patients who used any cough or cold medication or honey in the previous 24 hours were also excluded.

Parents were asked to evaluate the children the day of presentation, when no medication had been given, and then again the day after a single dose of 10 g of eucalyptus honey, citrus honey, labiatae honey, or placebo (silan date extract) had been administered before bedtime. Pre- and postintervention subjective assessments were obtained using a 5-item Likert-scale questionnaire regarding the child's cough and sleep difficulty. Only those children whose parents rated severity as at least a 3 (on a 7-point scale) for at least 2 of the 3 questions related to nocturnal cough and sleep quality on the preintervention questionnaire were included.

Of the 300 patients enrolled, 270 (89.7%) completed the single-night study. The median age of these children was 29 months (range, 12 - 71 months). There was no significant age difference among the treatment groups. Symptom severity was also similar among all 4 treatment groups.

Adverse events were reported for 5 patients and included stomachache, nausea, and vomiting and were not significantly different between the groups.

The authors acknowledge the limitations of the study, including the subjective nature of the survey and the fact that the intervention period was limited to a single dose. In addition, they note that some of the improvement measured may be attributed to the natural progression of URIs, which may improve with supportive care and time.

"On the basis of our findings, honey can be offered as an alternate treatment to children >1 year of age," note Dr. Cohen and colleagues.

"Honey may be a preferable treatment of cough and sleep difficulties associated with childhood URI," they conclude.


 The HOPAK SYMPOSIUM

The 9 Annual Symposium will be held on the 11th & 12th August 2012 at Laico Regency Hotel, Nairobi.

Theme:

Specialization: Changing the Face of Pharmacy Practice.

Sub-themes

• Mentorship for pharmacist specialization

• Impact of specialization

• Initiating and Sustaining Pharmacists-led Programmes

• Medication safety

Registration

Registration Fee: Kshs 1500

Registration commences at 8:00am

For more information visit our website: http://www.hopak.or.ke


Pharmaceutical Technologist-Avenue Hospital

Job Details

 Minimum requirements:

  • Diploma in pharmaceutical technology from a recognized institution, 
  • Current Registration from the Pharmacy & Poisons Board. 
  • 2 years work experience in busy computerized pharmacy.
  • Applicants with 6 years experience have an added advantage.

Requirements

 

If you meet the above requirements please e-mail, or deliver your application and detailed CV on or before 15th August 2012 to:
 

The Human Resources Dept., 

Administration Block
Avenue Hospital

First Parklands Avenue, 

Nairobi

 

E-Mail: hr@avenuehealthcare.com


When emailing your application please include the position you are applying for in the “subject”.


National Quality Control Laboratory (NQCL) Director Job Re-Advertisement.

 

The National Quality Control Laboratory (NQCL) is a corporate body established under Cap 244 of the Pharmacy and Poisons Act with the mandate to perform chemical, biological, biochemical, physiological and pharmacological analysis and other pharmaceutical evaluation of locally manufactured and imported drugs or medicinal substances with the view of determining whether such drugs comply with the requirements of the above Act.
The National Quality Control Laboratory (NQCL) wishes to recruit a competent candidate for the position of Director as outlined below:

Director (Re-Advertisement)
Ref No: NQCL/HR/06/2012 

The Director will be reporting to the Board of Management and will be responsible for the day to day management of the laboratory.

Key responsibilities
    Articulating the policies of the Board and ensuring that appropriate business strategies are developed and implemented.
    • Coordination of all official activities related to the quality control of pharmaceuticals and medical devices for human and veterinary use carried out at the laboratory.
    • Monitoring performance and putting into place the necessary management and administrative systems and procedures
    • Ensuring the proper allocation and utilization of resources in order to achieve organizational goals and
    objectives of the laboratory.
    • Ensuring that modern human resources management practices are adopted and implemented
    . Ensuring compliance with statutory requirements and any agreed protocols
    . Enhancing the image of the organization
    . Advising the board on quality standards to be applied to pharmaceutical products and medical devices approved for the Kenyan market.

Qualification, competencies and experience
    Must be a registered pharmacist with the Pharmacy and Poisons Board
    Must hold a Masters Degree in Pharmaceutical Analysis
    A Masters degree in Business Administration will be an added advantage.
    Has at least 5 years working experience in senior management in the pharmaceutical sector
    Has excelled in such functions as strategic planning, people management, resource mobilization and donor relations.
    Has a proven track record of professional integrity, good conduct, visionary leadership, staff development and motivation.
    Is an effective communicator, dealing effectively with local and international stakeholders.

Applications consisting of 
(i) a cover letter quoting the job reference number, 
(ii) a detailed CV with email address and telephone contacts and indicating your current position and remuneration level and 
(iii) copies of all relevant certificates and testimonials should be addressed to

The Chairman
Board of Management
National Quality Control Laboratory
Hospital Road, KNH Complex
P. 0. Box 29726 - 00202
Nairobi, Kenya.


The deadline for receipt of applications is 21st August 2012. 
A hard copy application is NOT mandatory. 
Note: Those who applied earlier may need to reapply electronically to this email: job@nqcl.go.ke. 
Any form of direct or indirect canvassing will lead to automatic disqualification. 
NQCL is a World Health Organization pre-qualified quality control laboratory.


Pharmacist Job vacancy.

 

Mater Hospital is looking to recruit qualified Kenyan citizens who are ambitious and career driven persons to fill in the following vacant positions:
 

Job Title: Pharmacist

 

Job Requirements

·                                 Must have a first degree in Pharmacy from recognized institutions

·                                 Must be registered with the Pharmacy and Poisons Board and have a current valid practicing license.

Interested candidates who meet the above required qualifications should send their application letters, detailed curriculum vitae listing three professional references and your 24 hours telephone contact to: The Chief Pharmacist, Mater Hospital, Nairobi Kenya.


Pharmaceutical Technologist vacancy:
Nairobi Women’s Hospital

 

The key responsibilities of this role will include but not limited to:-
    Receiving, filling and dispensing drugs and medical supplies  as  ordered or prescribed by a qualified medical practitioners
    Inventory control
    Ensuring pharmacy equipments are kept in good working condition
    Ensuring regular updates on the various pharmacies registers e.g. DDA, ARV’s e.t.c.
    Filling/storing  prescriptions and maintaining them for the required number of years as guided by law
    Ensuring prompt communication to clients of any therapeutic incompatibilities and potential drug interactions
    Clarification of prescription to patients and notification of any prescription errors to the prescriber
    Updating of drug patient bills
    Generating  relevant reports  as the basis for the statistical reports on the consumption and balances of stocks in the pharmacy
    Promoting rational drug therapy
    Ensure Superior Customer Experience to all internal and external clients

Qualifications and Skills
    At least 2 years experience
    Diploma in Pharmaceutical Technology
    Valid registration license by the Pharmacy and Poisons Board.

 

How to apply
Interested applicants are invited to send their applications detailing current and expected salary and CV with contact details of three referees to the General Manager Human Resource P.O. Box 10552-00100 Nairobi, clearly marking the application with position applied for. 

Applications can also be emailed to 
vacancies@nwch.co.ke with the position applied for as the subject line by Friday, August 3rd 2012. 
DO NOT attach your certificates.


Registration Officer-Laboratory and Allied. 

Laboratory and Allied a fast growing pharmaceutical and medical company dealing in the production of both Human and Veterinary products is currently looking for the most competent and suitable personnel to fill the vacancy positions of a Registration Officer
 

He will be reporting to the Product Registration Pharmacist


Job Duties and Responsibilities

  • Prepare and review the dossiers for registration as per guidelines of relevant countries.
  • Preparation and follow up of dossiers for queries and registration status.
  • Maintain all the documents of registration.
  • Ensure formulation is consistent with that in BMR.
  • Prepare and ensure the stability & compatibility protocols and any other reports as per guidelines.
  • Make sure that follow-up is made in order that registration is not delayed and expired.
  • Prepare monthly plans with achievement reports for product registration.
  • Ensure co-ordination of registration dossiers with QA, QC and production departments.
  • Any other duties that may be assigned to me by Product Registration Pharmacist or other Senior Managers.

Requirements

Education Requirements

  • Graduate degree in Bachelor of Science
  • Minimum 2-3years related experience in a pharmaceutical industry.

Other Qualifications

  • Strong experience with computer proficiency Internet, E-mail, MS Office
  • Must have worked in a pharmaceutical firm
  • Candidate should have the experience of registration of the drugs to different countries and health ministry.

Urgently Required: Asap


Kindly send your CV’s, copy of the Identification Card and other testimonials either through hand delivery or email


Kindly note that only successful candidates will be shortlisted and invited for an interview

 


Oxygen gas-fiiled microparticles provide Intravenous Oxygen Delivery.

 

In an article published online in Science Translational Medicine, John N. Kheir et al report the development of Oxygen Gas - Filled Microparticles  that can be injected directly into the boodstream to hand off oxygen molecules to red blood cells to carry throughout the body, keeping organs such as the brain from hypoxia.

 

The new microparticle-based oxygen-delivery technology is a potential breakthrough for short-term resuscitation of pulmonary function.  If it works in large animal trials that are currently underway and moves to human clinical trials, the therapy could eventually hold promise for critically ill patients with severe lung disease, asthma attack, or blocked airway. It could even be an addition to CPR.

 

This idea of a new and novel technique for short-term rescue of profoundly hypoxemic patients, by selectively augmenting oxygen delivery to at-risk organs is very exciting!

 

The injectable foam suspension containing self-assembling, lipid-based microparticles encapsulating

a core of pure oxygen gas for intravenous injection. Prototype suspensions were manufactured to

contain between 50 and 90 ml of oxygen gas per deciliter of suspension. Particle size was polydisperse, with a mean particle diameter between 2 and 4 mm. When mixed with human blood ex vivo, oxygen transfer from 70 volume % microparticles was complete within 4 s. When the microparticles were infused by intravenous

injection into hypoxemic rabbits, arterial saturations increased within seconds to near-normal levels; this

was followed by a decrease in oxygen tensions after stopping the infusions. The particles were also infused

into rabbits undergoing 15 min of complete tracheal occlusion. Oxygen microparticles significantly decreased the degree of hypoxemia in these rabbits, and the incidence of cardiac arrest and organ injury was reduced compared to controls. The ability to administer oxygen and other gases directly to the bloodstream may represent a technique for short-term rescue of profoundly hypoxemic patients, to selectively augment oxygen delivery to at-risk organs, or for novel diagnostic techniques. Furthermore, the ability to titrate gas infusions rapidly may minimize oxygen-related toxicity.



Pharmacist Job vacancy.

 

M. P. Shah Hospital is looking to recruit qualified Kenyan citizens who are ambitious and career driven persons to fill in the following vacant positions:
 

Job Title: Pharmacist

Ref#HR/MPSH/35
 

Job Responsibilities

  • Co-ordinating with departmental heads in establishing their medical and surgical requirements
  • Ensuring all patients medication is accurately dispensed and proper accounting done.
  • To analyse discharge charts and make proposals for improvement.

Job Requirements

  • Must have a first degree in Pharmacy from recognized institutions
  • Must be registered with the Pharmacy and Poisons Board and have a current valid practicing license.
  • A minimum of 3 years post registration working experience in a busy hospital pharmacy is essential.

Interested candidates who meet the above required qualifications and experience should email their application letters quoting reference number, detailed curriculum vitae listing three professional references (including your recent supervisor) and your 24 hours telephone contact to: hr@mpshahhosp.org
 

Applications should be received not later than 6th August 2012.
 

Only short listed candidates will be contacted.

 


Pharmaceutical Technologist – Outreach Services at Aga Khan University Hospital in Nairobi.

The Aga Khan University Hospital, Nairobi, invites applications from suitably qualified individuals for the following positions:

PHARMACEUTICAL TECHNOLOGISTOUTREACH SERVICES

The Pharmaceutical Technologist will ensure accurate compounding, dispensing, patient education and handling of pharmaceutical supplies for all orders. S/he will provide effective pharmaceutical services to meet customer needs. Applicants for the position must have a Diploma in Pharmacy and a Practicing License from the Pharmacy and Poisons Board of Kenya. S/he should be registered with the Kenya Pharmaceutical Association and have a minimum of six (6) years hospital experience working in pharmaceutical services. Clinical pharmacy experience and evidence of continuous education will be an added advantage. The successful candidate should be flexible and willing to work in any of the outreach centres countrywide.

To Apply:
Applications together with detailed Curriculum Vitae, names of three referees, telephone contact, e-mail address and copies of certificates and testimonials should be sent to the Manager, Recruitment, Aga Khan University Hospital, Nairobi. P. O. Box 30270-00100, NAIROBI or by email to hr.recruitment@aku.edu

so as to reach not later than 3rd August 2012. Applications by email are preferred quoting the position as the subject. Visit our website www.aku.edu for more information.

Only short listed candidates will be contacted.


Vacancies → Pharmacist

Our client, a well established medical supplier dealing in supply of dental, theatre, surgical and other general hospital equipments and machines, wishes to recruit a qualified Pharmacist. S/he will report to the Managing Director.

Duties and Responsibilities:

·         Manage company registration with the necessary Pharmaceutical board(s) among other government agencies.

·         Dispense medications following prescriptions issued by an authorized medical practitioner.

·         Performs or oversees the performance of packaging, labeling, measuring, compounding, storing, charging, and recording medications used in patient care.

·         Reviews prescriptions for appropriateness of therapy to determine ingredients needed and to ensure correct dosage.

·         Inventories, orders, and maintain supply of drugs, chemicals, and other pharmaceutical stock.

·         Advice patients and care providers of potential drug interactions, possible side effects, storage information, and instructions on usage of the medications.

·         Prepares sterile products for patient administration; determines proper preparation, packaging, sterilization, storage, and stability requirements of the product.

·         Trains and supervises Pharmacy Assistants as assigned.

·         Develops or participates in clinical pharmaceutical research.

Knowledge, Skills and Abilities:

·         A degree in pharmacy from a reputable university

·         Must be licensed as a Registered Pharmacist with the Drugs and Poisons board of Kenya

·         Knowledge of chemical, biological, and comparative therapeutic properties of a wide range of drugs

·         Knowledge of state laws regarding regulation of pharmacy practices

·         Skill in the compounding and manufacturing of drugs

·         Team player with an added advantage as a member pharmaceutical Society of Kenya

If you are a qualified and interested candidate, send your updated CV and a cover letter toapply@kenyajobsconnection.com by 27th July 2012.

Kindly indicate Pharmacist position on the subject line.

 


Poor Quality Enzoy vitality drink adulterated with Sildenafil citrate 

It has come to the notice of PPB that the following medicine is not registered by PPB, has a quality problem and is adulterated with Sildenafil citrate:

 

Name of Product:            Enzoy Vitality Drink

Batch numbers:               GML/EZ 13/10/11 and GML/EZ 15/12/11

Manufacturing Date:       Oct. 2011 and Dec 2011

Date of Exp:                     Sept. 2013 and Nov 2013

Packing size:                   10g sachets (shown below)

Manufactured by:            Global Merchants Ltd, Nairobi

Country of origin:             Kenya

 

Nature of Problem: Product adulterated with Sildenafil citrate and fails to comply with specifications for microbial load test. 

 

You are required to quarantine any stocks of Enzoy vitality drink mentioned above and inform the Pharmacy and Poisons Board immediately.




Quinine Sulphate Tablets BP manufactured by “FARMACEUTICOS Lakeside, Netherlands” not registered by PPB and has a quality problem.

 

It has come to the notice of PPB that the following medicine is not registered by PPB and has a quality problem:

 

Name of Product:            Quinine Sulphate Tablets BP

Batch numbers:               D469

Manufacturing Date:       Oct. 2009

Date of Exp:                     Oct. 2013

Packing size:                   1 x 1000 tablets

Manufactured by:            FARMACEUTICOS Lakeside SA DF. S. C. V.

Country of origin:             Netherlands

 

Nature of Problem:  Product not registered by PPB and does not contain Quinine Sulphate.

 

You are required to kindly check and quarantine any stocks of Quinine Sulphate manufactured by “FARMACEUTICOS Lakeside, Netherlands” and inform the Pharmacy and Poisons Board immediately.


Quality Assurance Manager Post in Nairobi Kenya

 

USAID | Kenya Pharma is a USAID funded project managed by Chemonics International that seeks to establish and operate a reliable, sustainable pharmaceutical supply chain management system. 
Its aim is to forecast, procure, store, and distribute drugs, supplies, and equipment needed for the care and treatment of persons with HIV/AIDS in Kenya. 
Kenya Pharma has the following vacancy.
Position Title
: Quality Assurance Manager
Reports to: Director of Technical Coordination
Location: Nairobi
 
Position Description
The Quality Assurance Manager oversees all aspects of the quality assurance component of the project. Working with subcontractors and suppliers, s/he ensures the quality and suitability of pharmaceuticals and commodities procured for the project.

S/he ensures the quality and safety of delivered products through independent testing and ensures that project staff and all subcontractors follow proper pharmaceutical handling procedures to guarantee that product quality is maintained. 

S/he will also keep up to date on HIV/AIDS-related pharmaceutical information and ensure that the project makes procurement decisions based on the latest information about drug safety and availability.

Specific Duties:

1. Subcontract management: Liaise with, and oversee, subcontractors on inspection, sampling and chemical analysis of procured commodities prior to shipment.
2. Procurement: Manage technical aspects of the procurement component; update RFPs with technical specifications and requirements of products to be procured; update procurement manual with the quality assurance requirements; advise the bid and evaluation committee on products’ and manufacturers’ documentation relating to Pharmacy and Poison’s Board registration and USFDA approval; undertake supplier prequalification and selection.
3. Inspection, sampling and analysis: Work closely with the warehouse team to undertake inspection and sampling of commodities in the warehouse prior to distribution. Carry out regular random sampling and quality checks on products supplied; analyze reasons for poor quality, with the aim of minimizing the incidence of this problem; liaise with local and international WHO prequalified labs in undertaking laboratory analysis of products procured by Kenya Pharma.
4. Management of medical waste: Work with the necessary national regulatory authorities (NEMA and PPB) to ensure safe disposal of medical waste i.e. expired, damaged or obsolete commodities.
5. Drug quality concerns: Investigate and respond to customer concerns relating to drug quality; develop a database of reported cases of adverse drug reactions, labeling changes, safety alerts and recalls; oversee the drug recall process; carry out post-distribution surveillance to identify and respond to customers’ complaints and needs.
6. Drug manufacturer and supplier audits: Carry out manufacturer/supplier audits to ensure compliance with Good Manufacturing Practices and Good Distribution Practices.
7. Documentation, Storage and handling: Develop data collection tool templates for QA, storage and handling; oversee the development, implementation and review of standard operating procedures, systems and work instructions on QA, storage and handling, compliant with Government of Kenya laws and regulations, ISO 9001:2008 principles, Chemonics International procedures and USAID rules and regulations
 
Minimum Qualifications
    Formal education and license in pharmacy at the masters level (or higher);
    At least 5 years’ demonstrated experience in pharmaceutical management;
    Demonstrated knowledge of pharmaceuticals and commodities for HIV/AIDS, particularly Anti-Retroviral Therapy (ART) regimens;
    Demonstrated knowledge of Quality Assurance procedures and QA program implementation, particularly laboratory operations analysis and process improvement;
    Ability to effectively communicate both orally and in writing;
    Demonstrated ability to administer effective working relationships with senior Government personnel, health workers, procurement officials, U.S. and foreign government organizations, and the private sector;
    English fluency.

Send your CV and cover letter with three professional referees to
recruit@kenyapharma.org not later than 22 July, 2012.

Please include position title in the subject line of the email.
For a more comprehensive scope of work for this position, visit
http://www.kenyapharma.org/about_us/careers
Register your CV with Us For Free.  


Nairobi Hospital CME schedule for July.

 

DATE

TOPIC

SPEAKER

03/07/12

12.30pm

Vaccines and How they work - The future of Vaccination

Prof. Omu Anzala,

Chairman - Medical Microbiology University of Nairobi 

10/07/12

12.30pm

Recent Advances in Technology in  Urology and Onco-Urology

Dr. Kandarp Parikh Ms. Mch, DNB. Honorary Onco-Urosurgeon, Urologist and Kidney Transplant Surgeon

31/07/12

12.30pm

Challenges in Management of Epilepsy

Dr. Donald P.  O. Oyatsi

Consultant Paediatrician/ Neurologist



NQCL Director Job Opportunity in Kenya

 

National Quality Control Laboratory- NQCL
Employment Opportunity in The National Quality Control Laboratory
The National Quality Control Laboratory (NQCL) is a body corporate established under Cap 244 of the Pharmacy and Poisons Act with the mandate to perform chemical, biological, biochemical, physiological and pharmacological analysis and other pharmaceutical evaluation of locally manufactured and imported drugs or medicinal substances with the view of determining whether such drugs comply with the requirements of the above act.
The National Quality Control Laboratory (NQCL) wishes to recruit a competent candidate for the position of Director as outlined below:-

Director:
REF. NO. NQCL/HR/05/2012

The Director will be reporting to the Board of Management and will be responsible for day to day management of the laboratory.

Key responsibilities:
    Articulating the policies of the board arid ensuring that appropriate business strategies are developed and implemented.
    Coordination of all official activities related to the quality control of pharmaceuticals and medical for human and veterinary carried out at the laboratory.
    Monitoring performance and putting into place the necessary management and administrative systems and procedures
    Ensuring the proper allocation and utilization of resources in order to achieve organizational goals and objectives of the laboratory
    Ensuring that modern human resources management practices are adopted and implemented
    Ensuring compliance with statutory requirements and any agreed protocols.
    Enhancing the image of the organization
    Advising the board on quality standards to be applied to pharmaceutical products and medical devices approved for the Kenyan market.

Qualification, competencies and experience
    Holds a minimum of a Master Degree in pharmaceutical analysis
    Post graduate qualification in Business Administration or related fields will be an added advantage
    Has at least 5 years working experience in Senior Management
    Must be a registered pharmacist with the Pharmacy and Poisons Board
    Has excelled in such functions as Strategic Planning, people management, resource mobilization and donor relations.
    Has a proven track record of professional integrity, good conduct, visionary leadership, staff development and motivation.
    Is an effective communicator, dealing effectively with local and international stakeholders.

If you believe you are the right candidate and can clearly demonstrate your ability to meet the criteria given above, please submit your application together with copies of your certificates, detailed CV, stating your current position, current remuneration level, email and telephone contacts quoting the job reference number for this position as indicated above so as to reach us on or before 11th July, 2012 addressed to:-

The Chairman
Board of Management
National Quality Control Laboratory
Hospital Road, KNH Complex
P. O. Box 29726 - 00202
Nairobi, Kenya.

Note that any form of direct or indirect canvassing will lead to automatic disqualification. 

NQCL is a World Health Organization (WHO) pre-qualified quality control laboratory 


UoN holds ground breaking ceremony for the School of Pharmacy Building

The foundation stone for the building was laid by Prof. George Magoha, Vice Chancellor, University of Nairobi, who led University staff members, students and alumni in a colourful ceremony for the School of Pharmacy building.The state of the art building will improve the School’s learning environment, attract collaborators and spur research geared towards attaining Vision 2030. In addition, the customized building will give the School the much desired corporate image of a world class University.In his remarks, Prof. Magoha challenged the School’s alumni to support the project by either endowing a lecture hall or sourcing for resources that will see the successful completion of the building.Established in 1974, the School of Pharmacy has grown to be a leader in the training of pharmacy professionals, innovative research and provision of quality pharmaceutical services. Currently, it is the only facility in Kenya offering degree courses in pharmacy at both undergraduate and postgraduate levels.In attendance was Prof. Peter Mbithi, Deputy Vice Chancellor, Administration and Finance, Prof. Prof. Isaac O. Kibwage, Principal, College of Health Sciences, various college principals, deans and directors.To mark the occasion, there was a ceremonial tree planting session that saw Prof. Magoha, Prof. Mbithi and Prof. Kibwage plant herbal trees.The site is next to Kenyatta National Hospital Casualty Unit bordering the Hospice plot.

 

REGIONAL PHARMACY AND COMMODITY MANAGEMENT SPECIALIST-MSH NAIROBI.

 

The Regional Pharmacy and Commodity Management Specialist (RPCMS) is responsible for coordinating, organizing and facilitating the supply chain management and appropriate medicines use activities for pharmaceutical and other medical or laboratory commodities in the region with a goal of ensuring their continuous and adequate availability at all facilities in the region, including but not limited to health commodities used in HIV/AIDS, TB, malaria, reproductive health and essential medicines program.

He/She will leverage on MSH/HCSM and partner resources and technical teams to strategize and/or implement workable solutions to ensure availability of health commodities at health facilities, including medicines and laboratory supplies.

The RPCMS will be responsible for providing technical leadership during implementation of pharmaceutical and commodity management interventions; strengthen coordination of pharmaceutical and commodity systems strengthening activities at regional level in support of the essential medicines and priority health programs such as HIV/AIDS, TB, Malaria and RH.

In addition, He/She will also be expected to represent MSH/HCSM at the regional level in other related health fora convened by the government and other implementing partners. The RPCMS will promote collaboration and best practices in the supply chain management; provide linkages with national level initiatives led by the GOK’s Ministries.

He/she will also advocate for pharmaceutical and commodity security strategies that integrate regional health facilities and their management in the planning, resource mobilization and monitoring activities.

Qualifications and Experience

·                          The successful candidate should possess a degree in pharmacy, laboratory sciences, medicine or a related field or must have attained post graduate qualification in a health related field. He/She should have at least 5 years relevant professional working experience.

·                          Candidate with an MPH will have an added advantage. In addition, applicants should possess significant experience working with the Kenya public health services, preferably with an NGO, on programs related to pharmaceutical management, logistics and systems strengthening or improving laboratory commodities management.

·                          He/she should have demonstrated experience in providing technical assistance to public health programs or projects and familiarity with broad based, multi sectoral framework and approaches to pharmaceutical and commodity management at the country, regional or global level.

Candidates will ideally be living in one of the mentioned regions, or be willing to relocate, and must be willing to travel extensively within the region and in the country. Expected travel is at least 50%.

Management Sciences for Health is an equal opportunity employer offering employment without regard to race, color, religion, sex, sexual orientation, age, and national origin, and citizenship, physical or mental handicap.

For further detail and to apply for this position, please visit the Employment Opportunities section of our website at www.jobsmsh.icims.com by 13th July, 2012.

If you cannot apply online or have difficulty doing so, please email an explanation of your problem to iRecruiterproblem@msh.org

Only shortlisted candidates will be contacted.


MIMOSA PHARMACY-PHARMACISTS JOB VACANCY.

 

We are looking for pharmacists for our expanding network.

 

The ideal candidate will be:

Bachelor of Pharmacy graduates (or equivalent).

Registered with the Pharmacy and Poisons Board.

In possession of a current practice license.

Have at least 2 years post-qualification experience in a busy upmarket retail pharmacy.

Confident, knowledgeable, presentable and well spoken.


If you believe your background and qualifications meet our requirements, please send your updated CV, copies of relevant certificates and testimonials under confidential cover to:

Strategy & Human Resources,

Mimosa Pharmacy Ltd 

2nd Floor Empress Plaza, Westlands

or email marym@mimosapharmacy.com to be received at our offices not later than 15th July 2012.

Only shortlisted candidates will be contacted.


ROCHE: Regulatory Affairs Pharmacist: East Africa

 

The position

 

Key responsibilities for this position include, but are not limited to:

  • To effect registration of medicines and obtaining approval for new indications of products according to the business strategy, as well as the maintenance of current product dossiers.
  • Provide advice and guidance to relevant Roche departments regarding local legislation, pharmacy practice, internal guidelines, directives and SOP’s.
  • Ensuring the submission and approval of dossiers/new indications within the Roche Global timeframes.
  • Ensure all action within East Africa comply with all aspects of local legislation relating to medicines and pharmacy practice and other internal guidelines, directives & SOP’s.
  • Ensure that collection, reporting and handling of safety information associated with Roche products is performed according to the global, local, regulatory requirements and company policy.
  • Provide and process medical safety information locally, to support all activities (local, regional and global) which have relevant safety aspects, and to maintain links and liaison with the Management Centre Local Safety Responsible, other internal parties and external parties on Safety matters.
  • Assume responsibility for educating and training relevant personnel in the affiliate.

The successful candidate should be in possession of:

  • Bpharm Degree
  • Relevant registration/regulatory courses beneficial
  • Minimum 3 years experience in the Health Care Industry, areas of registration and regulatory

The following special skills are key to this role:

  • Excellent communication and persuasive skills.
  • Good interpersonal skills and self motivated with a demonstration of initiative
  • Strategic with great problem solving and analysis skills
  • Ability to work independently as well as in a team
  • Computer Literacy in MS Office
  • Willing to travel to East Africa regions
  • The successful candidate must be fluent in English.

Who you are

 

You’re someone who wants to influence your own development.

 

You’re looking for a company where you have the opportunity to pursue your interests across functions and geographies, and where a job title is not considered the final definition of who you are, but the starting point.

 

The vacancy is based in Kenya, responsible for Rwanda, Ethiopia, Uganda, Tanzania and Sudan.

 

The next step is yours.

 

To apply forward your application together with a detailed CV for the attention of: Simplicity Paneng, on simplicity.paneng@roche.com by 29 June 2012

 

Late applications will not be considered.


 Medical Representative: Laboratory and Allied 


Laboratory and Allied a fast growing pharmaceutical and medical company dealing in the production of both Human and Veterinary products is currently looking for the most competent and suitable personnel to fill the 3 vacancy positions of a Medical Representatives.


He will be reporting to the Marketing Manager.


Job Duties And Responsibilities

  • Arrange appointments with medical teams, doctors and pharmacists
  • Making presentations to the medical professionals like: doctors, pharmacists, nurses, practice staffs and to all the necessary personnel related to the sector concerning the products.
  • Build and maintain positive connections and working relationships with medical personnel and also with the supporting administration.
  • Contact customers to find out the needs of the customers, to uphold about the product to the customers, try to satisfy the needs and ensure the terms and conditions of the sale be concerned about the opinion of the customers after selling the product.
  • Monitor what are the competitive companies doing and about their products and how are they taking steps for taking the market and defeating others.
  • Getting information about the after effect of the product and how the users and consumers reviewed about the product.
  • Monitor and anticipate positive and negative effects and impacts of the market to the product and adapting proper strategy to prevent that.
  • Attend company meetings regularly; collect technical data, presentations and briefings.
  • Presenting and discussing the present which is supplied by the company with healthcare and medical professionals.

Academic Qualification

  • Degree holder in pharmacy/ Bsc.in science.
  • Must have a minimum of 3-5 years working experience in the respective position.

Other Qualification

  • Strictly MALE medical representative.
  • Must have worked in Eldoret, Kisumu and Mombasa.
  • Specifically only medical representative no sales representative.
  • Self- oriented/ self -driven person.
  • Good achievement track.

Urgently-needed:-ASAP.
Note: Only Serious Candidate Should Apply.


Kindly send your CV’s, copy of the Identification Card and other testimonials either through hand delivery or email to hr@laballied.com or marketing@laballied.com


Only successful applicants will be shortlisted and an interview will be conducted.


 Manufacturing Pharmacist 

 

SUMMARY    
Our client is one of the world’s leading research-based pharmaceutical and healthcare companies. They are looking for a highly motivated, ambitious and enterprising individual to join their Global Manufacturing and Supply Department as a 
Manufacturing Pharmacist.
The successful candidate’s principal job purpose will be to manage manufacturing operations, as per the agreed supply plan in accordance with legal pharmaceutical requirements and ensuring compliance within the value stream. 
This position reports to the Head of Production.

KEY RESPONSIBILITIES
•    Ensuring products are manufactured to the required quality and compliance standards.
•    Managing the implementation of the Company’s Quality Management System to ensure compli-ance with global standards.
•    Ensuring products are manufactured to the required Environmental Health and Safety standards.
•    Scheduling agreed supply plans, in conjunction with planners, to optimize manufacturing opera-tions and achieve maximum utilization of resources within the Value Stream.
•    Executing production activities in accordance with the agreed supply plan.
•    Ensuring plant and equipment are managed and maintained to achieve optimal performance.
•    Managing and motivating staff to achieve the agreed supply plan e.g. facilitating appropriate train-ings, monitoring staff attendance and conducting appraisals. 
•    Ensuring continuous improvements within manufacturing so as to reduce costs, increase produc-tivity and improve quality.

REQUIREMENTS
•    A Bachelors Degree within a Pharmaceutical field.
•    At least five (5) years work experience in a manufacturing pharmaceutical environment. 
•    Experience within a managerial role will have an added advantage.
•    Excellent interpersonal, communication and people management skills.
•    Impeccable integrity, passion for excellence, commitment and flexibility.
•    A good understanding on the various manufacturing practices, processes and principles is critical.
•    Good financial management e.g. activity based budgeting and controlling budgetary allocations.

How to apply: 
Send your application including a cover letter indicating your desire to work with our client; a detailed CV highlighting relevant experience, details of current and expected salary, a day time phone contact, email address, and the names of three professional referees by close of business Tuesday, 3rd July 2012.

Adept Systems
MANAGEMENT CONSULTANTS
P O Box 6416, Nairobi, GPO 00100
Email: 
recruit@adeptsystems.co.ke
Web:
 www.adeptsys.biz


Suspension of Market Authorization and Withdrawal of various medicines manufactured by: Saga Laboratories Ltd by the Pharmacy and Poisons Board-Clarification!

 

25/6/2012, On 18/6/2012 we published an article stating that the Pharmacy and Poisons Board had announced the Suspension of Market Authorization and Withdrawal of various medicines manufactured by: Saga Laboratories Ltd, Plot No. 1409, Phase III, G.I.D.C estate, Vatwa, Ahmedabad-382 445 after they failed to meet PPB cGMP requirements.

The board has since clarified that Saga Laboratories Ltd, survey no: 198/2, 198/3, Chachrawadi Vasna, Tal. Sanand, District Ahmedabad 382 210 site, does meet its cGMP requirements at present and hence products from this site are compliant at present.

 

Kindly reconfirm the site of manufacture of the products that you may be having.


Market Access Manager-Roche

Key responsibilities for this position include, but are not limited to:
 

Develop and implement a public sector strategy to improve access to Hoffmann-La-Roche-products
 

Engage & persuade senior decision-makers in order to improve reimbursement and access to Roche’s products.
 

Development of local patient access programs
 

Develop and implement clinical and economic tools (Pharmacoeconomic models, Budget Impact models and Value Dossier) that promote the value of Roche’s products and improve funding in private medical schemes, corporate and government.
 

Develop and Publish materials in conjunction with local KOL’s to show economic value of assigned products within the country’s health care setting.
 

The successful candidate should be in possession of:

  • A Degree in Health Sciences (e.g. BPharmacy/MBChB /BSc)or equivalent qualification;
  • Health Economics/Pharmacoeconomics/Public Health or Business qualification beneficial
  • Minimum 3 years experience in the Health Care Industry & minimum of 3 years previous experience in areas of Managed Care, Reimbursement, Access an advantage.

The following special skills are key to this role:

  • Excellent communication, negotiations and persuasive skills.
  • Well versed in proposal writing, follow up and implementation.
  • Good interpersonal skills and self motivated with a demonstration of initiative.
  • Ability to develop good relationships with key opinion leaders in the medical industry
  • Strategic with great problem solving and analysis skills
  • A motivated and highly innovative person with the ability to work independently as well as in a team
  • Computer Literacy in MS Office
  • The successful candidate must be fluent in English.

Who you are 

You’re someone who wants to influence your own development. 

 

You’re looking for a company where you have the opportunity to pursue your interests across functions and geographies, and where a job title is not considered the final definition of who you are, but the starting point.

 

The next step is yours. To apply forward your application together with a detailed CV for the attention of: simplicity Paneng on simplicity.paneng@roche.com by 29/6/2012.

Late applications will not be considered.
If you have not heard from us two weeks after the closing date, kindly consider your application as unsuccessful.

 


Pharmacy Manager- Belladonna Pharmacy
Ltd

Belladonna Pharmacy Ltd, an established retail pharmacy, has offered services to its esteemed clientele from the Village Market Shopping Mall since 1992.


Through Belladonna Healthcare Services, we have partnered with Manipal Hospital (www.manipalhospitals.com) in Bangalore, having 15 branches and over 5,000 doctors in Southern India, to provide medical safari services in Kenya and East Africa at large.


Based on the above, the Board has created the position of a Pharmacy Manager to ensure our standards are enhanced and the growing business is well managed.


About the Position

  • Reporting to the Board, the Pharmacy Manager will undertake the following duties and responsibilities:
  • Ensure that the pharmacy is run in an efficient and professional manner;
  • Give regular reports to the Board as required and implement the Board’s vision;
  • Supervise Staff and ensure targets are met, undertake performance appraisals, and oversee the pharmacy’s intern programme;
  • Ensure proper dispensing of prescriptions by following standard operating procedures for receiving, filling, dispensing, logging, and maintaining loss prevention controls;
  • Strengthen compliance with regulatory procedures and other industry standards including ensuring strict adherence to ethical and professional values;
  • Provide advice to patients in managing their pharmaceutical needs;
  • Ensure proper maintenance of records such as pharmacy files, clients profiles and charge file systems
  • Be the principal liaison with regulatory authorities and professional bodies that affect pharmacy
  • practice; and
  • Ensure that the pharmacy maintains a technological edge that will ensure that its efficient operations with top of the range customer care services.

Qualifications

  • At least a degree in Pharmacy from a reputable university;
  • At least 5 years experience in the management of a busy and reputable community pharmacy;
  • Excellent communications skills, be compassionate, a team player and demonstrate leadership;
  • Must be registered with the Pharmacy and Poisons Board; and
  • Must be a member of Pharmaceutical Society of Kenya (PSK)

Remuneration


A competitive package will be offered to the right candidate. 

 

Terms are negotiable, commensurate with qualifications and experience.

 

All applications must be received by 6th July 2012. 

 

Applications must include: C.V, Academic and Professional Certificates, three referees, and a daytime email contact. 

 

The applications should be sent to:


Village-Market-Shopping-Complex-Gigiri
Tel:+254-207122141 Mobile:+254-735122147 Fax:+254207122147
Email:admin@belladonnahealthcare.com
www.belladonnahealthcare.com


Area Manager – Universal Corporation.   

Category:

Sales & Marketing

Location:

Nairobi, Kenya

Employment Type:

Full-Time

 

 

Summary:

UCL is a growing Pharmaceutical Company in East & Central Africa.

 

To strengthen our team we require to fill the following vacant position.

Description:

Job Responsibility:

To effectively handle a sales team of 4/6 medical reps, Monitoring and enhancing performance through Support in terms of;

*       Ensuring that targets set are achieved,

*       Growing profitability in the product portfolio,

*       Execution of marketing strategies in collaboration with the marketing manager,

*       Regular in-depth sales analysis,

*       Creating valuable business relationships with the Key Customers including Retailers, Distributors, Doctors and Institutions,

*       Reporting to H.O.D as per schedules.

*       Reporting to Business Development Manager.

*       Growing market share of UCL’s products in his territory including entry of products into institutions.

Reports to Business Development Manager.

Requirements:

The candidate should have:

*       Flair for Sales & Marketing.

*       Bachelor of Pharmacy/Bachelor of Science/ Diploma in Pharmacy from a recognized institution.

*       Bachelor of Pharmacy and Diploma in Pharmacy applicants must be enrolled with PPB.

*       5 years relevant experience in Pharmaceutical Sales and Marketing.

*       1-2 year experience as a Pharmaceutical Sales and Marketing Area Manager.

*       Degree or Diploma in Management will be an added advantage.

*       Computer knowledge and analytical skills.

NB:

•Mention your email and phone numbers

•Basic computer knowledge is a requirement

•State current and expected remuneration

Please apply stating on the Subject line which position you are applying.

 

Closing Date:

29 June 2012

 

You can also apply through post:

To The Human Resources Office,

Universal Corporation Ltd,

P. O. Box 1748 00902,

Kikuyu.

 

 

 


Job Vacancy:Pharmacist.

A Pharmaceutical Company based in Nairobi requires a Pharmacist with over 2 years experience.

Kindly send your Application letter and CV to meditechkenya@gmail.com or info@meditechinternational.net

For more information about Meditech International PVT Ltd. please visit www.meditechinternational.net


CHEMIST FOR SALE:


Limuru Road, Nairobi. Asking 500,000/=

Contact sales manager, Pharmaudit Kenya, email pharmauditkenya@gmail.com or log on to our website www.pharmauditk.kbo.co.ke.


Researchers at CCMB make breakthrough discovery to contain diabetes.

A team of researchers at the Centre for Cellular and Molecular Biology (CCMD) in Hyderabad have come out with a major breakthrough discovery to contain diabetes by successfully deactivating a gene to regulate the functioning of beta cells in pancreas. The malfunction of these beta cells leads to non-production of insulin or production of ineffective insulin.

The research team conducted the experiments on the mouse model. In this model, the researchers could successfully regulate the mass of beta cells in pancreas of the mouse. Analysts say that this new research outcome will have many medical implications, the major among them being the successful management and control of diabetes. The quantity of pancreatic beta cells determines whether a person is diabetic or normal.

The members of the research team included Dr Satish Kumar, D Partha Sarathi, Shalu Singh and Vijay Pratap. The researchers created a mouse model without the presence of the gene, Wdr13 (WD-repeat protein), using genetic engineering technology. The team inactivated or knocked out the gene by disrupting it through insertion of an artificial piece of DNA in the embryonic stem cells.

The removal or inactivation of the gene WDr13 in mouse model led to formation of more pancreatic mass in the islets of Langerhans. This showed that the knocking of the gene would lead to formation of more beta cell mass in pancreas. The mouse showed higher levels of insulin in blood serum, and thus better management of blood glucose. This in other words means knocking off the gene WDr13 will help diabetics to clear blood glucose quite effectively.

According to the CCMB team, the protein could be helpful in finding a potential drug target to treat diabetes, which is becoming a major health problem. The team is now busy studying the health implications of the knocking off the gene WDr13 as the person ages.


Heavy tea drinkers at greater risk of prostate cancer: Study

The University of Glasgow study found that men who are heavy tea drinkers are having more chances of developing prostate cancer. The research was published in the journal ‘Nutrition and Cancer’.

The study, which was led by Dr Kashif Shafique of the Institute of Health & Wellbeing at the University of Glasgow tracked the health of more than 6,000 male volunteers over a period of 37 years and discovered that those who drank more than seven cups of tea per day had a 50 per cent higher risk of developing prostate cancer compared with non-tea drinkers or those drinking less than four cups per day.

The Midspan Collaborative study began in Scotland in 1970 and gathered data from more than 6,000 male volunteers, all between 21 and 75 years of age. Participants were asked to complete a questionnaire about their usual consumption of tea, coffee, alcohol, smoking habits and general health, and attended a screening examination.

Just under a quarter of the 6,016 men included in the study were heavy tea drinkers. Of these, 6.4 per cent developed prostate cancer during a follow-up of up to 37 years. Researchers found that men who drank more than seven cups of tea per day had a significantly increased risk of prostate cancer compared to those who drank no tea or less than four cups per day.

Dr Shafique said, “Most previous research has shown either no relationship with prostate cancer for black tea or some preventive effect of green tea. We don’t know whether tea itself is a risk factor or if tea drinkers are generally healthier and live to an older age when prostate cancer is more common anyway.”

“We found that heavy tea drinkers were more likely not to be overweight, be non alcohol-drinkers and have healthy cholesterol levels. However, we did adjust for these differences in our analysis and still found that men who drank the most tea were at greater risk of prostate cancer.”

Prostate cancer is the most common cancer amongst men in Scotland and between 2000 and 2010 incidence increased by 7.4 per cent.

The University of Glasgow is the fourth oldest university in the English-speaking world. Its broad-based, research intensive institution with a global reach.


Suspension of Market Authorization and Withdrawal of various medicines manufactured by: Saga Laboratories Ltd by the Pharmacy and Poisons Board.

 

18/6/2012, The Pharmacy and Poisons Board today announced the Suspension of Market Authorization and Withdrawal of various medicines manufactured by: Saga Laboratories Ltd by the Pharmacy and Poisons Board. 18/6/12.

 

The table below provides information of the products being withdrawn. The mentioned products are being withdrawn from the market with immediate effect following failure to comply with current Good Manufacturing Practices (cGMP).

 

Anyone in possession of the same is required to immediately return them to the manufacturer / supplier, who is in turn coordinating a National Recall with the Pharmacy and Poisons Board.

 

Any patients currently taking these medicines are required to consult their nearest healthcare provider for further advice.

 

Healthcare providers are advised to ensure that no patients are further initiated on the mentioned medicines.

 

Your earliest cooperation in the same will be appreciated.

 

 For further clarification, please contact:

 

The Registrar,

Pharmacy and Poisons Board

Nairobi

Tel: 020-3562107, 0733 88 44 11 or 0720 60 88 11

E-mail: info@pharmacyboardkenya.org or pv@pharmacyboardkenya.org

 

LIST OF WITHDRAWN PRODUCTS: SAGA LABORATORIES LTD

Manufacturer:

Saga Laboratories Ltd

Plot No. 1409, Phase III,

G.I.D.C estate, Vatwa,

Ahmedabad-382 445

 

Product                                              Formulation                 Active Pharmaceutical Ingredient

1 Zimycin 200mg/5ml                                  Suspension                                                      Azithromycin

2 Zimycin 500                                                Tablets                                                             Azithromycin

3 Fulcover 100mg                                         Capsules                                                            Itraconazole

4 Zyrtal OD                                                     Tablets                                                                Aceclofenac

5 Zyrtal SP                                                      Tablets                             Aceclofenac + Serratiopeptidase

6 Zyrtal MR                                                     Tablets        Aceclofenac + Chlorzoxazone + Paracetamol

7 Razid 20mg                                                 Tablets                                                             Rabeprazole

8 Razid-M                                                       Tablets                                       Rabeprazole + Mosapride

9 Diuride 10mg                                             Tablets                                                                  Torsemide

10 Diuride 20mg                                           Tablets                                                                 Torsemide

11 Ceflorex 100mg/5ml                              Syrup                                                                        Cefixime

12 Effercet                                                     Tablet                                                               Paracetamol

 


Pharmacy's big bucks

If you thought kenya is the only place where pharmacy is in a mess then read this article on the situation in the USA to understand the magnitute of the problem we are in……

That rumble you hear in the distance is not thunder. It is the roar made by pharmacists finally getting together and talking. Decades of whining and complaining have made us look like little girls whose pigtails get pulled on the playground. We have been grumbling and protesting since 1970, and what have we got from it? Nothing. No respect. Deteriorated conditions. "They" aren't even afraid of us, and their entire businesses are dependent on us cooperating.

That, my friends, is idiocy. No pharmacist, no pharmacy. A warm body with a license, and you get paint by numbers.

Smart rats change the game

Students are much smarter rats than they have ever been. They observe their preceptors' enduring indignities and they vow, "Not me." Recently I received an e-mail from a student. He concluded with this: 
"Remember the good old days of the neighborhood pharmacy where people knew each other, talked, and trusted each other? Somewhere along the way, our profession has allowed the bureaucrats to dictate what we should be doing, whether we should be eating lunch, or how many prescriptions we have to fill in X amount of time. Perhaps it is time we push back and say enough is enough."

That is from a kid who has not worked his first day as a registered pharmacist. He actually believes he can make a difference, and that makes him and his fellows very, very dangerous.

Pharmacists are fed up with the Prescription Mill conditions in retail that have smothered the practice practically to death. They are starting to remember that this is their profession, and they are getting ready to leave some blood and teeth on the floor to take it back.

Consider this

Let's guess that 90% of all office visits end at the pharmacy. Last year, 10% of our entire medical care budget went to Rx costs. In 2009, our industry sold $250 billion worth of prescriptions–up from $105 billion in 1999. That is an astounding 138% increase. We are headed to 1 trilliondollars in prescriptions, and sooner than later, is my call.

What does a drugstore chain need in order to get its share of the booty that is coming? Investors? An accomplished board of directors? MBA Masters of the Universe types, whose good ideas have practically killed the golden goose?

There is only 1 asset that the corporations cannot get along without.Pharmacists!

What is it about that kind of power that you don't understand? How does that not make the 3 men sitting at the tippy-top of the Big 3 drugstore companies tremble when they see just how tenuous their situation is?

The elephant in the pharmacy

Without pharmacists, those people are flat out of business. Why do you think they paid $20k sign-on bonuses and gave cars to kids 6 months before they even graduated? Did you know that a K-Mart on Whidbey Island had to remove all pharmacy signage because it could not find a pharmacist? Think about it.

I honestly believe that there are very few pharmacists who are so bitter that they are looking to blow up the ship. That would be lunacy. But thereare lunatics out there. You can see it in their eyes and in the set of their lips. They are the Yes Men, who are liable to go off in a righteous outburst at any time.

Three men rule over more than 20,000 drugstores. They have ultimate power over more than 50,000 pharmacists. What is wrong with this picture?

Practicing pharmacy has become a discretionary act, because counseling patients is a discretionary act. Painting by the numbers does not work here. That's for the Prescription Mill. In your practice of pharmacy, these 3 men have absolutely no standing.

Where it stops

Two of these men are pharmacists. One was spawned in the grocery business. One wears a white hat, one a black hat, and one a dunce cap. They preside over an industry that is a professional failure. What they have done has not worked. The ridiculous PBM contracts are the prime example.

To these 3 Big Hats I say: You gotta make money, boys, and not by ripping the skin off your most important employees. You have broken it. Now you fix it.

It's a tough job, but I'll parrot what I have heard numerous nonpharmacist managers sneer to me: That's why you make the big bucks.


VACANCY ANNOUNCEMENT KEMRI/CDC RESEARCH AND PUBLIC HEALTH COLLABORATION
Opening date:8/06/2012 Vacancy No.K71/05/12

Program description: This program is collaboration between Kenya Medical Research Institute and the US Centres for Disease Control and Prevention whose remit is to conduct research in malaria, HIV and other diseases. It is in this mandate that that the TB Research Branch has a vacancy

Position: Pharmacy Quality Control Officer MR 7 (1 position)
Reports to: Pharamacy Supervisor

ESSENTIAL REQUIREMENTS
Diploma in Pharmaceutical Technology.
1 year Experience in clinical research.
Trained in Good Clinical Practice (GCP).
Must be registered by the Board

DESIRED QUALITIES
Fluency in English and Kiswahili. Knowledge of Dholuo is an added advantage.
Excellent communication skills.
Comfortable in working with Microsoft office suite
Attention to details and good organizational skills
Ability to work well with the public, in a team and able to collaborate well with counterparts.
Be willing to work in Siaya and Kisumu.
Position description: Pharmacy quality control officers will report to the pharmacist and will carry out quality control duties, occasional pharmacy duties and data collection for the clinical trials. The study will include sites at health facilities in Siaya District, Siaya District Hospital and Kisumu clinical research centre.

Specific Duties and responsibilities:
Perform pharmacy quality control and generate report routinely.
Collect Study data (when involved in pharmacy duties).
Ensure that the pharmacy is in full compliance with the GCP regulations.
Assist in data compilation and preparation of reports.
Ensure implementation of SOPs and SSPs.
Implement the internal monitoring system which includes checks on the dispensing records and accountability documents.
Develop templates and tools to assist in pharmacy activities.
Communicate problems and sends reports to the pharmacist.
Liaises with trial study pharmaceutical technologists and pharmacist to identify problems with drug management, dispensing and maintenance of quality control system in the pharmacy.
Perform any other duties as requested by the pharmacist/management.

Terms of Employment: Contract for 1 year, renewable as per KEMRI scheme of service. Probation period is for the first 3 months. Salary negotiable within the appropriate grade depending on education, experience and demonstrated competency.

Applications MUST include the following:
Letter of Application (INDICATE VACANCY NUMBER)
Current Curriculum Vitae with telephone number and e-mail address
Three letters of reference with contact telephone numbers and e-mail addresses
Copies of Certificates, Diplomas or Transcripts
Applications are due no later than: 21st June 2012 To: The Human Resources Manager KEMRI/CDC Research and Public Health Collaboration P.O. BOX 1578, 40100, KISUMU Or e-mail to: recruitment@ke.cdc.gov or log into our web 
www.jobs.cdckemri.org
Internal candidates interested in applying for this position are strongly advised to access an internal candidate application form available in the CDC Intranet; print and process it through their project Managers and attach it before forwarding their application to HR.
Only short listed candidates will be contact
ed


Job Vacancy- Pharmaceutical Technologist.

Oceanview Pharmaceutical Ltd in Mombasa

Qualification, Skills and Competence
Applicants should have:

Diploma in Pharmacy from a college licensed by the Pharmacy and Poisons Board;

KCSE C+and above.

2 years experience in a community or hospital pharmacy;

Good knowledge of variety of drugs and medical supplies;

Ability to dispense, record and report accurately;

Good communication & interpersonal skills, flexible and with proven ability to work in a team;

Proficiency in Microsoft office applications

Send Applications to;

Oceanview Pharmaceutical Ltd in Mombasa

Fimbo Building 1st Floor Digo Road,

P.O.Box 90669,80100,Mombasa

Deadline 6/7/2012


A Possible New Treatment for Drug-Resistant TB.

13/6/2012 — The addition of delamanid, a new nitro-dihydro-imidazooxazole drug, to a standard regimen improved sputum-culture conversion rates at 8 weeks in patients with multidrug-resistant tuberculosis compared with placebo.

Maria Tarcela Gler, MD, from the Makati Medical Center, Manila, and the Tropical Disease Foundation, Makati City, Philippines, and colleagues reported the results of a multinational randomized trial in an article published in the June 7 issue of the New England Journal of Medicine. At 2 months, 45.4% of patients who received 100 mg of delamanid twice daily in addition to a background drug regimen had sputum-culture conversion in liquid broth medium compared with 29.6% of patients receiving placebo plus the background drug regimen. This demonstrated a statistically significant increase of 53% (95% confidence interval, 11% - 112%; P = .008).

Patients who received a higher dose of delamanid (200 mg twice daily) had a similar rate of sputum-culture conversion (41.9%) compared with patients receiving the lower dose of the drug. The difference in conversion rate was significantly higher than in the placebo group (P = .04).

A higher proportion of patients receiving delamanid plus the background drug regimen also demonstrated sputum-culture conversion earlier than patients in the placebo group. The researchers note that previous studies have shown that faster conversion rates are associated with a reduction in the duration of treatment.

"Approximately 440,000 cases of multidrug-resistant tuberculosis occur worldwide annually, accounting for nearly 5% of the global burden of tuberculosis," write Dr. Gler and colleagues. "As a result, the Global Plan to Stop TB, 2011 through 2015, calls for urgent development of new drugs involving new mechanisms to treat tuberculosis, including multidrug-resistant tuberculosis, as a key component of the response to the epidemic."

A total of 481 patients from 17 centers in 9 countries enrolled in the trial between May 2008 and June 2010. Among these patients, 402 had positive baseline sputum-cultures involving multidrug-resistant strains ofMycobacterium tuberculosis. These patients were considered the modified intent-to-treat population and were included in the efficacy analysis. Patients were randomly assigned to receive either delamanid, at a dose of either 100 mg twice daily (141 patients) or 200 mg twice daily (136 patients), or placebo (125 patients). All treatments were continued for 2 months, and all patients were concomitantly receiving a background drug regimen based on World Health Organization guidelines.

Sputum cultures were performed weekly, using both liquid broth and solid medium, and sputum cultures that were negative for growth of M tuberculosis on 5 or more consecutive cultures were considered converted. The culture conversion rate at 8 weeks was the primary endpoint.

Drug safety was assessed via monthly physical examinations, weekly evaluation of vital signs, electrocardiograms, clinical laboratory tests, and baseline audiometry. Patients receiving delamanid had more episodes of QT prolongation compared with patients in the placebo group; however, there were no clinical manifestations of a cardiac problem among the 481 patients in the safety analysis. The incidence of hepatotoxicity was the same across all 3 treatment groups.

"This trial shows that delamanid administered with the background drug regimen for multidrug-resistant tuberculosis enhanced and accelerated sputum-culture conversion," the authors conclude.

"This is an incredibly important study, in that delamanid is the first novel antituberculous agent tested against drug-resistant TB in a clinical population," said Jennifer Furin, MD, PhD, from the Tuberculosis Research Unit at Case Western Reserve University, Cleveland, Ohio, in an interview with Medscape Medical News.

"This study shows that a significantly higher proportion of patients convert their cultures at 2 months when delamanid is given with optimized backbone therapy," said Dr. Furin, who was not involved in the study.

"More long-term follow-up will be needed to see how the drug impacts final clinical outcomes. It is also not clear if delamanid should be used up front at the start of a regimen or 'spared' for patients with highly drug-resistant forms of TB. The implications of the QTc prolongation over the long term also merit follow up," Dr. Furin noted.


 Untreatable Gonorrhea Spreading Around World: WHO

Drug-resistant strains of gonorrhea have spread to countries across the world, the United Nations health agency said on Wednesday, and millions of patients may run out of treatment options unless doctors catch and treat cases earlier.

Scientists reported last year finding a strain of gonorrhea in Japan in 2008 that was resistant to all recommended antibiotics and warned then that it could transform a once easily treatable infection into a global health threat.

The World Health Organization (WHO) said those fears are now reality with many more countries, including Australia, France, Norway, Sweden and Britain, reporting cases of the sexually transmitted disease resistant to cephalosporin antibiotics -- normally the last option for drugs against gonorrhea.

"Gonorrhea is becoming a major public health challenge," said Manjula Lusti-Narasimhan, from the WHO's department of reproductive health and research. She said more than 106 million people are newly infected with the disease every year.

"The organism...has developed resistance to virtually every class of antibiotics that exists," she told a briefing in Geneva. "If gonococcal infections become untreatable, the health implications are significant."

If left untreated, gonorrhea can lead to pelvic inflammatory disease, ectopic pregnancy, stillbirths, severe eye infections in babies, and infertility in both men and women.

It is one of the most common sexually transmitted diseases in the world and is most prevalent in south and southeast Asia and sub-Saharan Africa. In the United States alone, according to the Centers for Disease Control and Prevention (CDC), the number of cases is estimated at around 700,000 a year.

The WHO called for greater vigilance on the correct use of antibiotics and more research into alternative treatments for gonococcal infections.

The emergence of drug-resistant strains of gonorrhoea is caused by unregulated access to and overuse of antibiotics.

Experts say an added problem with gonorrhea is that its strains tend to retain their genetic resistance to previous antibiotics even after their use has been discontinued.

Major producers of antibiotics for gonorrhea include global drugmaking giants GlaxoSmithKline, Pfizer and Abbott, as well as Indian firms like Cipla.

The WHO said it is not yet clear how far or wide drug resistance in gonorrhoea has spread, as many countries lack reliable data. "The available data only shows the tip of the iceberg," said Lusti-Narasimhan.

"Without adequate surveillance we won't know the extent of resistance...and without research into new antimicrobial agents there could soon be no effective treatment for patients."

"LIKE PASSING RAZOR BLADES"

Francis Ndowa, formerly the WHO's lead specialist for sexually transmitted infections, said gonorrhea has not only adapted to elude antibiotics but developed less painful symptoms, increasing its survival chances.

"They used to say that if you have urethral gonorrhea you go to the toilet to pass urine, it would be like passing razor blades. It was that painful," he explained. "Now people with gonorrhea sometimes...only notice the discharge if they look when they pass urine, it's not that painful anymore."

"So the organism has readjusted itself to provide fewer symptoms so that it can survive longer. It's an amazing interaction between man and pathogen," Ndowa said.

Experts say the best way to reduce the risk of even greater resistance developing -- beyond the urgent need to develop effective new drugs -- is to treat gonorrhea with combinations of two or more types of antibiotic at the same time.

This technique is used in the treatment of some other infections like tuberculosis in an attempt to make it more difficult for the bacteria to learn how to conquer the drugs.

Gonorrhea can be prevented through safer sexual intercourse. The WHO said early detection and prompt treatment, including of sexual partners, is essential to control sexually transmitted infections.


 PSK & KPA TO COOPERATE ON THE FIGHT AGAINST QUACKS.

The Pharmaceutical Society of Kenya (PSK) and the Kenya Pharmaceutical Technologists Association (KPA) will be forging a united war against quacks in the pharmaceutical sector. This was announced during the annual scientific conference for Pharmacists in Mombasa last weekend. The conference was also attended by the KPA chairman and secretary. The PSK chairman Dr. Mwaniki informed the members that the PSK council was working very closely with KPA and PPB to ensure that only qualified professional are allowed to practice in the retail pharmacy sector.

 

The KPA secretary James Githinji addressed the conference. He informed participants that there are 3366 government outlets offering pharmaceutical services using unqualified personnel. He pointed out that apart from this people taking up jobs that would otherwise be occupied by Pharmacists and Pharmaceutical Technologists; they are also the same people who open illegal private outlets, urgent corrective measures need to be taken by the responsible Ministry.

The two organizations were considering holding a joint pharmacy awareness month excercise to avoid duplication of activities.

 

The conference was informed that currently there are 3000 registered Pharmacists and 5000 enrolled Pharmaceutical Technologists in the country.

 

It was announced that KPA would hold its own scientific conference in July 2012 at Bontana Hotel Nakuru, PSK members were encouraged to attend. 


Job vacancy – Pharmaceutical Technologist.

6/6/12-The Aga khan Hospital, Kisumu is seeking to recruit a Pharmaceutical Technologist.

Applicants should have a diploma in Pharmacy, enrolled with PPB, one year work experience and knowledge of computer packages.

Applications including detailed curriculam vitae, names and contact of three referees should be forwarded by 15/6/12 to:

The Human Resources Department,

Aga khan Hospital, Kisumu.

P.O. Box 530-40100,

Kisumu.

Email: ksm.recruitment@akhskenya.org 


Job Vacancy for Pharmacists: Kenya National Medicines Regulation Officer.

Employment Type:

Full-Time

 

 

Summary:

Applications are invited from suitably qualified citizens of East African Community Partner State of Kenya for the following EAC regional health sector project staff position under the East African Community Medicines Regulatory Harmonization Initiative (EACMRHI) Project tenable in the Kenya National Medicines Regulatory Authority.


(One Post) - REF: EAC/HR/HEALTH/2011-2012/006


Grade: Consolidated Salary equivalent to EAC P1 Staff Grade
Reports to: Head, Medicines Registration, Pharmacy and Poisons
Duration of Contract: Initially Three (3) Years

Description:

Main Purpose of the Job:


In liaison with the Senior Health Officer (Medicines Regulation) at the EAC Secretariat headquarters in Arusha, Tanzania as well as the Head and other relevant technical officers of the National Medicines Regulatory Authority (NMRAs) in the respective East African Community Partner States, coordinate and facilitate the harmonization and implementation of various EAC regional medicines registration and regulation policies, legislation, strategies, guidelines, standards, legal and regulatory frameworks in order to enhance the affordability, quality, efficacy and safety of both human and veterinary medicines and related pharmaceutical products and supplies that are manufactured, imported and/or traded within the East African Community region.


Duties and Responsibilities:

  • Coordinate and facilitate the harmonization and implementation of various EAC regional medicines registration and regulation policies, legislation, strategies, guidelines, standards, legal and regulatory frameworks at national and sub-national levels in the respective East African Community Partner States in order to enhance the affordability, quality, efficacy and safety of both human and veterinary medicines and related pharmaceutical products and supplies that are manufactured, imported and/or traded within the East African Community region.
  • Coordinate the development and implementation of a Common Technical Document (CTD) for registration of medicines at national and sub-national levels in the respective EAC Partner States in accordance with the existing World Health Organization (WHO) Regulatory Documentation Package, International Conference on Harmonization (ICH) Global Cooperation Group (ICH-GCG) and other relevant international guidelines and standards;
  • Support the development and implementation of a common EAC regional Information Management System (IMS) for medicines registration linked to each of the EAC Partner States’ National Medicines Regulatory Authorities (NMRAs);
  • Provide technical support in the implementation of Quality Management System (QMS) in the respective National Medicines Regulatory Authorities (NMRAs) in each of the EAC Partner States using Risk-Based Approaches (RBAs) and processes in accordance with priority public health needs with regard to enhancing access to safe, effective, quality and affordable essential human and veterinary medicines and related pharmaceutical products and supplies that are manufactured, imported and/or traded within the EAC Partner States.
  • Develop and implement capacity building programmes at both national levels and sub-national levels in support of the harmonization and strengthening of medicines registration and regulation in the EAC Partner States.
  • Support the creation and operationalization of a web-based platform for information sharing on harmonized medicines registration and regulation systems and procedures among key stakeholders at both national and subnational levels in the EAC Partner States.
  • Support the development and implementation of a regional policy as well as a legal and regulatory framework for mutual recognition of the registration and regulation of both human and veterinary medicines and pharmaceutical products and supplies based on Chapter 21, Article 118 of the Treaty on the Establishment of the East African Community.
  • Support the establishment of the decentralized East African Community Medicines and Food Safety Commission (EACMFSC) which will be an autonomous institution of the Community responsible for regional coordination of the regulation and safety of all human and animal medicines, foods, feeds as well as human and veterinary pharmaceutical products, supplies, cosmetics, devices, vaccines, vitamins, sera and others biological products that are manufactured, imported and/or traded within the EAC region.
  • Establish a national mechanism for using regulatory information from the respective EAC Partner States’ National Medicines Regulatory Authorities (NMRAs) (assessments/decisions, etc) and for making information available to the general public and other multisectoral stakeholders and partners (legislation, guidelines and lists of registered products, including rejected applications, etc.)
  • Support the implementation of the EAC regional policies, guidelines, standards, procedures as well as legal and regulatory framework for joint evaluations of dossiers and inspections of medicine manufacturing sites and to ensure that these assessments are integrated into national and subnational decision-making processes as applicable.
  • Build national capacity to implement medicines registration and regulation harmonization (including developing a capacity building programme for technical, financial and management staff and project management inc. monitoring and evaluation) including contributing to the establishment of the decentralised East African Community Medicines and Food Safety Commission (EACMFSC);
  • Develop and implement a national advocacy and communication strategy to sensitize key stakeholders at national and sub-national levels and to build ongoing multisectoral stakeholder commitment (including political and local community commitment for developing and implementing policy and legislative amendments on medicines registration and regulation)
  • Facilitate national medicines registration and regulation policy and legislative review in the respective East African Community Partner States in order to incorporate the changes that will occur as a result of the harmonization of medicines registration and regulation among the Countries.
  • Coordinate and facilitate operational research, monitoring and evaluation and reporting of various national and sub-national medicines registration and regulation projects, programmes and initiatives in liaison with the relevant technical counterparts in the National Medicines Regulatory Authorities (NMRAs) of the respective EAC Partner States

Requirements:

Qualification and Experience:

  • A Bachelors Degree in Pharmacy from a recognized University;
  • A Masters Degree or other relevant post-graduate qualification in Pharmaceutical, Public Health or other Health-Related Sciences is an added advantage
  • Work experience of five (5) years of which two (2) should be in medicines regulation, policy, guidelines and standards development.
  • Demonstrated regional and international training experience in the harmonization medicines registration and regulation will be an added advantage.

Skills and Competencies:


Analytical skills, interpersonal communication, report writing, leadership, teamwork, supervisory and planning skills.


Candidates eligible for the position: Citizens from the Republic of Kenya


How to Apply


Interested candidates should submit their applications quoting the reference number of the position applied for by registered mail or courier service and dispatched directly together with the full curriculum vitae, copies of both academic and professional certificates and testimonials, names and addresses of three referees, day time telephone /cell phone numbers to: the Permanent Secretary Ministry of Medical Services.

 


Terms and Condition of Service


This EAC Country level health sector project staff position has an initial three year contract that may be renewed subject to satisfactory performance and availability of donor funds.


Closing Date: All applications together with copies of relevant attachments should be received at the respective EAC Partner States’ National Ministries responsible for Health no later than Friday, 15th June 2012.


New drug for Acne approved 

Cip-isotretinoin, a novel, patented brand formulation of the currently available acne medication isotretinoin, was approved by US Food and Drug Administration (FDA).Cip-isotretinoin is indicated for the treatment of severe recalcitrant nodular acne. It is expected to be available in the United States in the fourth quarter of 2012 under the brand name Absorica.

In comparison with current isotretinoin formulations on the market, cip-isotretinoin uses Cipher's patented Lidosedrug delivery system, which the company says offers more precise, consistent, and uniform drug delivery than currently available isotretinoin. In phase 1 clinical studies, cip-isotretinoin demonstrated a "significant competitive advantage in the treatment of severe, recalcitrant nodular acne,"

A major issue for existing isotretinoin products is patient compliance, as the active ingredient should be taken with a high-fat meal to ensure consistent absorption.Teenage eating habits are typically irregular compared to working-age adults. Cip-Isotretinoin has been proven to provide a more consistent absorption under fed and fasted conditions, compared to existing isotretinoin products that exhibit a 65% reduction in absorption under fasted conditions. Cip-Isotretinoin offers more consistent absorption day-in and day-out over the course of a typical 3- to 5-month treatment period.

In 2011, Cipher completed a pivotal phase 3 randomized double-blinded trial comparing the safety profile of cip-isotretinoin with an FDA-approved, commercially available isotretinoin product. The safety, efficacy, and population pharmacokinetic data generated from this study formed the basis of the company's regulatory approval application in the United States.

Cip-isotretinoin is a "valuable option for the dermatologist and patients who need treatment for severe recalcitrant nodular acne," Venkat Krishnan, senior vice president and regional director, Americas, for Ranbaxy Laboratories Inc, said in a statement. Cipher Pharmaceuticals is partnering with Ranbaxy Laboratories Inc to launch the product in the US market.

Cip-isotretinion is currently under review by Health Canada, and Cipher Pharmaceuticals says it anticipates a decision in the first quarter of 2013.


Job Vacancies- Pharmacists.

 

Our client a busy retail chain of chemists with branches in Nairobi, Mombasa, Eldoret, Thika, and Mtwapa is seeking to recruit Pharmacists for the following positions:

  1. Nairobi: Pharmacist, rotation at two locations, Gigiri and Greenspan Mall. (full time)
  2. Mombasa : Pharmacy Manager, Nyali Centre, (full Time)
  3. Mombasa: Pharmacist full time rotation Nyali Centre and Mtwapa.
  4. Thika : Pharmacy Manager- full time.
  5. Thika: Pharmacists- locum.
  6. Mtwapa Mombasa :Pharmacy Manager.(full Time)

 

 Applicants for the job must have a degree in Pharmacy, and have a valid annual practice licence.

 

Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on tohttp://www.pharmauditk.kbo.co.ke/news to send us your details.

Deadline 8/6/2012.

 

Job Vacancies- Pharmaceutical Technologists..

 

Our client a busy retail chain of chemists with branches in Nairobi, Mombasa, Eldoret, Thika, and Mtwapa is seeking to recruit Pharmaceutical Technologists for the following positions:

 

  1. Nairobi. Full time Pharmaceutical Technologist, rotation at two locations Gigiri and Greenspan Mall.
  2. Mombasa : Pharmaceutical Technologist, Nyali Centre (fulltime)
  3. Mtwapa Mombasa: Pharmaceutical Technologist, (fulltime)
  4. Thika: Pharmaceutical Technologist, (fulltime)

 

 Applicants for the job must have a diploma in Pharmacy, and have a valid annual practice licence.

 

Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on tohttp://www.pharmauditk.kbo.co.ke/news to send us your details.

Deadline 8/6/2012.

 


Job Vacancy- Superintend Pharmacist.

 

Our client a busy retail chemist in upmarket Nairobi is seeking to recruit a  Superintend Pharmacist. Applicants for the job must have a degree in Pharmacy, and have an annual practice licence.

 

Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on to http://www.pharmauditk.kbo.co.ke/news to send us your details.

Deadline 31/5/2012.


NEW FOUR-DRUGS-IN-ONE TREATMENT FOR HIV IN LINE FOR APPROVAL IN AUGUST 2012.

The new drug named Quad by Gilead Sciences Inc's, combines the experimental integrase inhibitor elvitegravir with the boosting agent cobicistat and two older nucleotide reverse transcriptase inhibitors - emtricitabine and tenofovir.

If approved by the FDA, Quad would provide HIV suffers with the first ever once-daily integrase inhibitor, a class of drug designed to block the spread of HIV by preventing the virus from binding with the DNA of host cells.

A U.S. Food and Drug Administration panel of outside experts recommended the use of Gilead Sciences Inc's Quad pill for untreated HIV patients. The FDA advisory committee voted 13-1 to endorse the four-drugs-in-one treatment, but members said there should be effective monitoring for potential kidney problems among patients and urged further research to determine the drug's safety profile for women, who have been under-represented in clinical research.

The panel's recommendation will now be taken into account by agency regulators, who are expected to decide on final approval for Quad by Aug. 27.An overwhelming number of the experts said they were satisfied with Gilead's demonstration of safety and efficacy.

Company research shows Quad to be 88% effective at suppressing HIV infection. But data also indicated a disproportionate number of kidney problems among the hundreds of patients who participated in clinical trials.

Advocates said the one-a-day regimen would encourage patients to adhere to the treatment with Quad, boosting the likelihood of high efficacy outside the clinical atmosphere.


Job Vacancy-Pharmaceutical Technologist.

 

Le Grand Pharmacy a fully fledged Specialty Pharmacy seeks to employ a Pharmaceutical Technologist.

Requirements:

  • Registered with the Pharmacy & Poisons Board and having worked in hospital or retail pharmacy for more than 4 years.
  • Ages between 25 -32yrs
  • NB: Resumes to be received before 1st June 2012

 

Apply to the Manager:

Le Grand Pharmacy

5th Avenue Ngong Offices, 3rd floor Suite 3-2


CHEMIST FOR SALE:


City Centre, Nairobi. Asking 5,000,000/=

Contact sales manager, Pharmaudit Kenya, email pharmauditkenya@gmail.com or log on to our website www.pharmauditk.kbo.co.ke.


PSK CONFERENCE: ATTENDANCE TO EARN MEMBERS 15 CPD POINTS.

 

The Pharmaceutical society of Kenya announced that attending the annual scientific conference to be held at the Whitesands Hotel in Mombasa from 31st May-3rd June will earn members 15 CPD points.

 

The conference whose theme is: Improving Healthcare by Advancing the Practice of Pharmacy will be officially opened by the minister for Industrialisation Hon. Amason J. Kingi.

 

The conference program includes two breakout sessions one for hospital pharmacists and another for industry, retail and distributors. There will also be learning, team building, sports, speed networking, night events and lots of prizes to be won for participants.

 

Attendance will be taken through a biometric system (finger prints) to avoid long queues and confusion. The council has approved purchase of a biometric machine that will be used in other PSK meetings as well.

 

The CPD log book and  a new look Journal will be launched at the Symposium.


Job Vacancy- Company Pharmacist.

 

Our client a Pharmaceutical distributor based in Nairobi is seeking to recruit a Company Pharmacist. Applicants for the job must have a degree in Pharmacy, and have an annual practice licence.

 

Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on to www.pharmauditk.kbo.co.ke to send us your details.

Deadline 29/5/2012.


New exocrine pancreatic insufficiency drug approved by FDA

The US Food and Drug Administration (FDA) has approved pancrealipase delayed-release capsules (Pertzye, Digestive Care Inc) for the treatment of children and adults with exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF) or other conditions.

The unique pancreatic enzyme product contains bicarbonate-buffered enteric-coated microspheres and is protected by several US and international patents. It has been marketed by the company under the trade name Pancrecarb MS-16 since 2004.

Representing the sixth such product for patients with CF, Pertzye comes on the heels of 2 other newly FDA-approved similar products (Ultresa, Aptalis Pharma US Inc; and Viokace, Confab Laboratories Inc), .

Other previously FDA-approved pancrealipase pharmaceuticals include Creon (Abbot Labs), Zenpep (Eurand SPA), and Pancreaze (Ortho-McNeil-Janssen Pharmaceuticals Inc).

Small Study Leads to Big Results

FDA approval was based on data from a small, randomized, double-blind study of 21 patients aged 8 to 43 years (mean, 20 years) who were randomly assigned to receive the study drug at individually titrated doses or matching placebo for 6 to 8 days of treatment, followed by crossover to the alternate treatment for an additional 6 to 8 days.

Results showed that the mean difference in coefficient of fat absorption (CFA) was significantly higher for the study drug relative to placebo, as determined by a 72-hour stool collection during both treatments to measure both fat ingestion and excretion (83% vs 46%; 95% confidence interval [CI], 28% - 45%; P < .001).

The coefficient of nitrogen absorption was likewise significantly increased (79% vs 47%), as evaluated using the same stool samples, with the assumption that proteins contain 16% nitrogen.

No differences were found between children and adults with respect to the severity of pancreatic insufficiency or response to the study medication.

"The improvement in mean CFA observed in the controlled study represents a clinically meaningful treatment benefit.... Availability of this unique buffered formulation of pancreatic enzyme is an important addition to the therapeutic options for CF and other patients with EPI," stated Michael W. Konstan, MD, chairman of pediatrics, Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio, in a company news release.

The most commonly observed adverse events were diarrhea, dyspepsia, and cough (10% vs 4% for those receiving placebo, for each event).

Recommended Dosing

Pancrealipase delayed-release capsules will be available in 2 formulations:

  • 8000 USP units of lipase with 28,750 USP units of protease and 30,250 USP units of amylase; and
  • 16,000 USP units of lipase with 57,500 USP units of protease and 60,500 USP units of amylase.

Children aged from 1 to less than 4 years and weighing 8 kg or more should begin with a dose of 1000 lipase units/kg body weight per meal (maximum, 2500 units or ≤10,000 units/kg/day) or less than 4000 lipase units/g fat ingested daily.

Older children and adults should start with a dose of 500 lipase units/kg body weight (maximum, 2500 units/kg per meal or ≤4000 lipase units/g fat ingested daily).

Because ingestion of larger amounts is linked to a risk for fibrosing colonopathy, the FDA warns patients to contact their clinician immediately if they have unusual or severe abdominal pain, bloating, and trouble passing stool, nausea, vomiting, or diarrhea.

Capsules should be taken whole to avoid irritation of the oral mucosa, but contents may be mixed with applesauce for infants and others having difficulty swallowing.

Treatment is associated with a risk for hyperuricemia, so uric acid level monitoring should be considered in patients with gout or renal impairment. Caution is advised when prescribing pancrealipase delayed-release capsules for patients with a known allergy to proteins of porcine origin.


Pharmacist Job Vacancy.   

Location:

Nairobi, Kenya

Employment Type:

Full-Time

Pay:

90,000

Summary:

Required to work for a busy upmarket pharmaceutical outlet in Nairobi.

Description:

 

Requirements:

Degree in Pharmacy, registered by the board and at least 1 year experience in dispensing and pharmacy administration

Closing Date:

22 June 2012

 

Contact Info:

PeopleLink Consultants Limited
PeopleLink Consultants Limited

Web Address :   
http://wwww.peoplelink.co.ke


Pharmacist Job Vacancy.    

Location:

Bungoma, Kenya

Employment Type:

Full-Time

 

 

Summary:

Company Description:

A medium sized private hospital with a 100 bed capacity and is located within Bungoma town.

Description:

Job Description:

•Dispensation of medication prescribed by the doctor or the clinical officer.
•Ordering and monitoring of drug dispensation.
•Proper documentation of prescriptions.
•Formal and informal training of other health personnel.
•Monitoring, training and evaluating of pharmaceutical assistant

Requirements:

Requirements:

Education:

•Degree in pharmacy.
•Registered by the pharmacy and poisons board
•B. Experience:
•2 years in a busy hospital or health institution or 3 years as a pharmacist assistant.

Send your application including a cover letter and a detailed C.V and your current and expected pay.

Closing Date:

28 May 2012

 

Contact Info:

Hechar Contours
Hechar Contours


Human Resource Manager,
P.o Box 175-00600,
Nairobi.

 


CHEMIST FOR SALE:

Alsop, Ruaraka. Asking 500,000/=

Contact sales manager, Pharmaudit Kenya, email pharmauditkenya@gmail.com or log on to our website www.pharmauditk.kbo.co.ke.


Pharmacist II (2) - Muhimbili National Hospital, Dar es Salaam, Dar es Salaam

Job Details

 Phone: No Calls Please
Area: Dar Es Salaam
Application Deadline: May 31, 2012

 Reports to:Head, Pharmacy Department

Duties and Responsibilities

To supervise dispensing of medicine as per doctor's prescriptions

To supervise making of extemporaneous preparations (compounding)

To organize preparation of sterile and non-sterile pharmaceuticals.

To provide drug information to both patients and health care personnel.

To provide ward pharmacy services i-e. In-patients prescription monitoring, therapeutic drug monitoring etc

To supervise, appraise staff and identify development and training needs. To perform any other duties as assigned by supervisor from time to time.

 Requirements

Qualifications

Holder of Degree in Pharmacy or equivalent qualification who has completed internship

Must have completed a one year internship programme and registered by the Pharmacy Council.

At least one to two years working experience is desirable Computer literacy is essential

 Application Instructions:

All application letters should be sent by post using the address below and letters delivered by hand shall not be considered.

Applications accompanied with a detailed CV and copies of certificates, testimonials and names of three referees should be addressed to the

Executive Director
Muhimbili National Hospital
P.O BOX 65000
Dar es Salaam.

 


PSK UPDATES!!

 

  • No general meeting this month.
  • Very few spaces remaining at travelers beach hotel.
  • KQ charges up by 1,000/=
  • Day participants to pay 10,000/= at PSK Nairobi office.

 The tentative programme for the PSK symposium Mombasa.


THEME;           “Improving Health by Advancing the Practice of Pharmacy”.

DAY 1: Thursday 31ST May, 2012

 

 

VENUE

NEXT TO MAKUTANO HALL,  WHITE SANDS BEACH HOTEL

Time

 

14 00 – 17 00

Arrival and registration

 

 

18 30 – 20 30

BONDING AND NETWORKING

END OF DAY 1

DAY 2:Friday 1ST JUNE, 2012

 

 

VENUE

WHITESANDS BEACH HOTEL  (MAIN HALL - MAKUTANO)

 

Official Opening Ceremony

06.30-7.00am

Walk on the beach/yoga/gym-Dr Aneez coordinator.

8.00-8.30am

Registration

SESSION 1

<!--[if !supportLists]-->v      <!--[endif]-->        SESSION ONE

IMPROVING PHARMACY REGULATION & PRACTISE

Moderator

Dr. Rogers Atebe

Rapporteur

Dr.Lilian Balusi

08 30 – 08 40

Welcome remarks, Dr. David Wanjala, PSK Coast Branch Chairman

08 40 – 08 50

Conference Overview:  Dr Aneez –Symposium convenor.

08 50 – 09 30  

KEY NOTE SPEECH

 

SESSION 1

 

<!--[if !supportLists]-->v      <!--[endif]-->IMPROVING PHARMACY REGULATION & PRACTISE

09 30 – 09.40 

 Assessing Readiness and Standards for Accrediting Pharmaceutical Services and Facilities- The way to go with the Green Cross Scheme?-Dr Jayesh

09.40  – 09.50 

Pharmaceuticals Anti-Counterfeit Supply Chain Management System-Dr. Mwaniki Simon Gachago.

09.50  – 10 00

Promoting Patient Safety through Strengthening Pharmacovigilance and Post Marketing Surveillance Systems in Kenya -:Dr Ndinda Kusu

10.00-10.15

               Question & |Answer session

10.15 – 10.45

HEALTH BREAK(Tea break)- Viewing of Exhibition stands

SESSION II

           PHARMACEUTICAL CARE IN HIV/AIDS.

Moderator

DR.GLADYS WAWERU

Rapporteur

DR LABAN CHWEYA-NORTH RIFT PSK CHAIR.

10.45 – 10.55

The Role of Pharmacists in the Elimination of Mother to Child transmission (eMTCT) - Targeting MTCT rates of less than 5% by 2015 in Kenya-   Dr .Anyona M

10.55 – 11.05

Pharmacists’ role in management of long term HAART patients –Dr Majimbo j.

11.05 – 11.15

Evaluating the impact of pharmacy staff on quality of ART services: Dr. Cecilia Muiva

11.15 – 11.30

       Question & |Answer session-panel

11.30 – 11.40

                       ENERGIZER BREAK - Aneez

 

IMPROVING PRACTICE THROUGH QMS AND HEALTH SYSTEMS.

11.40 –11.50

Factors affecting utilization of healthcare services by undergraduate university students at Kenya Methodist University Nairobi campus- DR.LUCY NJOGU-MUTURI.

11.50 – 12.00

Using QMS  to improves the efficiency and sustainability of a pharmaceutical supply chains  - Dr Esther Turunga

12.00-12.10

Role of Information Technology (IT) in improving Patient Centered Pharmacy Practice - Dr Njunguru Jesse.

12.10-12.25

       Question & |Answer session

12.25-12.55

SPONSOR 1 TALK –stanbic Bank  PRESENATION

12 55 – 14 00

LUNCH BREAK

SESSION III

                  CURRENT ISSUES.

Moderator

DR. AHMED TAWAKAL

Rapporteur

DR. NELLY OWINO

14.00 – 14.10

Trivia – Dr Erick Onkoba  

14.10 – 14.20

Emergency preparedness and terrorism: The role of the  Pharmacist

Dr Sylvia Opanga

14.20- 14.30

True story about HIV: theory of viral sequestration and reserve infection-Dr Simon Barasa

14.30 – 14.35

Question and answer session.

 

BREAK OUT SESSIONS –Hospital, retail, distributors & Industry

14.35 –15.45

Hospital break out session leader-Dr Wata

14.30- 15.45

Industrial policy session leader      –Dr kabiru.

14.30- 15.45

Retail  pharmacy session – Dr. James Wathigo

14.30- 15.45

Distributors and Allied session- Dr. Onkoba & Dr. Miano

15.45-16.30

Plenary discussion- Dr Mwaniki Chair PSK, PPB representative.( 10 minute presentation from each session)

16.30-17.00

Tea break & Beach Sports.

 20.00-

JOURNAL RELAUNCH & COCKTAIL -Dr Aneez.

 

MC: Dr Anthony Walela

END OF DAY 2

DAY 3: SATURDAY 2nd  JUNE 2012

06.30-7.00am

Walk on the beach/yoga/gym-Dr Aneez coordinator.

Session IV

ADVANCEMENTS IN PHARMACEUTICAL POLICY

Moderator

DR TOM MENGE

Rapporteur

DR.MECCA LUCY

08.30–08.45

Welcome remarks and Recap – Dr MARCELLAH OGENDO-PSK MSA.

08.45 –09.00

Turning point or missing the opportunity? - Dr W.O. Wanyanga.

09.00 – 09.10

Transforming healthcare through Informatics: Development of an adherence-promoting Pharmacy Database-Dr William O. Ogallo.

09.10 – 09.20

Task-Shifting, Availability of ARVs, and Pharmaceutical Care in ART Centres in Post-Conflict Northern Uganda-Dr Mshilla Maghanga.

09.20 – 09.35

       Question & |Answer session

09.35 – 10.05

Pfizer presentation

10.05-10.20

AFP-PRESIDENT SPEECH NIGERIA.

10.20 – 10.30

TEA BREAK and exhibition viewing

10.30 – 11.00

Address by the Chief Guest

 

 Transforming healthcare practice in line with Vision 2030.

 

Session 5

IMPROVING EDUCATION AND TRAINING FOR PHARMACISTS IN LINE WITH VISION 2030

11.00-11.10

Pharmacy education summit: advancing pharmacy practice through innovation in education- Prof. Ombega

11.10-11.20

Establishment of a Global Health Pharmacy Residency Program in Eldoret, Kenya-: Dr Maina Mercy

11.20-11.30

Clinical pharmacy training through an experiential learning process-Dr Simon Manyara

11.30-11.45

Question & |Answer session

Moderator

DR. W.NANDAMA

Rapporteur

DR. ESTHER GATHONI

11.45-11.50

                       ENERGIZER   -Dr Aneez

11.50-12.00

GSK PRESENATION

12.00- 12.10

Assessment of Continuous Professional Development programs for Pharmacy practitioners in Kenya-     Dr Charles Ouma

12.10 – 12.20

Question & |Answer session.

12.20 – 12.35

CPD booklet launch.-Dr Nelly Kimani

12.35-12.40

Question & answers

12.40 – 12.50

Reckitt presentation

12.5014.00

LUNCH /NETWORKING

Session V

PSK SESSION.

Moderator

DR.MUIRURI  WELLINGTON

Rapporteur

DR GLADYS MWANGI

14.00 – 14.10

Raffles &Ticket

14.10-14.20

GSK PRESENTATION

14.20-14.30

 Patients’ insights into male incontinence-Dr Muiru.

14.30- 14.45

Question & answer session.

14.45 – 15.00

PSK Investment committee presentation-PSK TEAM.

15.00-15.15

Team Building Session.

16.00 – 17.00

Entertainment and Closing Ceremony

20.00

Karaoke Night

<!--[if !supportLists]-->v      <!--[endif]-->Symposium End.

DEPARTURE

DAY 4: SUNDAY 3nd  JUNE 2012

 

 


 

                                                    HOSPITAL BREAKOUT SESSION

14.30-14.40         Microbial resistance and threats: the state of the Kenyan pharmaceutical sector –Dr Apollo Odhiambo Maima.

     14.40-14.50          A descriptive retrospective study on rational drug use undertaken in KNH Private Wing pharmacy. -    Dr E.Lule.

14.50-15.00          Question & Answer

15.00-15.45           HOPAK discussion-Dr.Wata & Dr Jao Majimbo.

                   INDUSTRY,RETAIL & DISTRIBUTORS  BREAK OUT SESSION

14.30-14.40        A comparative analysis of in-market pharmaceutical distribution channel strategies in sub-Saharan Africa-Dr James Mwenda Riungu.

14.40-14.50          Encouraging good storage practices in service delivery points-Dr.Grace Waiharo.

14.50-15.00          Question & Answer

15.00-15.45           Industrial Business   discussion-Dr Kabiru.

Overall Master of Ceremony: Dr Aneez/ Dr Shangalla.

Overall rapporteur – Dr Sam Kerama.

Computer logistics – Dr. Peris & Winnie.   

Overall Conference logistics/time keeping – Dr. Erick Onkoba.

Breakout session logistics: Dr K.Irungu.          

Program flow; Dr Okiko.



Employment opportunity.

Maryland Global Initiatives corporation.

Position/title: Health Supply Chain specialist, two positions; 1. Kenya Northern Arid lands region 2. Central province of Kenya.

Qualifications & experience.

·         Hold a B. Pharm degree and a valid practice licence.

·         Minimum 3 years experience in providing technical and managerial services in drug inventory management.

·         Must be experienced in hospital pharmacy operations and hospital inventory management operations.

·         Have excellent facilitation skills with emphasis on adult learning techniques.

·         Familiar with local logistical operations in the country such as distribution inventory management and warehousing operations.

·         Has demonstrable ability to provide training in rational use of medicines, inventory management and issues related to drug supply management.

·         Be willing to travel extensively and regularly and stay for extended periods in the respective regions.  May be required to live in the regions.

·         Post graduate training in public health is a plus.

·         Assist health facilities put in place structures to enable integrated health care delivery.

Apply to; The HR Manager, Maryland Global Initiative, P.O. Box 495-00606, Nairobi.

Documents to be included: a cover letter with applicants current contact information, CV showing the names and contacts of three professional referees, testimonials and two recommendation letters. Incomplete applications will not be considered. Deadline 1/6/2012.


Wanted: Chemist to buy or space for a pharmacy.

Our client wants to buy an existing chemist or space to rent for a chemist.

Suitable location: Nairobi city centre or estate shopping centre.

 

Contact: Sales  Manager, Pharmaudit Kenya email: pharmauditkenya@gmail.com


Plots for sale!!!

Afya investment co-operative society Limited. The society is offering for sale prime plots along kangundo road at KBC station in Malaa area.

 

The plots are in phase 2 located in an ideal place which is developing fast along the bypass. The plots are 1/8 acre(100x50ft)

 

Terms

Society members  - ksh. 280,000.

Non-members       - ksh. 330,000.

 

Application forms are available at the society head office in Afya Centre or in branches. Payments can be made by bankers cheque or cash at head office in Afya centre or any of the Afya Sacco FOSA branches.

 

Allocation will be on first come first fully paid basis. Payments by installment is allowed upto 4 monthly installments.

 

For further inquiries/details contact the investment office, 5th Floor, Afya centre Tel: 2223970/50/60 email: investments@afyasacco.com.   


CHEMISTS FOR SALE.

1. Chemist Buruburu Phase 2 shopping centre. asking price Ksh. 750,000.

contact Sales Manager Pharmaudit kenya. pharmauditkenya@gmail.com 

 

Job Vacancy- Enrolled Pharmaceutical Technologist.

 

Our client a retail pharmacy in Nairobi is seeking to recruit a Pharmaceutical Technologist. Applicants for the job must have a diploma in Pharmacy, and PPB enrolled.

 Applications, telephone contact, email address be send by email to, the Recruitment Manager, Pharmaudit Kenya, pharmauditkenya@gmail or log on to www.pharmauditk.kbo.co.ke to send us your details.

Deadline 21/5/2012.


FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death


[05-17-2012] The U.S. Food and Drug Administration (FDA) is aware of the study published in the New England Journal of Medicine, on May 17, 2012, that compared the risks of cardiovascular death in patients treated with azithromycin (Zithromax), amoxicillin, ciprofloxacin (Cipro), levofloxacin (Levaquin), and no antibacterial drug.  The study reported a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment.  FDA is reviewing the results from this study and will communicate any new information that results from the FDA review.

Patients taking azithromycin should not stop taking their medicine without talking to their healthcare professional.

Healthcare professionals should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering antibacterial drugs. (See additional information below.)

Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. Prolongation of the QT interval can lead to torsades de pointes (TdP), an abnormal heart rhythm, which can be fatal.  Azithromycin was the only macrolide examined in the published study; the study did not address other macrolide antibacterial drugs, such as clarithromycin (Biaxin) and erythromycin, regarding the potential for cardiovascular death.

In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP. The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low. The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.

FDA-approved indications for azithromycin include:

<!--[if !supportLists]-->·                          <!--[endif]-->Acute bacterial exacerbations of chronic pulmonary disease

<!--[if !supportLists]-->·                          <!--[endif]-->Acute bacterial sinusitis

<!--[if !supportLists]-->·                          <!--[endif]-->Community-acquired pneumonia

<!--[if !supportLists]-->·                          <!--[endif]-->Pharyngitis/tonsillitis

<!--[if !supportLists]-->·                          <!--[endif]-->Uncomplicated skin and skin structure infections

<!--[if !supportLists]-->·                          <!--[endif]-->Urethritis and cervicitis

<!--[if !supportLists]-->·                          <!--[endif]-->Genital ulcer disease 

FDA will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review.


 

Proposed County Level Structure for the Ministry of Health


The proposed structure for the county level is in line with the position paper that stipulates that a minimum management capacity should be established for operational management of county health services. The County Executive Committee (CEC) member designated as responsible for health should provide the political linkage to the CEC and work with this minimum management capacity to manage health.

The committee proposed that the country health management should be comprised of the following:


Overall County Director
Disease Prevention and Health Promotion Unit
Medical (Clinical) Services Unit
Nursing Services Unit
Planning and Monitoring Unit
Health Administration


Duties and Responsibilities of County Coordinators of Health

Capacity Building and Technical Assistance to the County
Strategic Leadership and Operational Planning for all County Health Services
Facilitation of Implementation of National Health Policies, Strategic Plans and Programmes
Coordination of County Blood Transfusion Services
Coordination of Mental Health and Substance Abuse Services
Prevention and Control of Epidemics in liaison with the National Government
Coordination of County Diagnostic and Forensic Services
Registration and Regulation of County Health Facilities and Services
Prevention and Management of Disasters
Participation in coordination of Resource Mobilization for County Health Services
Monitoring and Evaluation of County Health Services to conform to international and national standards

THE KMWA/KMA/KMPDU PROPOSAL
PROPOSED COUNTRY LEVEL STRUCTURE


The proposed structure for the country level is in line with the position paper that stipulates that a minimum management capacity should be established for operational management of county health services. The County Executive Committee (CEC) member designated as responsible for health should provide the political linkage to the CEC and work with this minimum management capacity to manage health.

The committee proposed that the country health management should be comprised of the following:

Overall County Director
Disease Prevention and Health Promotion Unit
Medical (Clinical) Services Unit
Nursing Services Unit
Planning and Monitoring Unit
Health Administration
Deputy Director :- Pharmaceutical Services
Deputy Director:- General Technical Services

Proposed county level structure (organogram)

1. COUNTY DIRECTOR OF HEALTH

Duties and Responsibilities

a) Capacity Building and Technical Assistance to the County

b) Strategic Leadership and Operational Planning for all County Health Services

c) Facilitation of Implementation of National Health Policies, Strategic Plans and Programmes

d) Coordination of County Blood Transfusion Services

e) Coordination of Mental Health and Substance Abuse Services

f) Prevention and Control of Epidemics in liaison with the National Government

g) Coordination of County Diagnostic and Forensic Services

h) Registration and Regulation of County Health Facilities and Services

i) Prevention and Management of Disasters

j) Participation in coordination of Resource Mobilization for County Health Services

k) Monitoring and Evaluation of County Health Services to conform to international and national standards


Requirement for appointment of County Director of health

Qualification

a) M.B;Ch.B or BDS from a university recognized in Kenya

b) M.MED or M.P.H in health-related field from a university recognized in Kenya

c) Training in Management and Leadership will be an added advantage

d) Must be of good Professional Standing, currently registered by the relevant professional body

e) Must be a registered member of the medical professional body

f) Corporate Governance\ and or MBA will be an added advantage.

Experience

a) Should have demonstrable clinical or public health experience of at least 5 years from the date of the second degree

b) Performance: At least 3 years experience in management at at health institution

c) Demonstrate knowledge of National Health System

d) Integrity: Must meet the spirit of Chapter 6 of the constitution on leadership and integrity

(2) DEPUTY COUNTY DIRECTOR OF HEALTH (HEALTH PROMOTION & DISEASE PREVENTION)

The Deputy County Director of Health (Health Promotion and Disease Prevention) will be responsible to the County Director. She/he will be responsible for providing leadership, management and coordination of the health promotion and disease prevention initiatives at county level.

Major responsibilities will entail:

a) Provide technical advice to the County Director on Public Health matters

b) Designing, planning. Organization, coordination and management of the health promotion and disease prevention programs and initiatives at county level

c) Monitoring and reporting of the health promotion and disease prevention programs and initiatives at the county level

d) Provide leadership and management of primary health care services and adherence to policy and clinical guidelines and standards

Requirements for Appointment

For appointment to this grade, one must possess the following

a) Bachelors degree in health sciences and MPH or its equivalent Served in the health sector for a minimum 3 years from the date of acquiring second degree

b) At least 3 years experience in health management

c) Be a registered member of a regulatory body and must be of good professional standing

d) Be a person of high integrity

(3) DEPUTY DIRECTOR (MEDICAL SERVICES UNIT)

The Deputy Director Medical Services will be responsible to the County Director of Health. S/he will be responsible for organization control and coordination of the medical services unit at the county level.

Major responsibilities will entail

a) Strategic operations management and coordination of medical services provision in the country

b) Ensure delivery of quality services and adherence to policy and clinical guidelines and standards

c) Monitoring of clinical care and emergency services, referral systems within and outside the country

d) Oversee rehabilitation and ambulance services. S/he will also be in charge of regulation of health service providers in the country


Requirements for Appointment

For appointment to this grade, one must possess the following

a) MBChB or BDS and MMed or its equivalent

b) Served in the health sector for a minimum 3 years from the date of acquiring second degree

c) At least 3 years experience in health management

d) Be a registered member of a regulatory body and must be of good professional standing

e) Be a member of a professional association of good standing

f) Be a person of high integrity

(4) DEPUTY DIRECTOR NURSING SERVICES

The Deputy Director Nursing Services will be responsible to the County Director of Health for organization, control and administration of nursing services at the county level

Major responsibilities will entail:

a) Community nursing and midwifery

b) Supervision and implementing of nursing policies

c) Supervision of nursing services within the county

Requirements for Appointment

For appointment to this position, one must have the following:

a) Advanced nursing or Bachelor’s degree in Nursing or its equivalent from a recognized university

b) Masters Degree in Health Related

c) Served for a minimum period of 10 years in either public or private sector ; 3 years of which must be in Job Group ‘P” or its equivalent

d) A 4 weeks course in health systems management on appointment or should undertake the course immediately after appointment

e) Be a person of integrity as stipulated in chapter six of the constitution

f) Be registered by the relevant regulatory bodies and must be of good professional standing

5. DEPUTY DIRECTOR PHARMACEUTICAL SERVICES

The Deputy Director Pharmaceutical Services will be responsible to the CountyDirector of Health. S/he will be responsible for organization control and coordination of the Pharmaceutical services unit at the county level.

Major responsibilities will entail

a) Provide professional expertise to the overall county director

b) Ensure quality assurance to ensure safety and accuracy of all pharmaceutical products and commodities

c) Establish and maintain policies and procedures concerning pharmacy operations for all facilities and programmes

Requirements for Appointment

For appointment to this grade, one must possess the following

a) Bachelors degree in pharmacy

b) Served in the health sector for a minimum 3 years from the date of acquiring second degree

c) At least 3 years experience in pharmaceutical management

d) Be a registered member of a regulatory body and must be of good professional standing

e) Be a member of a professional association of good standing

f) Be a person of high integrity

(6) DEPUTY DIRECTOR GENERAL ADMINISTRATION AND FINANCE (HEALTH ADMINISTRATION)

The Deputy Director Finance and General Administration will be responsible to the County Director of Health for organization, control and coordination of Finance and Administration roles at the county level

Major responsibilities will entail:

a) Planning, management, coordination of finance, procurement, human resources, management and human resources development and general administration

b) Institutionalize administrative human resources and procurement systems to support effective delivery of services at the county level

c) The job holder will oversee policy adherence and implementation for specific units and provide eriodic reports

Requirements for Appointments

For appointment to this position one must have the following:

a) Bachelor’s degree in business management or its equivalent from a recognized university

b) Masters Degree in Business Administration or related field from a recognized institution

c) Served fro a minimum period of 15 years in either public or private sector, 3 years of which must be in Job Group P or its equivalent

d) A 4 weeks course in health systems and management on appointment or should undertake the course immediately after appointment

e) Be person of integrity as stipulated in Schedule six of the constitution

f) Be registered by the relevant regulatory bodies and must be of good professional standing

7. DEPUTY DIRECTOR PLANNING AND MONITORING UNIT

Should provide for health economists, disaster preparedness and procurement

8. DEPUTY DIRECTOR GENERAL TECHNICAL SERVICES (Allied medical services)

 


 MINUTES OF PSK GENERAL MEETING HELD ON 25th APRIL 2012 FROM 6.30PM AT KENYATTA INTERNATIONAL CONFERENCE CENTRE, ABARDARES ROOM.

PRESENT

As per attendance list –129 members were present for the meeting

Apologies received:

Dr. J.A.Orwa, Dr. Nelly Kimani, Dr. Binita Shah, Dr. Maureen Kinyua, Dr. Wilberforce O.Wanyanga, Dr. James Mwenda

Dr.John Aduda, Dr .S.C.Seckhar, Dr. D.V.Shah, Dr. Rupen Sigey, Dr. Radiyah Shabbir Jafferji, Dr. Aziz.A. Janoowalla

Dr. Clare Kagambi

AGENDA

The Secretary read out the General notice and agenda as follows:

1. Matters arising from the previous meeting

2. Annual Scientific Conference

3. Communication from other standing committees

4. AOB

Meeting was called to order at 6.45pm by the chairman.

MIN 1/4/2012: Matters arising from the previous meeting

a) NHIF outpatient scheme – Consultants have been engaged to do a proper proposal that members will approve and will be officially presented to NHIF

b) Pharmacy and Poisons Board; will be inaugurated by the Minister hopefully next week so that the board can start it’s work. There has been concern on the delay and the chairman is following up with the registrar.

c) The education committee has received various input from members on the CPD framework especially the penalties.The final penalty framework will be given at next general meeting. The CPD framework passed in the previous meeting will remain in operation.

The previous meeting minutes were confirmed as follows:

Proposer: Dr. S. K Shah

Seconder: Dr. Sitti

MIN 2/4/2012: ANNUAL SCIENTIFIC CONFERENCE

The annual scientific conference was discussed as follows:

a) Venue: White sands Hotel Mombasa

b) Arrival date: 31st May 2012

c) Departure date: 2nd June 2012

2/4

d) So far 23 abstracts have been received for presentation. Members are still encouraged to send more though the deadline has elapsed. The committee will decide which abstract will be presented.

e) 8 exhibitors (pharmaceutical & non-pharmaceutical) have confirmed participation

f) PSK has only reserved limited number of seats on Fly 540 & KQ at special rates, once all those seats are taken, members will have to pay higher rates as given by the airlines.

g) White sands hotel is under renovation so only 100 rooms are available to PSK; once those are taken the other members will have to stay at travellers hotel.

h) The committee is looking at high profile key note speakers and the Vice President has been invited as the chief guest however still not confirmed.

i) The programme will include: learning, team building, sports, speed networking, night events and lots of prizes to be won for participants.

j) Attendance will be taken through a biometric system (finger prints) to avoid long queues and confusion. The council has approved purchase of a biometric machine that will be used in other PSK meetings also.

MIN 3/4/2012: COMMUNICATION FROM PSK STANDING COMMITTEES

a) Education Committee

 CPD Log Book to be rolled out at the Symposium. Members will be able to record all the activities they attend for easier record keeping. It is being sponsored by MSH.

 PPB in conjunction with MSH conducted a survey on CPD around the country, and is now analyzing the results.The results will also help us adjust the program appropriately.

 Committee members and the Chairman made a courtesy call at PPB and had a meeting with the CPD and

Accreditation Department together with Dr. Inyangala.

b) PJK Editorial Team Report

 PJK is still requesting members to send in Manuscripts and Articles.

 HMI - Health Media International is going to publish the Journal.

 A new look Journal will be launched at the Symposium.

c) Legal and Ethics Committee

 Under the new constitution and in the face of the health law, pharmacy as a profession has to come up with requisite legislations that will place the pharmaceutical industry in line with existing or envisioned laws and

ensure that the place of the profession is strengthened and safeguarded in the process.

 Pharmacy and Poisons Act - there exists various drafts by previous committees on pharmacy practice and that varied recommendations reached were not implemented.

3/4

 To conform to the constitution the Pharmacy and Poisons Act be overhauled. The committee was of the opinion that it can borrow from existing legislations from other countries like South Africa or Tanzania to come up with an acceptable model e. g the FDA model. In this, the composition of the FDA shall include primarily of Pharmacists with representatives from other sectors and will regulate all sectors involved through the various committees, retaining the overall regulatory mandate.

 A sequestered 2 day forum to be arranged to come up with a comprehensive document that can be used as a benchmark to draft the Pharmacy law. A stakeholders meeting can then be called, including the pharmacy and poisons board, to review the draft. External funding for this activity is being looked into.

 There is need to come up with a devolved system in the practice of pharmacy. Given the current trends and governance structures, there is need for capacity building in the profession to ensure that members are well qualified for most of the post or positions that may arise from these changes.

d) Investment committee

Updates of registration of Sacco and company

PSK – SACCO – Name search has been resubmitted afresh since the previous reservation lapsed due to conflicting information given to committee that a minimum capital required to register a SACCO is currently Kshs. 20 million. For this reason the registration of the Sacco was temporarily put on hold. It has been established that the information was not reliable and hence the process has been re-started.

PSK HOLDING LTD – The name has been accepted by the Registrar of companies. Registration of the company has commenced. PSK Holdings Ltd shall be a private limited liability company with powers to float shares to PSK members for purposes of raising capital.

The committee proposes that:

 PSK as an entity will be the majority share holder

 Members of Pharmaceutical Society be mobilized and encouraged to buy into the company

 Individual members are given opportunity to buy up to Ks 60,000.00 worth of shares to be paid up by way of installments

 Authorization to proceed with this option of investment be sought from members at the general meeting through a motion

 A motion regarding flotation of shares of PSK Holding Ltd to be moved at the general meeting

Investments Update Committee members were in agreement that PSK should purchase a parcel of land of not less than 1 acre within Nairobi and in a desirable location. As at April 14, 2012 a parcel of land of 2 acres costing Kshs. 55m was identified in Langata (Site visit by Dr James Mwenda, Dr Winnie Munene, and Dr Dick Ayieye).4/4

The committee proposes that PSK Council be involved in appraisal of the land and further search for other properties before making commitments

Members at the meeting asked the investment committee to circulate details of the company PSK holding Ltd before approving floatation of shares and a comprehensive report on the investments proposed before approval. This should be done before the next meeting. Details should include company structure, how much the shares are worth etc.

e) Industrial Pharmacy Committee

 Will send invites to industrial pharmacists to participate in various planned activities for the year.

 Is planning on having monthly trainings on pertinent issues on industrial practice. Trainings will be at

professional center. Members to be informed on email.

 Plan to have career talks at UON and MKU on Industrial pharmacy.

 The committee is keen on working on a GMP video that Industries can use for training workers.

 Will have a presentation at the annual conference on “promotion of quality products by local manufacturing firms”.

MIN 4/4/2012: AOB

a) The Council is urging members to take initiative and take up consultancy work for PSK; members can introduce viable project proposals for the society.

b) The pharmacists working in the public service are also required to attain the annual CPD points and get an annual practice license. Failure to do so may lead to cancellation of their non-practicing allowance. The board will give a final decision on CPD requirements and penalties applicable to pharmacists who work in the civil service.

There being no other business the meeting was adjourned at 8.30pm


NEW ANTI-MALARIA DRUG LAUNCHED IN INDIA.

Opening a new chapter in the history of Research & Development in India, Ranbaxy Laboratories Limited (Ranbaxy) today launched India’s first new drug, Synriam, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults.

 

Heralding the arrival of the new drug, Dr. Sudershan Arora, President-R&D, Ranbaxy, said. "The new drug, which will be marketed first in India, is developed as a fixed dose combination consisting of arterolane maleate 150 mg and piperaquine phosphate 750 mg drug, in line with WHO recommendations. It is among the best options available today. I applaud the success of R&D at Ranbaxy in the creation of this New Age Cure for Malaria and am sure that innovative drug products will continue to be developed at Ranbaxy-R&D labs, even in the future."

 

 At a function held in New Delhi,  Ghulam Nabi Azad, Hon’ble Minister of Health and Family Welfare, Govt. of India and Vilasrao Deshmukh, Hon’ble Minister of Science & Technology and Earth Sciences, Govt. of India, unveiled India’s first new drug Synriam with Ranbaxy dedicating the New Age Cure for Malaria to the Nation, on World Malaria Day.

 

The new drug, has been approved by the Drug Controller General of India (DCGI) for marketing in India and conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Synriam provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 per cent.

 

Phase III clinical trials for the drug conducted in India, Bangladesh and Thailandsuccessfully demonstrated the efficacy and tolerability of Synriam as comparable to the combination of artemether and lumefantrine.

 

The dosage regimen is simple as the patient is required to take just one tablet per day, for three days, compared to other medicines where two to four tablets are required to be taken, twice daily, for three or more days. This makes Synriam a convenient option, leading to better compliance. The drug is also independent of dietary restrictions for fatty foods or milk, as is the case with older anti-malarial therapies. Since Synriam has a synthetic source, unlike artemisinin-based drugs, production can be scaled up whenever required and a consistent supply can be maintained at a low cost.

 

Felicitating the scientific team from Ranbaxy, Dr. Tsutomu Une, Chairman, Ranbaxy, said, “I applaud all our scientists who have worked incessantly over 8 years and with great diligence to successfully develop a new drug. This is a tribute to the indomitable spirit of the Indian scientific community. The drug fills a vital therapy gap not only inIndia but also worldwide. We will make all possible efforts to make Synriam accessible to the world.”

 

Arun Sawhney, CEO and Managing Director, Ranbaxy said, “It is indeed gratifying to see that Ranbaxy’s scientists have been able to gift our great nation its first new drug, to treat malaria, a disease endemic to our part of the world. Synriam will certainly become the preferred option in the hands of doctors to fight malaria, which every year claims more than half a million lives globally.”

 

“This is a historic day for science and technology in India as well as for the pharmaceutical industry in the country. Today, India joins the elite and exclusive club of nations of the world that have demonstrated the capability of developing a new drug.”added  Sawhney.

 

 Ranbaxy is also working to make this new treatment available in African, Asian and South American markets where Malaria is rampant. Synriam trials are ongoing forPlasmodium vivax malaria and a paediatric formulation.

 

Traditional drugs are proving ineffective against the deadly malarial parasite because it has progressively acquired marked resistance to available drugs. Availability of plant based Artemesinin, a primary ingredient in established anti-malarial therapies is finite and unreliable. This leads to price fluctuations and supply constraints. Most of the existing therapies have a high pill burden that increases the possibility of missing a dose. There was a critical need for a new anti-malaria drug that would address these challenges. Ranbaxy embarked upon this development project with the aim of coming up with a new anti-malarial drug that would be highly effective as well as address the issues associated with the most commonly used therapies.


FDA Safety Changes: New Adverse Events Added to Finasteride Label 

In 2011, both labels for finasteride 1 mg and finasteride 5 mg were revised to include erectile dysfunction that continued after drug discontinuation.

The FDA approved finasteride 5 mg in 1992 to treat benign prostatic hyperplasia and finasteride 1 mg in 1997 to treat androgenic alopecia in men. Finasteride 1 mg is also used off-label to treat unwanted facial hair in women. It has also been studied for chemoprevention of prostate cancer and is used off-label for this, but this use has not been approved by the FDA.

Adverse Event Reports Prompt Action

The FDA notes that sexual adverse effects were reported by patients during clinical trials of finasteride, a 5-alpha reductase inhibitor, and that this information was included in the drug's labels at the time of approval. In clinical trials, these adverse effects resolved in patients who stopped taking finasteride, as well as in most patients who continued therapy.

For finasteride 1 mg, the FDA reviewed 421 postmarketing reports of sexual dysfunction submitted to the agency's Adverse Events Reporting System database between 1998 and 2011. Of these, 59 cases reported sexual dysfunction that lasted for at least 3 months after discontinuation of the drug, and included erectile dysfunction, decreased libido, problems with ejaculation, and orgasm disorders.

For finasteride 5 mg, the FDA reviewed 131 cases of erectile dysfunction and 68 cases of decreased libido associated with the drug that were submitted to the drug sponsor's global safety database between 1992 and 2010. Where information was available, these reported events of erectile dysfunction and decreased libido lasted for at least several weeks after drug discontinuation, the FDA says.

"Despite the fact that clear causal links between finasteride (Propecia and Proscar) and sexual adverse events have NOT been established, the cases suggest a broader range of adverse effects than previously reported in patients taking these drugs," the FDA notes in a statement. "Information about these adverse events may be important to individual patients. Therefore, prescribers and patients need to be aware of them, as part of a discussion of risk and benefits of finasteride when determining the best treatment options," the statement continued.

The agency notes that in controlled clinical trials of finasteride 1 mg, 36 (3.8%) of 945 men reported 1 or more adverse sexual experiences compared with 20 (2.1%) of 934 men who received placebo.

Sexual adverse events associated with finasteride 5 mg surfaced in 2 clinical trials. In 1 trial, these events were reported more frequently during the first year of treatment compared with in men who received placebo. In years 2, 3, and 4 of the trial, there was no significant difference between treatment groups in the incidences of impotence, decreased libido, and ejaculation disorder, the FDA says.

 


FDA panel approves OraSure's home HIV test kit

<!--[if !vml]--><!--[endif]-->


(AP) WASHINGTON - A panel of HIV specialists is recommending that U.S. regulators approve the first over-the-counter HIV test designed to quickly return a result in the privacy of a person's own home, a new option which could expand testing for the virus that causes AIDS.

The 17 members of the Food and Drug Administration advisory panel voted unanimously that the benefits of OraQuick HIV test outweigh its potential risks for consumers. The test kit uses a mouth swab sample to detect the presence of HIV within 20 minutes.

The manufacturer OraSure already sells a version of the test to doctors and other health professionals. Studies showed the test was less accurate when used by consumers, but panelists said that the benefits of expanding HIV testing outweigh a small decrease in test accuracy.

According to OraSure's website, more than 1.1 million people in the U.S. are infected with HIV and 232,700 don't know it. These uninformed people "cause 54-70% of the 56,300 new infections annually."



NEW ANTI-MALARIA DRUGS ON THE HORIZONE?

A joint research program is ongoing at the Novartis Institute for Tropical Diseases, Genomics Institute of the Novartis Research Foundation, Swiss Tropical and Public Health Institute and Scripps Research Institute to discover the next generation of antimalarial drugs.

The program is funded by the Welcome Trust, the Development Board of Singapore and the Medicines for Malaria Venture (MMV).

In 2010, the research led to a promising new drug candidate for the treatment of malaria which began a phase 2 clinical trial during 2011. Even if these tests are successful, the route to regulatory approval could take up to eight years. This compound is the first in a new class called spiroindolones and kills the blood stages of Plasmodium falciparum and Plasmodium vivax through a mechanism of action that is different from existing antimalarial drugs.1 The compound has demonstrated great antimalarial potential and pharmacokinetic properties suitable for a once-daily oral dose.1 Recognized for its potential as a next generation treatment for malaria, this new compound received the MMV “Project of the Year Award 2009.” 2

In 2011, the same group announced the discovery of a new dual-acting class of antimalarial compounds – called imidazolopiperazines – that act on both blood and liver infections, and could become the first class to prevent and treat malaria if it can be confirmed in clinical trials.3 The results and methodology of this successful study have been released to the public domain with the aim of facilitating global discovery efforts.


 

EU Approves Pixantrone for Non-Hodgkin's B-Cell Lymphomas

May 11, 2012 — Pixantrone (Pixuvri, Cell Therapeutics) has received conditional marketing authorization from the European Commission as monotherapy for the treatment of adults with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas (NHL).The drug is the first approved treatment in the European Union (EU) in this patient setting.As part of the conditional marketing authorization for pixantrone, Cell Therapeutics will be required to complete a postmarketing study to confirm its clinical benefit.According to the company, it will make pixantrone immediately available in the EU through a "named patient program," and will conventionally market the drug in the second half of this year.Pixantrone "is a welcome addition in our efforts to control disease progression in these late-stage aggressive NHL patients, as it has demonstrated a significant benefit compared to standard treatments used at this stage of disease. By addressing this unmet need, [pixantrone] adds an important treatment option for patients," said Norbert Schmitz, MD, PhD, from the Department of Hematology at the Askelepios Klinik St. Georg in Hamburg, Germany, in a press statement from the company.The conditional approval comes only 2 months after pixantrone received a positive opinion from the European Committee on Medicinal Products for Human Use.The agent has not fared as well in the drug approval process in the United States.In January, the company withdrew its New Drug Application from the US Food and Drug Administration (FDA), saying it needed additional time to prepare for a second review by the FDA Oncologic Drugs Advisory Committee (ODAC). In 2011, the ODAC rejected the drug and requested further data.Pixantrone is described by the manufacturer as a novel anthracycline-like product, but with structural differences and modifications that give it enhanced antilymphoma activity and a reduced propensity for acute cardiotoxicity.The conditional approval of pixantrone in the EU is based on the results of a phase 3 study showing that a greater proportion of patients with relapsed aggressive B-cell NHL achieved a complete response or unconfirmed complete response to pixantrone than patients receiving gemcitabine/rituximab (20% vs 6%). Patients receiving pixantrone also had superior progression-free survival (10.2 vs 7.6 months).Cell Therapeutics reported that the most frequent adverse effect seen in the clinical studies was suppression of bone marrow, resulting in low levels of white blood cells, platelets, and red blood cells.According to the company, a summary of product characteristics, which includes full prescribing information, will be posted to the European Medicines Agency Web site in the next few weeks.One vial of pixantrone contains 29 mg of the agent; it must be reconstituted and diluted before use. The recommended dose is 50 mg/m² on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles. The dose has to be adjusted before the start of each cycle on the basis of nadir hematologic counts or maximum toxicity from the preceding cycle of therapy.There are many subtypes of NHL, but aggressive B-cell NHL is the most common. Initial therapy for aggressive NHL with anthracycline-based combination therapy cures up to 60% of patients. Of the remaining patients, approximately half will respond to intensive second-line treatment, and some are cured with stem cell transplantation.Until pixantrone, there has been no drug approved for patients who further fail to respond or who relapse.


European Medicines Agency approves 100th herbal Community monograph

The Committee on Herbal Medicinal Products (HMPC) at the European Medicines Agency has approved its 100th herbal Community monograph since the Committee began work in 2004. This is a significant achievement for the Committee and a key step in supporting the harmonisation of procedures and provisions for herbal medicinal products within the European regulatory framework. The information contained in a herbal Community monograph is used by Member States to support the evaluation of marketing applications from companies for medicines containing a herbal substance, a herbal preparation or a combination of one or more of both herbal substances and herbal preparations. A Community herbal monograph comprises the HMPC’s scientific opinion on the herbal medicine based on its evaluation of available scientific data (well-established use) or on the historic use of that product in the European Community (traditional use) and includes:  

  • what the herbal product is used for;
  • who can take the herbal product (e.g. adults only or children as well, in pregnant and lactating women, etc.);
  • safety information such as information regarding undesirable effects and interaction with other medicines.

All of the Committee's assessment work on herbal medicinal products including the herbal Community monographs can be searched under herbal medicines for human use


Breaking news…....

PPB published a list of all practicing Pharmacists and the premises they are licenced to practice in the Standard today (Friday 11/5/2012). 


Job opportunity.


Nairobi Hospital-Pharmacist. REF:HRD/P/05/12.

Requirement: 1 year experience, annual practice license.

 

Apply to;

The Human Resources manager,

The Nairobi Hospital,

P.O. Box 30026,

Nairobi-00100.

Or

recruitment@nbihosp.org

Deadline 25/5/12.


 

Ministry of Medical services-Pharmaceutical Technologists.

4 posts- 1 coast, 3 Northern arid lands.

Attach copy of ID.

Salary per month: 32,032.

Deadline 25/5/12

Apply to.

The provincial Director of Medical services,

Nairobi Province,

Nyayo House, 10 floor room 24.

P.O. Box  34349,

Nairobi-00100.


 

Pan Pharmaceuticals- Med Reps- Pharmaceutical Technologists.

Apply to:

The human resources manager,

Pan Pharmaceuticals Ltd,

House of Vanguard building, Fuji plaza Westlands,

P.O. Box 47393-00100

Nairobi.

Or

humanresource@panpharmaceuticals.co.ke

Deadline 31/5/2012.

 


Kemsa to commercialise its operations

State medical distribution firm Kenya Medical Supplies Agency (Kemsa) has received Sh900 million from USAid to help overhaul its operations.The parastatal’s overhaul has been in the pipeline since 2008 when the Medical Services ministry dissolved the board and put in place new management.Under the programme facilitated by Deloitte Consulting, the parastatal’s legal framework will be redrawn with the Kemsa Bill already in the process of enactment.In the reforms, the firm will explore means of recapitalisation to improve sustainability and its service to State health centres countrywide. Kemsa is supposed to commercialise its operations after strengthening its huge supply chain.The firm recently unveiled its 2011-2016 Strategic Plan to guide its reforms.“The reviewed plan lays foundation for the achievement of Kemsa’s policy objectives and aspirations for the next five years,” Ms Mary Ngari, the Medical Services PS, said in a statement. the American development agency has been supporting the firm since mid last year and has helped automate its operations including the setting up of an Enterprise Resource Planning.The government has also offered Kemsa five acres of land to expand its stores.The changes has won the agency trust of government and donors, said Mr Dominic Kabiru, Kemsa communication officer.



MHRA suspends licence for generic levothyroxine 100 microgram tablets (TEVA and Numark)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 medicines recall alert (action within 5 days) for all remaining in date stock of Levothyroxine 100 microgram tablets issued under the Teva UK or Numark liveries.

Pharmacists should quarantine remaining stock of the affected batch and return them to the original supplier.Levothyroxine 100 microgram tablet (Teva UK) had its marketing authorisation suspended in February 2012  following manufacturing difficulties and concerns about its interchangeability with other available levothyroxine 100 microgram tablets. Pharmacists receiving enquiries from patients currently on Teva or Numark levothyroxine 100 microgram tablets and who are in the group of patients identified where control of thyroid function is particularly important should advise them to contact their doctor for an early appointment. These patients include:

• Patients  with heart disease
• Pregnant woman, throughout pregnancy but especially those in the first trimester
• Patients who following treatment for thyroid cancer are on TSH suppressive doses of levothyroxine


 

HOPAK CPD committee.

An invitation is hereby extended to you to attend this month's CPD on Health Economics as a specialization in Pharmacy on Thursday, 10th May 2012, 6.30pm at The Panafric Hotel, Nairobi.

Please extend this invitation to your fellow colleagues by placing the attached flier on your notice board. We would request members attending to send questions regarding Health |economics/Pharmacoeconomics in advance to be handled by the speaker 

 


The Nairobi Hospital CME Schedule.

Recent Advances in Management of Breast Cancer by Prof. J. A. Adwok Consultant General Surgeon 0n 22/5/2012 at 12:30pm


 

CHEMISTS FOR SALE.

1. Chemist Buruburu Phase 2 shopping centre Telephone no. 0722288484.

2. Chemist Ongata Rongai-Well located & established  Telephone no. 0735319991

 

KMTC-SECOND SCIENTIFIC CONFERENCE 9-11/MAY/2012.

Venue: school of Nursing assembly hall-KMTC Nairobi.

Theme: Medical training & innovations towards realisation of vision 2030. 


Career opportunities.

The Aga khan University Hospital Nairobi, invites applications from suitably qualified individuals for the following positions:

1) Pharmacist: The Pharmacist will ensure correct interpretation of prescriptions and physicians orders at both in-patient and out-patient levels to enable accurate compounding, dispensing, patient education and handling of pharmaceutical supplies for all orders. S/he will provide effective pharmaceutical services to meet customer needs.

 2) Supervisor, Pharmacy Stores: will plan, supervise and monitor the activities and services of the pharmacy stores and will be responsible for overall operational management of the pharmacy drug stores, including purchasing, financial performance, inventory control, customer service (internal/external) and staff.

Applicants for both jobs must have a degree in Pharmacy, annual practice licence, registered with PSK, have minimum 3 years hospital experience working in pharmaceutical services and 3 years experience in stores management respectively.

Applications together with detailed CV, names of 3 referees, telephone contact, email address and copies of certificates and testimonials should be send to, The Manager, Recruitment Aga Khan University Hospital, Nairobi P.O. Box 30270, 00100, Nairobi or by email to hr.recruitment@aku.edu so that to reach not later than 23/5/2012. Applications by email preferred. Only shortlisted candidates will be contacted. 

 

 

 


 

INVITATION TO PRACTICE BASED TRAINING WORKSHOP FOR HIV/AIDS PRACTITIONERS IN PRIVATE AND COMMUNITY SETTINGS

DRUG RELATED CHALLENGES IN THE MANAGEMENT OF HIV/AIDS: HIV/AIDS, NUTRITION AND ART

Dates: 26th May 2012

Time: 8.30 am to 5.00 pm

Venue: Hotel Cathay

Workshop Goal

To discuss pharmaceutical related challenges in the care and treatment of PLWHA with focus on Nutrition and ART and potential drug- food interactions.

Target Audience

Healthcare workers involved in the treatment and care of PLWHA in the private and community settings. Includes physicians, nurses, pharmacists, nutritionists, pharmaceutical technologists, laboratory staff and adherence counselors.

Registration

Registration is Free. Space is limited to 90 persons per workshop. Participants are encouraged to confirm attendance to PSK regional offices.

Future Topics

  1. TB & TB/HIV AIDS Collaboration

RSVP

Dr. Lian Siti 0722427721

Dr. Joseph Chege 0722373195 jcmuhunyu@yahoo.com

Dr. James Kamote 0733898911

Organized by the Pharmaceutical Society of Kenya, Nairobi with support from USAID and Management Sciences for Health/ Health Commodities and Services Management (MSH/HCSM) program

 



P S K ANNUAL CONFERENCE THURSDAY 31ST MAY – SUNDAY 3RD JUNE 2012 
 

CONFERENCE PACKAGE 

 

 

Option A – Flight Package with KQ AT WHITESANDS

 

The Package Includes RETURNS FLIGHT, CONFERENCE AND TRANFERS at Mombasa but Excludes drinks.                                                                                                                               

                                                                                                                      Three Days                Two Days           One Day

Per Adult single room                                                                                      Ksh. 51,500                Ksh.  42,500       Ksh. 31,500          

Adult sharing double room (2 people Flight) (one Pharmacist)         Ksh.86,000                 Ksh.  73,000       Ksh.55,500

Adult sharing double room (2 people Flight) (Two Pharmacist)       Ksh.88, 000                 Ksh 75,000        Ksh.58,000

Child 3-12 Years sharing with parents                                                    Ksh.29,420                  Ksh 26,170         Ksh 20,420

Child under 3- 12 Years in an Exclusive room (2 kids)                          Ksh. 74,250                 Ksh 64,500           Ksh 49,750            

 

Flight cost for children below 3yrs                                                         Ksh 1000.00

Option B – Flight Package with FLY 540 AT WHITESANDS

 

The Package Includes RETURNS, FLIGHT and CONFERENCE at Mombasa but Excludes drinks.                                                                                                                                  

                                                                                                                     Three Days                Two Days           One Day

Per Adult single room                                                                                         Ksh 48, 500               Ksh 39,500        Ksh 28,500

Adult sharing double room (2 people Flight) (one Pharmacist)         Ksh 80,000                Ksh 67,000        Ksh 49,500

Adult sharing double room (2 people Flight) (Two Pharmacist)       Ksh 82,000               Ksh 69,000         Ksh 52,000

Child 3-12 Years sharing with parents                                                         Ksh 26,000                Ksh 22,750        Ksh 17,000

Child under 3- 12 Years in an Exclusive room (2 kids)                           Ksh 61,750               Ksh 52,000         Ksh 37,250            

 

Flight cost for children below 3yrs                                                       Ksh 1000.00

Option C – Accommodation Package half- board 3 nights At WhiteSands.

 

Per Adult single room                                                                                           Ksh 34,000             Ksh 25,000           Ksh 14,000

Adult sharing double room (2people 2Pharmacist)                                  Ksh 53,000              Ksh 40,000          Ksh 23,000

Adult sharing double room (2people, 1Pharmacist)                                 Ksh 51,000               Ksh 38,000         Ksh 20,500

Child 3-12 Years sharing with parents                                                          Ksh 14,750                Ksh 11,500         Ksh 5,750

Child under 3-12 Years in an Exclusive room (2 Kids)                              Ksh 39,250               Ksh 29,500          Ksh 14,750

 

Option D- FLIGHT Package with Kq at Travellers

The package includes Return Flight, Conference and Transfers

 

                                                                                    Three Days                   Two Days                    OneDay

Per Adult Single Room                                                    Ksh 48, 500              Ksh.40, 500              Ksh30, 500

 

Adult Sharing Double Room (2peopleFlight1Pharmacist) Ksh 83,000                    Ksh.71, 000                 Kshs.54,500

 

Adult sharing double room (2people 2Pharmacist)                 Ksh 85,000                         Ksh 73,000                      Ksh 57,000

 

Child 3-12 Years sharing with parents                                Ksh 28,670               Ksh25, 670              Ksh20, 170

 

Child under 3-12 Years in an Exclusive room (2 Kids)             Ksh 66,340                       Ksh 57,340                     Ksh 43,340

 

 

 

 

Option E – Flight Package with FLY 540 AT Travellers

 

The Package Includes RETURN FLIGHT, Conference and Transfers at Mombasa but Excludes drinks.                                                                                                                                  

                                                                                                                    Three Days                Two Days           One Day

Per Adult single room                                                                                      Ksh 45,500               Ksh 37,500          Ksh 27,500

Adult sharing double room (2 people Flight) (one Pharmacist)      Ksh 77,000                   Ksh   65,000        Ksh 48,500

Adult sharing double room (2 people Flight) (Two Pharmacist)     Ksh 79,000             Ksh         67,000         Ksh 51,000

Child 3-12 Years sharing with parents                                                      Ksh 28,500                Ksh   25,500         Ksh 20,000

Child under 3- 12 Years in an Exclusive room (2 kids)                        Ksh   59,500             Ksh 50,500         Ksh 36,500

 

 

 

Option F – Accommodation Package half- board 3 nights At Travellers

 

Per Adult single room                                                                                      Ksh 31,000             Ksh 23,000           Ksh 13,000

Adult sharing double room (2people 2Pharmacist)                              Ksh 50,000            Ksh 38000             Ksh 22000

Adult sharing double room (2people, 1Pharmacist)                             Ksh 48,000            Ksh 36,000           Ksh 19,500

Child 3-12 Years sharing with parents                                                      Ksh 14,750            Ksh 11,500           Ksh 5,750

Child under 3-12 Years in an Exclusive room (2 Kids)                         Ksh 19,750            Ksh16, 500            Ksh 8,250

 

 

 

 

 

 

 

OPTION G.CONFERENCE ONLY

2 Days is Ksh.7000

1 Day is Ksh.5000

 

LATE PAYMENTS

If Payment for the conference is received after 1st May, 2012, you add Ksh 1500

If Payment is received after 20th May, 2012 you add Ksh 3000

 

Above conference Package includes:

*       Am/pm tea, coffee, cookies and mineral water in the conference hall.

*       Use of fully air conditioned conference room

*       Buffet lunch with one soft drink per person

*     PA system with two codeless mics, flipcharts,screen,markers, pen, writing pads, TV, video, and screen

*       One secretariat room

 

 

 

 

 

 

FLIGHT SCHEDULES NAIROBI – MOMBASA 31ST MAY- 3RD JUNE 2012

 

 

 

 

 

KQ

 

 

31st May  2012

 

3rd June 2012

 

Departs  Nairobi

Arrives Mombasa

Departs Mombasa

Arrives Nairobi

9.30am

10.30am

11.30am

12.30pm

11.10am

12.10pm

13.10pm

14.10pm

1.00pm

2.00pm

7.00pm

8.00pm

3.00pm

4.00pm

6.00pm

7.00pm

4.30pm

5.30pm

8.00pm

9.00pm

8.00pm

9.00pm

8.00pm

9.00pm

 

 

 

 

 

 

 

 

 

 

 

 

 

Fly  540

 

 

31st May  2012

 

3rd June 2012

 

Departs  Nairobi

Arrives Mombasa

Departs Mombasa

Arrives Nairobi

6.45am

7.45am

8.20am

9.20am

9.30am

10.30am

1.30pm

2.30pm

 4.00pm

 5.00pm

 

 

7.00pm

8.00pm

 

 

 

 

 

 

Note:

1. Subject to Confirmation of timings for Fly 540 ONLY.

2. Change of ticket after Reservation Ksh.2000/= will be charged by KQ.

3. For other flights date and time please conduct PSK office.  

 

 

FDA Panel Recommends Lorcaserin for Obesity

May 15, 2012 — In an 18 to 4 vote with 1 abstention, the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee recommended the approval of lorcaserin for the treatment of obesity, paving the way for the first approval of a prescription drug to treat obesity in more than a decade.

The panel was asked to evaluate the safety and efficacy of lorcaserin as an adjunct to diet and exercise for weight management in patients with a body mass index (BMI) of 30 kg/m2 or a BMI of 27 kg/m2 with weight-related comorbidities.

The panel was charged with answering a single question: "Do the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals?"

The FDA previously rejected a new drug application for lorcaserin in 2010, citing increased risks for cancer. New data submitted by Arena Pharmaceuticals appeared to alleviate many of those concerns, and the FDA agreed in a background report that the risk for tumors in patients is "negligible."

However, despite voting yes, panel member Jack Yanovski, MD, PhD, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development in Rockville, Maryland, argued that Arena had not conclusively demonstrated that lorcaserin did not increase the risk for breast cancer.

The panel also expressed concern about the apparent increased risks for valvulopathy and adverse cardiovascular events associated with lorcaserin. A number of panel members suggested requiring echocardiograms before prescribing lorcaserin.

Panelists who voted against approval indicated that the drug's uncertain risk profile outweighed the modest benefits of the drug. In clinical trials, participants taking lorcaserin lost only 3.1% more weight in 1 year than those in the placebo group, falling short of a key FDA criterion for drugs targeting obesity.

However, 38% of participants in the lorcaserin group lost at least 5% of their starting body weight compared with 16% of those in the placebo group.

In voting no, Sanjay Kaul, MD, from the University of California, Los Angeles, argued that the benefits of lorcaserin do not exceed its risks.

"Benefit–risk assessment is essentially a qualitative science grounded in quantitative data and dependent upon judgment," Dr. Kaul said during the meeting. "Using this framework, the totality of evidence does not persuade me to conclude that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals."

If granted full approval by the FDA later this year, lorcaserin would become the second prescription medication approved for treating obesity, joining orlistat (Xenical, F. Hoffmann-La Roche; Alli, GlaxoSmithKline), which was approved by the FDA in 1999.


Blood Glucose Monitor App Gains FDA Approval.

May 15, 2012 — The iBGStar blood glucose monitor for iPhone and iPod touch, manufactured by Sanofi Diabetes, has now gained clearance by the US Food and Drug Administration, making it the first blood glucose meter that directly connects to the iPhone and iPod touch.

The company announced last week that the iBGStar Blood Glucose Monitoring System, consisting of the iBGStar blood glucose meter and iBGStar Diabetes Manager App, would be available in the United States. It had already been available in the United Kingdom.

According to the company, the iBGStar system consists of a glucose monitor that attaches to an iPhone or iPod Touch via the 30-pin dock connector. The app is designed to track glucose, insulin, and carbohydrates, and it charts individualized glucose patterns over time. Data can be emailed to healthcare professionals as needed.

Information collected and displayed by the device includes a trend chart, which shows a graph plotting glucose readings and gives a visual representation of blood glucose levels over time; a logbook, which provides a detailed record of glucose readings, organized by meal relationship tags for each reading; statistics, which offer preset average glucose results for a period of 7, 14, 30, or 90 days or a customized date range; and alerts, which provide color-coded hypo and hyper alerts when blood glucose readings are out of range.

The device is compatible with the second-, third-, and fourth-generation iPod Touch and the iPhone 3G, 3GS, and 4.

 


Plavix Set to Lose Patent Protection

For more than a decade, cardiologists treating patients who have had a heart attack have routinely scribbled one drug onto their prescription pads: clopidogrel bisulfate, better known as Plavix.

“It’s a mainstay,” said Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic. Before Plavix arrived in 1997, aspirin was the standard treatment for preventing blood clots that led to heart attacks and stroke. Combining aspirin with Plavix, though, “tremendously improved” the results, Dr. Nissen said.

But now, in a farewell that has been years in the making, the story of Plavix is coming to an end. The drug is set to lose its patent protection on Thursday. Faced with an expected influx of cheaper generic alternatives, Bristol-Myers Squibb, which sells Plavix in the United States under a partnership with Sanofi-Aventis, has said it no longer plans to actively promote the drug.

“This is one of the behemoth drugs that really defined the drug industry in the ’90s,” said Catherine J. Arnold, an analyst for Credit Suisse.

Bristol-Myers is hardly the only company to face the loss of a best-selling drug: at least 19 are set to lose patent protection this year, which is expected to cost the pharmaceutical industry about $38.5 billion in lost sales, according to an analysis by Barclay’s. About 80 percent of the prescriptions written in the United States are now filled with generic drugs.

The loss of the company’s top product is sure to sting. Plavix brought in $7.1 billion in net sales in 2011, accounting for a third of revenue for the year, according to Bristol-Myers filings. In the 15 years since it entered the market, Plavix generated $42.8 billion in sales for Bristol-Myers, according to IMS Health, a health care services company. It is the biggest name-brand drug to lose patent protection since Lipitor, made by Pfizer, encountered generic competition late last year.

With the loss of patent protection for Plavix and Lipitor coming in such quick succession, “this year is a year that pharmaceutical insiders refer to as ‘pharmageddon,’ ” Dr. Nissen said.

But while Pfizer moved to retain its market share of Lipitor for as long as possible — by selling its own authorized generic version and negotiating aggressive deals with insurers and pharmacy benefit managers to match or beat the price of generic alternatives — Bristol-Myers has said it has no plans to hold onto Plavix, other than to offer a limited-time discount plan for patients who wish to continue with the brand-name drug. The company stopped running television advertisements in June.

“We expect a rapid, precipitous and material decline in Plavix net sales,” company officials wrote in the 2011 annual report. Analysts expect the price of generic alternatives to be substantially lower than brand-name Plavix.

Usually, drug prices take several months to drop because one generic company — the first to file an application with the drug agency — is granted the exclusive right to market the drug for the first six months. But Plavix is different because the company that won that right, the Canadian drug maker Apotex, forfeited its exclusive period after it flooded the market in 2006 with unauthorized generic versions of the drug.

In what amounted to a dress rehearsal for this year, Plavix lost an estimated $1 billion in sales when Apotex, which had challenged the drug’s patent, managed to distribute a six-month supply before a judge ordered the company to stop.

Negotiations with Apotex over the patent also landed Bristol-Myers in trouble with federal authorities. Bristol-Myers ultimately paid more than $3 million in civil and criminal fines after the Justice Department claimed it had entered into a secret deal with Apotex to delay offering its own generic version of the drug during Apotex’s exclusivity period. A former Bristol-Myers senior vice president pleaded guilty to making a false statement to the government in the case.

Because Apotex lost its exclusivity, seven companies have received tentative approval to market the generic drug. Dr. Reddy’s Laboratories received approval in 2008 to market a 75-milligram dose, but it has been prevented under a court order from selling the drug. The agency often, but not always, gives final approval to generic drug companies on the day the brand-name drug loses patent protection.

Uday Baldota, a spokesman for Sun Pharmaceutical Industries, an Indian drug maker that has received tentative approval to sell generic Plavix, said his company often planned for the introduction of a new drug seven to eight years ahead of time, with the goal of shipping the new drug “as soon as the patent expires,” he said in an e-mail. Once the company receives final approval, the plan unfolds with extreme precision, he said. “I would not be surprised if there was a stopwatch involved!”

A spokeswoman for the large drug distributor Cardinal Health said the company planned to begin shipping generic Plavix on Friday.

Analysts have largely credited Bristol-Myers with successfully planning for its future after Plavix. In recent years, it has moved away from its primary care business and into specialty pharmaceuticals, using cash from the sales of smaller business units to finance the purchase of several small biotechnology firms.

Last year, the company won approval of a drug to treat melanoma, Yervoy. In June, the Federal Drug Administration is expected to decide on approval of a blood-thinning drug, Eliquis, that Bristol-Myers is developing in partnership with Pfizer. Eliquis belongs to a new class of drugs intended to help prevent strokes in people with the heart arrhythmia known as atrial fibrillation. If approved, analysts expect it to bring in billions of dollars in revenue.

“It really turned out to not just be rhetoric,” Ms. Arnold of Credit Suisse said. “They really have created a confidence in investors that there is life beyond Plavix.”

 


 

University of Nairobi, Bachelor of Pharmacy Alumni 1978-2006.

 UNDERGRADUATE

1978

1. Amani, Rashid Abdi

2. Dalizu, Paul Agutwi

3. Gachanja, James Mungai

4. Guantai, Anastasia Nkatha (Mrs.)

5. Indalo, Ane Achiando (Mrs.)

6. Inyangala, Alice Kigadi

7. Itotia, Esther Wanjiru

8. Kailemia, Iruki

9. Karenju, Simon

10. Kerongo, Charles Joseph

11. Masafu, George Sirengo

12. Mbugua, Paul Mungai

13. Mareka, Joseph Kanyotu

14. Mkoji, Lambert Maganga

15. Muchemi, Deborah Shadrack

16. Mwangi,Chris James Waithaka

17. Mwangi, Jane Catherine

18. Nandy, Philip Harold Agola

19. Ndarathi,Christopher M

20. Ngumboh, S. D. N

21. Nyariki, Samuel

22. Ochieng, Mary Edith

23. Omondi, James Jure

24. Onyango, Gilbert

1979

1. Aluoch, Jeniffer Akinyi

2. Gatukui, Samson Kanyeki

3. Gikunda, Joyce Nkatha

4. Karanja, Gabriel John Wainaina

5. Kerewoi, Joseph Ernest Bionosia

6. Kibwage, Ongubo Isaac

7. Kingori, Duncan A. Ndirangu Jr.

8. Kirugumi, Joel Riua

9. Lawuwala, Kulsum A. H.

10. Mitha, Mahmud Kasamaly

11. Mutisya, Benard J.N.

12. Mutungi, Samson Kithinji

13. Mwangi, Joseph Gitau

14. Mwangi, Julius Wanjohi

15. Njogu, Florence Mumbi

16. Nkabu, Grace Karegi

17. Odhiambo, Edward

18. Ominde, Elizabeth Mary O

19. Ouma, Manuel

20. Owuor, Edwin Hezron

21. Sarang, Khadija Husein Esmael

22. Wako, Abdulahi Haji

23. Wakori, Kamunyu Edith (Mrs.)

24. Wandera, Wa Nachieri

25. Wanjau, Johnson Kamunya

26. Wangia, Christine Ong’ayo (Mrs.)

27. Onyango, James D.

1980

1. Benderi, Stephen Mulama

2. Cheruiyot, Mike Kipkoros M.

3. Isiolo, Solomon Aligula

4. Kamau, John Kago

5. Karangu, Kamau

6. Kiama, Bilha Muthoni (Mrs.)

7. Kagotho, Wallace Kamau

8. Kimani, Lawrence Mirie

9. Kunga, Jacob Mututa

10. Macharia, James Githigia

11. Monda, Jason Makori N

12. Muverethi, Bibiana Kanduka

13. Njagi, Anthony Nyaga

14. Njega, Eunice Adhiambo

15. Njeru, Stephen Tennyson

16. Njoki, Angelina Gakuya

17. Odula, Olale Petronilla

18. Lwenya, Mario Ogonji

19. Oyaro, Charles

20. Salim, Jamila

21. Shah, Raksha Kantilal

22. Ssinei, Kipruto Arap

23. Wahome, Githui Gikuhi

24. Mulaa, Alice (Mrs.)

1981

1. Ajuan’g, James Ongoro

2. Amakobe, Wycliffe Roosevelt Nam Uteya

3. Kamau, Ruth B

4. Kanjagua, John Mwaniki

5. Karaba, Leonard Mwangi

6. Karago, Polly Njoki

7. Kigondu, Rosemary Wambui

8. Matharu, Gursharanjit Kaur

9. Mburu, Patrick Ngugi

10. Mwangi, Nelly M. Nyambura

11. Mwangi, Mary M. Wairimu

12. Mwangi, Tabitha Kabura John

13. Ndwiga, Pius Ngondi

14. Ngetheh, John Njenga

15. Njenga, Naomi Waithera

16. Njug’e, Kung’u

17. Odeck, Margaret Ng’wono

18. Odwako,Beatrice Alice

19. Okumu, Francis Ochola

20. Opannga ,Lavender

21. Peera, Sheila

22. Runyora, Stephen Kihagi

23. Wanyaga, Wilberforce Omutanyi

24. Aseka, Lydia Ometa

25. Kinyua, Harris Chabi

26. Waithaka, Catherine Wambui

27. Marigah, Joseph O.M.

28. Ongusi, Noel Atemi

1983

1. Alai, Sarah Akoth

2. Hajee, Yasmin

3. Bururia, John Mutwiri A.

4. Kaponda, Desiderious Kinyua

5. Gakuya, Mary W

6. Kidero, Odhiambo Evans

7. Gatheru, Murungi Mary

8. Kimachia, John

9. Maina, Francis Mugoro

10. Maina, Josephat Waimutitu

11. Masita, James Isaboke

12. Mucheru, Mary Njeri

13. Muchiri, Tabitha Wanjiku

14. Mungai, Godfrey Kamau

15. Ndung’u, Lucy Njery

16. Ngaya, Aloyo Beauttah J

17. Ngugi, Margaret Njeri

18. Njiru, Dolly Muthoni

19. Ogoro, William Gisore

20. Okech, Catherine Atieno

21. Rae, Samwel Ouma

22. Shah, Priti Amritlal

23. Wachira, Purity N

24. Wambugu, Joseph Kahugu

1984

1. Aduvagah, Isaac Alutah Mazozo

2. Auma, Joe P. Otieno

3. Ganiwalla, Imtiaz Karim

4. Gikore, Solomon K.

5. Hezekiah, Michael Thuo

6. Inyagala, Peter

7. Ikugu, Simon K.

8. Kamau, Peter Wainaina

9. Karuri, Gerald Maina

10. Kanyogo, J.K Waweru

11. Kiarie, William Njoroge

12. Kinyanjui, Mbugua James

13. Malji, Asad S. E

14. Mbatia, Jane Muthoni

15. Miyawa, Gabriel Wanyama

16. Mukoya, Gabriel Wanyama

17. Mwamuzi, Catherine Kijala

18. Mwaura, Lawrence Kinuthia

19. Njoka, Nicholas J.

20. Nyagah, Pattedy

21. Owino, Peter James

22. Roberts, Anna

23. Sama, Abduba Wako

24. Tsiki, Maphomolo (Mrs.)

25. Tum, Henry Kimutai Arap

26. Wanyagah, James M. P

1985

1. Atebe, James Mandere

2. Gaku, Peter Muchiri

3. Gattimu, Agnes Kabithe

4. Githinji, David Gitindi

5. Kamau, Joycelyne

6. Kamau, Rechard Thuo

7. Kiare, Mary Wanjiku

8. Kitonyo, Jackson M

9. Kobia, Tarcisius

10. Koskei, Kipkerich Chumo

11. Mwendo, Joseph Robert

12. Mwathi, Isaac Ichang’a

13. Mwendia, Kunga N. J

14. Mtshangase, Herbert Nkosayibongwa

15. Odhiambo, Agullo Peter Stephen

16. Oduol, Caleb O. K

17. Ogonya, Martin H. O Shaft

18. Ombeng’I, David Nyarongi

19. Onyango, Simeon H. Otieno

20. Shah, Mahesh L

21. Vugigi, Sarah K

22. Walia, Rupa Rani

23. Wanjhala, David Wasike

1986

1. Amenya, Ngere John

2. Gachema, Serah Wanjiru

3. Gachuhi, J Munyua E

4. Getao, Dominic

5. Gichobo, Tabitha Wathoko

6. Kabuki, Tabitha Wathoko

7. Karanja, Grace Njeri

8. Kariu, Josiah Kamau

9. Kaara, Mukwamuso M

10. Kimani,Njoki Monica

11. Maina, David M

12. Midambo, Beatrice Kagai

13. Miti, Grace Wanjiku

14. Muchiri, Ndirangu Christopher

15. Mukhone, Joshua Malaba

16. Mukuria, Jesse Kang’ethe

17. Mwangi, Daniel Muigai

18. Ndivo, Julius Muoka

19. Ndua, J. Mburu

20. Ngayu, Anne Njeri

21. Njenga, Ndegwa Wa

22. Ochieng, Peter Otieno

23. Ojuang, Paskalia

24. Ombogo, Julius Okoth

25. Omete, Grace

26. Osendo, Horace Ochieng

27. Wadhwa, Dinesh

28. Wathiomo, M. G.

29. Wandera, Constence Nyakio

1987

1. Arimi, Salafino Kinoti

2. Gikonyo, Florence Wambui

3. Gitahi, Kiguongo

4. Gitau, Boniface Nganga

5. Kabue, Francis Nganga

6. Kahuo, Elizabeth Mwangi

7. Karekezi, Catherine Bangeranye

8. Kiama, Jong’e Joseph

9. Kigeni, Gabriel Kimutai

10. Kioki, Onesmus Mutinda

11. Kingori, Francis N

12. Kiruku, Moses Gakunga

13. Macharia, Esther Wambui

14. Maina, Hudson K. G

15. Mokaya, Daniel Mang’rea

16. Mwangi, Joses Ndungu

17. Mwaniki, Adrian Njoka

18. Mwanje, Kennedy Amunala

19. Nderitu, Patrick Ndirangu

20. Ojuang, Ruth O

21. Ongwae, Peter Saruria

22. Owiny, George Oguna

23. Riungu, Benson Mutwiri

24. Shah, Mala Shantilal

25. Shah, Bima

26. Thuku, Karungari Gathoni

27. Wathuku, Symon K. J

1988

1. Abdalla, Husein Jumma

2. Chavutia, Joseph Kithaka

3. Siyoi, Fred Moin

4. Gachunga, Peter Kimani

5. Gakura, Peter G. S

6. Gitonga, Richard Gataiku

7. Inyangala, Ronald Mwende

8. Kiamba, William M

9. Kimanga, Peter

10. Kimihiu, Ngiciri Wilfred

11. Kipkemoi, Wilson Rotich

12. Maina, Fredrick Kuria

13. Maina, Cynthia Waithira

14. Mangera, Kennedy Orina

15. Mbuva, Josephat N

16. Mugwika, Stanely Maore

17. Muriithi, George M

18. Ndirangu, Charles Kariuki

19. Ngenga, Joseph Nyoro

20. Njunu, Peter E. K.

21. Ramogo, Joel Aduma

22. Rutere, David Mutonga

23. Sifuma, Shaban W. Abdallah

1989

1. Asingo, Peter Ochieng

2. Barasa, Cosmas

3. Bonyo, Benjamin Odhiambo

4. Gitari, Mwangi

5. Hassan, Mohammed

6. Ngigi, Robert Kamau Willie

7. Kiprono, Barnaba Kirui

8. Lado, Peter A. Jaden

9. Maima, Apollo Odhiambo

10. Marete, Njoka Clifton

11. Mbindyo, Regina Munyiva

12. Mbugua, Paul Karanja

13. Munyu, John Mureithi

14. Muraa ,William Mutwiri

15. Muriuki, Geoffrey Kiambi

16. Mussango, Paul

17. Muturi, George Njau

18. Mwau, Maurice Ken Matibo

19. Ndahi, Moses N Mwaniki

20. Ndege, David Kamau J

21. Ndubahi, Ngeera

22. Nganju, Daniel Maina

23. Nguyu, Eliud I

24. Njaramba, J. Peter

25. Njoroge, Ephantus Irungu

26. Njue, Nelson Kirimi

27. Nyabuto, James Kinanga

28. Ogonji, O Benson

29. Wambui, Jane

30. Wandia, Susan Wachira

31. Wanyoike, Anthony Ndungu.

1990

1. Odhiambo, Nelly Rangara

2. Aduda, John O

3. Alagoroselin, Osiemo

4. Avoga, Francis Mmbai

5. Banda, Alusia Muthoni

6. Buttuck, Issac Kipkosgei

7. Chege, Veronica

8. Kabugi, Felix Wakabu

9. Kamau, Josephat

10. Karimi, Peter Ndirangu

11. Keige, John Njoroge

12. Masibo, James T

13. Mbugua, Geore Waweru

14. Muiru, Kibunja Boniface

15. Musili, Elizabeth Kamene

16. Mwangi, James Kamau

17. Nderu, Peter Wa Karanja

18. Ndiku, Cleopas Kyalo

19. Ndinika, Augustine M

20. Kayaka, Charles Musee

21. Ng’anga, Patrick Kamau

22. Otundo, Bernard Onkundi

23. Onyango, Juliana Atieno

24. Awuor, Seth Anjejo

25. Ratii, Morris Owino

26. Wachira, Ndegwa Tiras

27. Wanguba, Samuel H. O

28. Wanjithi, Joseph W. Kamana

29. Woyengo, Fredrick Cholwa

1992

1. Atieno, Mary Milcah

2. Ayoo, Edward Paul

3. Chahia, Paul Kisia

4. Gichuhi, Davies Njoroge

5. Imbambi, Phanwell Onacha

6. Chege, John Irungu

7. Kabera, Edwared Ndereba

8. Kajuju, Jane

9. Karuga, Catherine W.

10. Kibe, Kennethy Ndichu

11. Kipchumba, Yano Joseph

12. Kipkoech, Stanely Tangus

13. Machine, Ann

14. Maina, Amos G. Mureithi

15. Majong ,Florence Titu

16. Mbori, Freda Anyango

17. Mbuthia, Wanjao Wang’ombe

18. Marogo, Joseph Kibet

19. Muia, Steve Mweu

20. Muiruri, Wellington

21. Mshilla, Meshak Maghanga

22. Mwai, Samuel M.

23. Mwaniki, John Njagi

24. Kamau, Peter Njonjo

25. Mwangi, Benjamin Macharia

26. Mwasi, Stephen

27. Ndungu, Erastus Chege

28. Ngotho, Francis M.

29. Njenga, George David

30. Walela, Antony Thadeus

31. Wamae, Eric W. Gicheru

32. Wanjohi, Mishek W.

33. Wanyatu, Joan Wairimu

34. Gathura, A. Michael

35. Gitau, William Gicui

36. Gituku, John K.

37. Irungu, James C

38. Kahiga, Titus Muhu

39. Kamala, Michael Musyoki

40. Kamau, Moses Mbugua S.

41. Kamau, Peter Njonjo Kibobo

42. Kamonya, Beatrice M.

43. Karanja, Edwin Ng’ethe

44. Karugu, Henry Kamau

45. Kimani, Githiaga Isaac

46. Kimotho, Jemes Hungo

47. Kipsang, Wilson Rop

48. K’opiyo, Sammy Oyoo

49. Kotecha, Divesh Parshotan

50. Muema, Samuel Musau

51. Mugumura, John Rukungu C.

52. Muhutu, Joseph Chege

53. Mungai, Francis Maina

54. Muthike, Ceceilia Ndinda

55. Mwangi, Ayub Kariuki

56. Mwangi, Leonsrd Nduati

57. Ndirangu, Peter Karimi

58. Ndugu, Milicent Wanjiku

59. Ngigi, Dungan Wamwea

60. Njimia, Daniel W.

61. Njogu, Mwathi Wilson

62. Njoroge, Paul Timothy

63. Nthambara, Peter Njeru R.

64. Ogile, Elizabeth Akinyi

65. Ouma, Charles L.

66. Owino, Wycliffe Washington

67. Sindani, Tom Sifuna

68. Wambilibanga, Maureen

69. Wambugu, Ngugi

70. Macharia, Gerald Nderitu

71. Njuguna, Christine Njeri

1993

1. Atrithi, Japhet Kirimi

2. Asiko, Eustace O. Daniel

3. Audi, George Ouma

4. Chakava, George

5. Gatuiku, Japheth Mwaniki

6. Gichana, Methusella L.O.

7. Kabuu, Peter Ngugi

8. Kahura, Michael Njoroge

9. Kamau, Evangaline

10. Kamau, Jesse Gichema

11. Kamuren, Zipporah Toroitich

12. Mburu, David Njane

13. Karanja, David Kangethe

14. Kaugu, Stephen Kimathi

15. Kereka, Beatrice

16. Kimemia, Martha Wangu

17. Kinuthia, Mwenyura

18. Kiplagat, Charles Kandie

19. Kithuka, Jayne Mueni

20. Kombo, Thomas

21. Manyalla, Bernard W. Olila

22. Matimbai, George Mallory

23. Mbari, Margaret Wanjiru

24. Mburungo, W. Nixon

25. Menge, Tom Bosire

26. Mithamo, Patrik

27. Muchire, John Ndegwa

28. Muchiri, Zipporah Muthoni

29. Munene, Charles M.

30. Muthaka, Catherine Wangechi

31. Mutie, Dominic Mbullah

32. Mwagiru, Philip Mushiri

33. Ochieng, Spencer Osmond

34. Odhiambo, Peter F. Owino

35. Ohito, Shem Evans

36. Shah, Nitakshree

37. Thuita, Samuel Mwangi

38. Too, Kirwa

39. Tsiu, Malhoriso Paulina

1994

1. Bibi, Yuri W.

2. Cherongony, Kiplangat Robert

3. Dhanji, Jashuben

4. Gitau, Simon

5. Issac Kamamia, W. Murichu

6. Kung’u, Geoffrey Githiri

7. Lumasia, Douglas Lugaliku

8. Mak, ‘Oketch Paul Onyango

9. Mathu, Kimani Samuel

10. Mbogori, Sacket K.

11. Mbugua, Peter Muchina

12. Mburu, Mureithi Isaac

13. Momanyi, Mike Orina

14. Mukiri, Maina David

15. Mulilu, Julius Kisinga

16. Murage, Johnson K.

17. Muriithi, Thitu

18. Muthiani, Muli Ben

19. Mwaniki, Simon Gachago

20. Mwaura, John Ndichu

21. M’Mbwiri, George Mwiti

22. Ndirangu, Jackson Maina

23. Ndombi, Enock Juma

24. Neria, Christopher

25. Njagi, Jerusha Njoki

26. Nyalita, Anastasia Mutethya

27. Okalebo, Faith Apolot

28. Owino, Edwin Maua Khan

29. Ronoh, Kiplangat Wesley

30. Rotich, Thomas Kipkemoi

31. Sigei, Reuben Kiptoo

32. Thigiti, Peter Githinji

33. Thuku, Morrison Mbaro

34. Waithaka, Elizabeth W.

35. Wangai, Mary Wairimu

36. Wanyoike, K. Christopher

1995

1. Balusi, Lilian M.

2. Dave, Nahil H.J

3. Gachie, David Kariuki

4. Gichuru, Tabitha Wanjiru

5. Githendu, Mercy Nyawira

6. Githinji, Herbert Kariithi

7. Githui, Muriithi Peter

8. Ireri, Stanely Macharia

9. Irungu, Julius Ngigi

10. Kamau, Alice Gituto

11. Kamoto, James Matolo

12. Karanja, Ann Waithira

13. Kipkoech, Lucia

14. Kivoto, Patrick Musembi

15. Kusu, Ndinda

16. Marewa, Julius Wanyeki

17. Mburu, Kinuthia Samuel

18. Muiva, Cecilia

19. Mungania, George G.

20. Mutua, Wilson Kyalo

21. Mwaura, Daniel

22. Mwendawa, Daniel Mwenga

23. Ndiritu, Michael M.

24. Ngigi, Peter Ndungu

25. Ngugi, Jeremia Njogo

26. Njane, Chrispus Muiruri

27. Obat, Erick P.A

28. Ocheing, Nelson Odhiambo

29. Okelo, Jack Mark

30. Omenda, Sarah V.

31. Origa, John Odhiambo

32. Rugendo, Alfred Birich

33. Simiyu, Emmanuel Sibalileh

34. Wachira, Ashbell Macharia

35. Wangombe, Humphrey

36. Wanjiru, Grace

37. Waweru, Mwangi Peter.

1996

1. Abuga, Omondi Kennedy

2. Bosire, Kefa Ogonyo

3. Gatandi, Elizabeth Muthoni

4. Gichana, Nahashon Akunga

5. Gitei, Peter Ng’ang’a

6. Imbusi, Michael Lusiola

7. Kabuchi, Kanyiri Esther

8. Kamau, Stephen Njoroge

9. Kariuki, Nelson Kanyi

10. Kiiru, Nguru Jeremiah

11. Kinyua, Titus Kieni

12. Kising’u, Mary Nthambi

13. Komen, C. Kenneth

14. Kung’u, Ndung’u Samuel

15. Mbweka, Joseph

16. Muchiri, Franklin Kimandi

17. Mukabi, W. James

18. Muta, Boniface Mukiri

19. Mutuku, Ndungu Rose

20. Mvuria, Wambugu Caroline

21. Mwangi, W. Margaret

22. Nandama, Wycliffe Mugabane

23. Ngotho, Peter

24. Njenga, Murango Francis

25. Nyaroo, Eric Achoki

26. Vadher, Neema Devran

27. Varia, Ketan Nitin

28. Wachira, Warukira Teresia

29. Wafula, Ripu Simiyu M.

30. Wanjohi, W. Grace

1997

1. Aboge, Clement Odhiambo

2. Barasa, S. Situma

3. Boruett, Patrick Kibiwott

4. Durbar, Shabbir Anverali

5. Kamau, Njuguna Antony

6. Kang’ethe George Kimani

7. Kariuki, Kamamia L.

8. Kariuki, Laban Irungu

9. Keitany, Kibet Paul

10. Kihuni, Wamucii Margaret

11. Maina, Patrick Wachira

12. Masila, Martin Mutee

13. Matew, Peter

14. Moindi, Peter Cheboiwo

15. Muchiri,Njoroge Paul

16. Muigai, N.Simon

17. Mwenda, James

18. Ndirangu, Philip Mbururu

19. Nduati,Joyce Wanjiru

20. Ngacha,James Kiragu

21. Ntibi,Elijah

22. Ongale,Samuel

23. Onyango,Stanley Owade

24. Sagwa, Luvaha Evans

25. Tanui, Paul Kiptum

26. Wanyoike, Joseph N.

1998

1. Joseph, Alloise Mbithi

2. Kabare, David Watene

3. Kanyi, Maina Patrick

4. Karuri, Gordon Muchemi

5. Kigotho, Charles Wahome

6. Maina, David Thairu

7. Maina, Jonah

8. Maranga, Andrew C.

9. Mohamed, Bakari Mwamsonge

10. Muteru, Muchiri Stephen

11. Mwangi, W. Elisha

12. Mwangombe, D. Livingstone

13. Mwawaka, J. Shangala

14. Ndwigah, Stanley Njagih

15. Nyamu, Gitonga David

16. Omondi, Jackson

17. Oyamo,George Osanjo

18. Ruhiu, Francis Muigai

19. Wanyoike, Stanley Njoroge

20. Waturi, Zaveria Kimondo

1999

1. Abdinasir, A.Amin

2. Chemwolo, Andrew Kimutai

3. Gitau,Samuel Chege

4. Kimani, Rose Njoki

5. Kimathi, Dickson Mbaka

6. Kirira,George Muraya

7. Kiuri,Julius Ngunjiri

8. Mburu,Catherine Njeri

9. Mbuthia,James Gichane

10. Mukoko, Joseph Shitandi

11. Muriuki,Stephen Mwai

12. Muthurania, W. Kevin

13. Mutua, Timothy

14. Muturi, Ndiritu

15. Ng’ang’a, Stanley

16. Ochieng,Wilfred Ogutu

17. Njuguna, Vincent Njoroge

18. Thuo, Boniface Mburu

19. Wanjala, Jacinta Nasimiyu

20. Wanjala, Pius

21. Ngomo,Jeremiah Nding’u

22. Ngatia, Wangai George

23. Thuita, Njogo Stephen

24. Gachangaga, Peter Njihia

25. Nzioki, Christopher Wambua

26. Mbulo, Maurice Mutunga

27. Mwenda, Samuel M’arimi

28. Githinji, Githua Charles

2000

1. Apiyo, Eric Omondi

2. Bundotich, Joseph Kipkoech

3. Giathi, Patrick Boro

4. Gichuki,M.Susan

5. Kaburi, Albert Ndwiga

6. Karanja, John N.

7. Kimatu,M. Stephen

8. Maina,J.Kamau

9. Maiyo, Brian K.

10. Maronda, Ongeri Benjamin

11. Mburu, Emmanuel Njuguna

12. Mbwiiri, Peter Ikamati

13. Milai, Nicholas Mutua

14. Muthuma, Denis Kirubi

15. Ng’ang’a, Kiboi Gerald

16. Njuguna, Felix Muriu

17. Nzumbu,M.Lawrence

18. Ododa, Martin P. Agunda

19. Otieno,George

20. Ouma, A.Janet Julia

21. Sigege, Isaac Onunda

22. Walukana, George Juma

23. Wambua, Cosmas

24. Waweru,W. Catherine

2001

1. Awino, Susan Terry

2. Githendu, Patrick Warui

3. Jefferjee, Nafisa S.

4. Karara, Monicah Wanjiru

5. Kariuki, Dominic Munyoroku

6. Maingi Maitha Joseph

7. Muthiani,Victor Sumbi

8. Mwangangi, Evans Mumo

9. Mwangi, Waithira Irene

10. Mwaniki,Paul Nganda

11. Mwaura, Nicholas Njuguna

12. Ngovo Catherine Ndinda

13. Njeru, Njoki Rosaline

14. Njuguna, Charles Mwichigi

15. Olwande, A. Caroline

16. Wariero,James Ogola

17. Mwangi, Joseph Mburu

18. Nyaboga, Wilson Biticha

19. Wambua, Patrick M.

2002

B.Pharm. V

1. Atieno, Mary Onyango

2. Charoh, Jumwa Joyce

3. Chepwogen, Felista

4. Gachoki, Wilberforce K.

5. Kabiru, Micheal Njuguna

6. Kagai,Dorine Asirigwa

7. Kareithi,Charles Mvuru

8. Karita, Anthony Ndungu

9. Karweru, Wahome Francis

10. Kiarie, Hellen Wambui

11. Kitawi, Rose Chari

12. Macharia

13. Maina, Victor Kipyegon

14. Meriakol, Nawiy Jonathan

15. Mugo, Peter Mwangi

16. Musembi, Syombua Pyles

17. Mutai, Fredrick Mbwiiri

18. Muteru, Muthoni Serah

19. Mwangi,Anthony Irungu

20. Mwirotsi,Amanda Anyika

21. Ng’ang’a, Anthony Kimani

22. Njuguna, Simon Wachira

23. Nyaga,Kariuki Robert

24. Nyingi, Samuel Mwenje

25. Nzioka, George Mutua

26. Tarus,Noah Kprop

B.Pharm. Iv

1. Angwenyi, Martin Ocharo

2. Aywak, Dorothy Atieno

3. Bitange, Pamela Monyangi

4. Busolo,Seline

5. Chadha Rasvinder Kaur

6. Gathitu W. Eunice

7. Guantai, Eric Muriithi

8. Kamunyu, Wakori Joan Wanyuru

9. Kavili, Ambrose Kyalo

10. Kenyatta, Gloria Kavutha

11. Khacheha Mary Concepta

12. Kikete, Siambi H.

13. Kimani, Daniel Kamau

14. Kimani, Wang’ang’a George

15. Kimeu, Janet Nundu

16. Kiptanui, Zippora Cherop

17. Mbae, Ernest Gitonga

18. Memusi,Dorothy Naisiae

19. Misati, Rose Kwamboka

20. Misiko,Linda Tindi

21. Mudhune, Odhiambo Oscar

22. Munyaka, Benedict Kilonzo

23. Mwai, Odhiambo Geoffrey

24. Mwangi,W. Sarah

25. Mwaniki, Charles Kagwi

26. Ndung’u, Mary Wanjira

27. Njagah, Angeline

28. Njeru, Nancy Mucogo

29. Njogu,Mbugua Peter

30. Njonjo, Tracy Wanjiru

31. Odhiambo, Owuor James

32. Samoei, Kipkorir Josphat

33. Tarus,Jemutai

34. Tiren C.Evelyn

35. Turunga Gathoni Esther

36. Wahome, Simon Kanyoro

37. Waiguru,Njuguna Stephen

38. Wata, David Etale

2003

1. Abwao, Edward

2. Aketchi, Evans Imbuki

3. Anyona, Micah Onenga

4. Bosire Prisca Kerubo

5. Chege, Irene Njeri

6. Chepkoech, Irene Yegon

7. Chesaro, Sarah Chebet

8. Gikaru, Ibrahim Muchiri

9. Gikonyo, Shadrack Wachira

10. Hamumy, Fathiya Said Ali

11. Kajumbi, Christine Jemo

12. Kaminjuki, Waruguru Muthoni

13. Kamirah, Frachiah

14. Karimi, Daniel Muriuki

15. Karumi, Esther Wamuyu

16. Kauki, Tom Mwangi

17. Keige, David Njenga

18. Kigera, Njeri Jeniffer

19. Kigundu, Phoebe Kirigo

20. King’au, Samuel Kabara

21. Kinyanjui, David Ndungu

22. Kipyegon, Chepkwony Richard

23. Kisengi, John Munguti

24. Kwena, Mathayo Hope

25. Mainnah, Nyawira Evelyne

26. Makokha, Linus Wafula

27. Makoyo,Kefa Bota

28. Mbugua, Hellen Gakenye

29. Mohamed Hanif Ebrahim M. Hussein

30. Mokaya, Roselyne Alexis

31. Mudhune, Otieno Victor

32. Muendo,Gerald Munyao

33. Muiruri, Josephine Wahito

34. Murungi, Edwin Kimathi

35. Mutai, Chepkoech Peggoty

36. Mutua, Peter Muinde

37. Mutwiri,Ashford Nkari

38. Mwai,Leah Wanjiru

39. Mwangi, Kamau Robert

40. Mwangi, Wangechi Gladys

41. Mwendwa, Jacquiline Ndinda

42. Ndege, Muriithi Franklin

43. Ndungu, Wanjiku Cathrine

44. Ndungu, Charles Gathigi

45. Nguru, David Njuki

46. Owegi, Dorothy Atieno

47. Ogolla, Christine

48. Ongarora, Dennis Sure Bagwasi

49. Otieno,Lawrence Ochieng

50. Thuku, Veronica Wanjiru

51. Torome,Allen Letoya

52. Vito, Sylvia W. Nyonyozi

53. Wagura, Jason Wang’ombe

54. Waithaka, Muthoni Wambui

2004

1. Aciata, Kimathi Claver

2. Ang’wa Newton Ondiayo

3. Birundu, Bonface Nyabengi

4. Chamngei, Sichei Cheworei

5. Chepkech, Noah Kipkurui

6. Gacheru,David Mburu

7. Gichobi,Alice Njeri

8. Gikundi,Kananu Maureen

9. Kanguru,Lovney Njeri

10. Katatha, Wanza, Nthambi

11. Kibet, Kurgat Nicholas

12. Kimbui, Mitheu Kobia Robert

13. Kipngetich, Mutai Aaron

14. Kiongo, Stephanie Wambui

15. Kipleting, Tanui Emmanuel

16. K’odhiambo, Maurice Onditi

17. Kungu, Benina Muthoni

18. Macharia, Edwin Munene

19. Macharia Maina Joseph M.

20. Maiyo,Vicky Chelagat

21. Makau,John Kioli

22. Manani, Rebeccah Ogake

23. Masila,Chris Wambo

24. Masinde, Peace Ruth

25. Mboya, Judy Achieng

26. Mburu, John Mwenda

27. Muchoki, Irene Njeri

28. Mukonzo, Nthambi Jacinta

29. Murage, Winfred Mugure

30. Murithi, Eddy Kirimi

31. Muturi, Alex Njuki

32. Mutua, Elizabeth Mukenye

33. Muyu, Mwende Gratia

34. Mwandawiro, Edgar Kale

35. Nderitu, Hilda Esther Wairuri

36. Ndungu, Micheal Muturi

37. Ngugi,Njenga David

38. Njunguru, Jessee Kamau

39. Nyakiba Okoyo Jarred

40. Nyandigisi, Andrew J.

41. Ogola Adhiambo Beatrice

42. Okoth, Molly Elsa

43. Okubasu, Etsimile Leunora

44. Ong’ayo, Marion Nyamokami

45. Ongere Nyaramba Stephen

46. Panga, Timothy Kipkopus

47. Sang, Tony Mutai

48. Sultani, Hadley

49. Tirop, Jemutai Lucy

50. Wachira, Peter Gichohi

51. Wafula, Carolyne Nasambu

52. Wafula, George Wangasa

53. Wafula, Nyongesa Francis

2005

1. Akaranga ,Irene Mwenderani

2. Ayuma, Nilian Mukungu

3. Barasa, W.Edwin

4. Chirchir, Elvis

5. Duya, Atieno Pauline

6. Elamenya, Linet Kanaga

7. Gakuo,Esbon Mwangi

8. Guchu, Kathryn

9. Gikaria, J. Waithanji

10. Kamau, Silas Mwangi

11. Kanja, Joe Kihono

12. Kimaru, Daniella Njeri

13. Kiminza, Benjamin Musyoki

14. Kiprop, Leonard Mutai

15. Korir, Emmanuel

16. Lwanga, Charles Omondi

17. Machogu, Louis Somoni

18. Maina, Esther Wanjiru

19. Mbithi, Joyce Mumbua

20. Mecca, Lucy Winkie

21. Muema, Stanley Mule

22. Mulaku, Namuma Mercy

23. Muriuki, Job Maingi

24. Musajee,Munira Abutalib

25. Musau, Mutile Jackline

26. Mutiria, Njagi Gricola

27. Mwaniki, Francis

28. Mwaniki, Samuel Waweru

29. Mwavali, A.K. Humpreys

30. Ndigirigi, Charles Guandaru

31. Nguhiu, Peter Kariuki

32. Ngumo, Peter Mwangi

33. Ngunjuri, Esther Waguthi

34. Njaria, Paul Magutu

35. Njega, Eric Kithinji

36. Njuguna, Heather Waithera

37. Njuguna, Stella Wambui

38. Nyamweya, Paul

39. Odhiambo, Jackline Achieng

40. Odhiambo, Washington Odingo

41. Oiruria, Victor Magiya

42. Opanga,Sylvia

43. Orina, Dan Ong’oi

44. Simiyu, Caleb

45. Suri, Amatjit

46. Vgutsa Veronica

47. Wambeo Jacqueline Naliaka

48. Wanga, Karim

49. Wanjala, N.M. Felix

50. Wanjiru, Nyambura Mercy

51. Wesonga, Shunet Willies.

2006

1. Ososo, Wandera Ronald

2. Maina, Duncan Githinji

3. Mbondo,Kathina Josephine

4. Nduruke, Mary Gakunga

5. Lyani, Simon Sitti

6. Gitonga Sospeter Ngugi

7. Obonyo,Clare Achieng

8. Ooga,Oghera Wesley

9. Maina,Susan Wacera

10. Ambale, Clarice Akatsa

11. Okaru,Alex Ogero

12. Mwangi,Wanjiku Winnie

13. Wekesa, Wanyonyi Vincent

14. Mwakio, Victor Tole

15. Kagunya, Emma Wanjiku

16. Muriithi, Beatrice Mugure

17. Iddi, Waititu Abdallah

18. Otieno, Marsellah Ogendo

19. Weru, Douglas Maina

20. Charles, Mulwa Nicholas

21. Chebon Joel Korir

22. Wanyonyi, Elisha Makokha

23. Mbasu, Mwaka Paul

24. Adiado, Samson Nyalwal

25. Obwocha, Nyaruri Adams

26. Masese, Linus Atisa

27. Anyango, M. Ongas

28. Mugendi, Arthur George

29. Kisang, Kibet Andrew

30. Kairang'a Samson Kuhora

31. Mbaya, Grace Kiende

32. Rukuiomi, Masiga Vivian

33. Kamau, Pauline Watahi

34. Adala Tom Geoffrey

35. Macharia, Wanjiku Agnes

36. Nambwa, Pamella Nambande

37. Kamau,Esther Wanjiru

38. Kaumbuthu, Raphael Kaberia

39. Mwangi, Roseline Njeri

40. Mwaniki,Annie Wamaitha

41. Mutwiri, Loise Nailantei

42. Masara, Angela Kerubo

43. Kirimi, Eric Mugambi

44. Njoroge, Micheal K.

45. Ogbogu, Chinwe Perpetua

46. Manji,Imran Nawaz

47. Amwayi, Evah Nanga

48. Kamau, Nellie Njoki

49. Njoroge, Esther Njeri

50. Mandale, Martha Were

51. Otieno, Christine Aluoch

52. Muiruri, Emily Ngonyo

53. Waweru,Gladys Njeri

54. Mangongo, David Olungo

55. Muchemi, Samuel Karugu

56. Ndambuki, David Kasanga

Aspirin vs warfarin: which is better?

Taking aspirin to reduce blood-clotting is “as safe and just as effective as warfarin”, The Daily Telegraph has today reported. Both drugs have long been used to prevent potentially dangerous blood clots, but there is much debate over which is better for patients. Unfortunately, both can cause unpleasant side effects, such as major internal bleeds.

The news is based on a well-designed trial looking at aspirin and warfarin that compared their safety and effectiveness when treating patients who had heart failure but a normal heartbeat. Heart failure occurs when the heart can't pump enough blood around the body to meet its needs, leading to tiredness, shortness of breath and fluid retention. Anti-clotting medications such as aspirin or warfarin aren't always part of the standard medical treatment of heart failure, but they may be judged suitable for people who are also at increased risk of blood clots due to related problems such as cardiovascular disease.

During the study, 2,305 people with heart failure but no clear need to take anti-clotting drugs were randomly selected to take either warfarin or aspirin. Researchers found that there was no difference in the rate of clot-based strokes, bleeding in the brain or death in patients receiving aspirin compared with patients receiving warfarin. When strokes caused by clots (ischaemic strokes) were considered separately, warfarin was significantly better than aspirin at reducing the risk of stroke, although the rate of major bleeding was significantly higher with warfarin.

These findings provide a good indication that warfarin and aspirin are both comparable as treatments, at least in people with heart failure, a normal heart rhythm and no apparent high risk of clots. The findings do not alter the current medical management of heart failure or clot-prevention, so it is likely that the choice between prescribing warfarin and aspirin will continue to be made on a case-by-case basis.

 

Where did the story come from?

The study was carried out by researchers from Columbia University Medical Centre, New York, and several other international medical centres and universities. It was funded by the US National Institute of Neurological Disorders and Stroke. The study was published in the peer-reviewed New England Journal of Medicine.

The BBC and The Daily Telegraph both did accurate reports on this study.

 

What kind of research was this?

A range of conditions relating to the heart and circulatory system places individuals at greater risk of blood clots, which can be serious and even fatal. Blood clots can:

  • block blood vessels connected to the lungs, causing "pulmonary embolism"
  • block vessels to the brain, causing ischaemic stroke
  • block vessels to the heart, causing a heart attack

To discourage blood clots, certain individuals may be placed on long-term courses of anti-blood-clotting drugs, including low-dose aspirin and warfarin.  

Both aspirin and warfarin have been shown to be effective at cutting the risk of dangerous blood clots, but both can cause side effects and have drawbacks. For example, both drugs can increase the risk of bleeding. In addition, dosages of warfarin need to be carefully controlled, as slightly too small a dose may not prove effective, but slightly too high a dose can greatly increase the risk of side effects, such as bleeding.

This new research was an international double-blind randomised controlled trial comparing the use of warfarin and aspirin in patients with heart failure but no heart rhythm problems. Heart failure refers to a condition where the heart can't pump enough blood around the body to meet its needs. Heart failure is a different, distinct condition from cardiac arrest (where the heart stops beating) and heart attack, where there is reduced blood flow to the heart. People with chronic heart failure can get tired and short of breath easily and often have fluid build-up in the ankles.

Rather than being a single disease, heart failure can be caused by a variety of underlying problems with the heart. Coronary heart disease (often leading to a heart attack) is the most common underlying cause of heart failure, but it can be caused by many other diseases such as heart rhythm problems, high blood pressure or heart valve disease. Anti-clotting medications such as aspirin or warfarin aren't always part of the standard medical treatment of heart failure, but they may be prescribed to people who are recognised to be at increased risk of blood clots due to a pre-existing condition such as cardiovascular disease or problems with their heart rhythm.

This study aimed to compare the “efficacy” of aspirin and warfarin for the treatment of patients with heart failure and normal heart rhythm who did not otherwise have a clear indication for taking either of these drugs. Efficacy means effectiveness within the controlled setting of a trial. A randomised controlled trial is the best type of study to address this question.

 

What did the research involve?

The researchers recruited 2,305 patients with heart failure and a normal heart rhythm, and randomised them to receive either warfarin or aspirin, in addition to any other medication to treat heart failure. Patients were judged to have heart failure on the basis they demonstrated “reduced left ventricular ejection fraction”, a phenomenon where the lower chamber on the left side of the heart pumps out less blood than it should as it beats.

Neither the patients nor the doctors that monitored them knew whether they were receiving warfarin or aspirin. This helped to ensure that their opinions, and therefore the results of the study, were unbiased. To achieve this, patients either received warfarin and a placebo (dummy pill) or aspirin and a placebo. Warfarin requires the blood to be able to clot in order for it to be monitored, and its dosage needs to be adjusted, if necessary, to meet a specific clotting target. Patients were followed up each month to monitor blood clotting and adherence to the drugs. Clinical examinations were performed every three months. Patients were followed up for at least one year, with an average follow-up time of three-and-a-half years.

The researchers analysed whether the rate of ischaemic strokes (stroke due to a blood clot), bleeding in the brain or death from any cause was different between the two groups. They also looked at the rate of heart attacks, hospitalisation for heart failure or any other major or minor bleeding in the body.

 

What were the basic results?

  • Among the 2,305 participants, there were 531 deaths, 84 strokes and seven cases of bleeding in the brain during follow-up.
  • The researchers found no significant difference in the rate of ischaemic stroke, bleeding in the brain or death from any cause between the patients receiving warfarin or those receiving aspirin (hazard ratio with warfarin 0.93, 95% confidence interval [CI] 0.79 to 1.10).
  • The rates of heart attack and hospitalisation for heart failure did not differ significantly between the two groups.
  • When ischaemic stroke by itself was considered, warfarin was better than aspirin at reducing risk of stroke (HR 0.52, 95% CI 0.33 to 0.82).
  • However, the rate of major bleeding was significantly higher with warfarin (adjusted rate ratio 2.05, 95% CI 1.36 to 3.12).

 

How did the researchers interpret the results?

The researchers concluded that, given the finding that warfarin did not provide an overall benefit and was associated with an increased risk of bleeding, there is “no compelling reason” to prescribe warfarin rather than aspirin for patients with a reduced left ventricular ejection fraction and normal heart rhythm. They also stated that: “The choice between warfarin and aspirin should be individualised.”

 

Conclusion

This well-designed trial has compared the efficacy and safety of aspirin and warfarin in patients with heart failure, a normal heartbeat and no clear medical condition requiring anti-clotting medication. In these patients, the study found that there was no difference in the rate of ischaemic strokes, bleeding in the brain or death from any cause between the two groups. The rates of heart attack and hospitalisation for heart failure also did not differ significantly between the two groups. When stroke was considered by itself, warfarin was significantly better than aspirin. However, the rate of major bleeding was significantly higher with warfarin. This study has shown that neither drug has a clear advantage over the other in people with heart failure but a normal heart rhythm who do not have a recognised increased risk of blood clots.

But although the number of strokes in this study was significantly reduced with warfarin, the number of strokes in each group was low: 0.72 strokes per 100 years of patient follow-up in the warfarin group compared with 1.36 strokes per 100 years of patient follow-up in the aspirin group. The increase in major bleeding observed with warfarin was mostly due to bleeding in the gut. Previous studies have found that mild-to-moderate heart failure is associated with an annual stroke risk of approximately 1.5%, and severe heart failure is associated with a risk of approximately 4%, compared with a risk of 0.5% in the general population. A recent Cochrane review concluded that the data available does not support the routine use of oral anticoagulation in patients with heart failure and a normal heartbeat.

These findings do not alter the current medical management of heart failure. There are various reasons why a person with heart failure may be identified to be at increased risk of blood clots, including people who have underlying cardiovascular disease (which could include a past heart attack or stroke), an abnormal heart rhythm or heart valve disease.

Overall, it is likely that the decision as to whether or not to treat heart failure patients with anti-clotting drugs (and subsequently whether to choose between aspirin and warfarin) will continue to be made on a case-by-case basis. When making their decision, doctors will continue to weigh up the benefits of, for example, reducing the risk of stroke against the risks of side effects, such as an increased risk of bleeding.

 

A brighter tomorrow? New anemia treatment strategies on the horizon

 

KEY POINT

Several emerging strategies for managing anemia in patients with chronic kidney disease (CKD) offer potential advantages over erythropoiesis stimulating agents (ESAs) such as epoetin alfa (Epogen—Amgen; Procrit—Ortho Biotech) and darbepoetin alfa (Aranesp—Amgen), according to a recent review article. Advantages and disadvantages of promising agents, including the recently approved peginesatide (Omontys—Affymax), discussed below.

 

Peginesatide

(Omontys—Affymax)
New once-monthly ESA approved
Uses:

Treatment of anemia in patients on dialysis  

The FDA announced the approval of peginesatide for the management of anemia in adult patients who have chronic kidney disease (CKD) and are receiving dialysis. This new erythropoiesis-stimulating agent (ESA) is a once-monthly injection, minimizing the need for more frequent injections.

Approval was based on data from two randomized, active-controlled, open-label, multicenter clinical trials involving 1,608 patients with CKD who were on dialysis. The trials randomized patients with hemoglobin levels initially stabilized by ESA to receive either peginesatide once monthly or to continue their current ESA (epoetin) treatment. Results showed peginesatide to be as safe and effective as epoetin in maintaining hemoglobin levels within the studies’ prespecified range of 10–12 g/dL.

The most common adverse events, observed in 10% or more of patients receiving dialysis who were treated with peginesatide, were diarrhea, vomiting, hypertension, and arthralgias. As with other ESAs, peginesatide has numerous safety considerations and was approved with a Risk Evaluation and Mitigation Strategy.

 

PREMISE LICENCES READY FOR COLLECTION from Pharmacy and poisons board.

For the full list for this link http://www.pharmacyboardkenya.org/index.php?id=54